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In prostate cancer (PCa), stromal tissues co-evolve through reciprocal interactions 
with the tumour to support tumour growth and suppress the immune response. 
WFDC1/ps20 is a secreted whey acid protein (WAP) four-disulphide core (WFDC) 
family member highly expressed within the prostate stroma. Ps20 expression has 
been frequently observed to be down-regulated or lost in cancers including in prostate 
cancer, and numerous lines of evidence suggest that ps20 has intrinsic growth 
suppressive function in numerous tumour model systems. However, ps20 remains 
biochemically uncharacterised and the mechanisms by which it functions are 
unknown. 
WFDC1/ps20 is expressed in numerous mRNA and protein isoforms some of which 
result from proteolytic cleavage. These post-translational modifications affect the 
ability of the protein to inhibit the proliferation of PCa cells. We demonstrated that 
ps20 undergoes oligomerisation by transglutaminase, and crosslinking to fibronectin. 
We show that ps20 is cleaved by cathepsin L, which while failing to abrogate function 
of the protein, does liberate cross-linked ps20 from solid phase fibronectin. We show 
that ps20 binds to glycosaminoglycans (GAG) and interacts with cell surfaces in a 
GAG dependent manner. 
To further investigate the cellular effects of ps20 we overexpressed ps20 in PCa cell 
lines. Transgenic overexpression of WFDC1/ps20 reduced proliferation in WPMY-1 
cells, and conditioned media (CM) from these cells had potent pro-apoptotic effects 
on a range of PCa cell lines. Whole genome differential transcriptome analysis of 
WPMY-1-EV v WPMY-1-ps20FL/WPMY-1-ps20TR cells identified numerous factors, 
including IL-8, IL-32, COX2, and SerpinF1 to be upregulated in WPMY-1 cells. 
Addition of a COX2 inhibitor reversed the suppressive effect of WPMY-1-ps20 CM, 
suggesting that expression of ps20 in the prostate stroma can regulate growth of 
epithelial and other tissues through the prostaglandin synthase pathway. 
Lastly, using ps20 overexpression in WPMY-1 prostate stromal cells, we 
demonstrated that CM from ps20 expressing cells inhibits proliferation of CD4 and 
CD8 T cells. Using depletion of ps20 from CM we show that suppression is indirectly 
mediated. We show that ps20 expression in WPMY-1 cell CM inhibits both anti-
CD3/28 and IL-7/15 dependent T cell. However no effect on the secretion of IFNγ or 
expression of common T cell activation markers is observed. We demonstrate that 
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Humans have had knowledge of cancer since at least the ancient Egyptians, with the 
first known references being to an untreatable tumour of the breast found in the Edwin 
Smith Papyrus, dated between 3000-2500BC. Later, the 4th century BC Greek 
physician Hippocrates coined the term carcinoma, referring to the finger like 
projections that tumours manifest, resembling a crab. Our modern English word for 
the disease stems from Celsus, a Roman physician who used the Latin word for crab; 
cancer (Hajdu, 2011). 
 
In high-income countries cancer is the second leading cause of death after 
cardiovascular disease, and represents a significant economic and health burden. 
Cancer is primarily a disease caused by dysregulation of cellular growth, leading to 
uncontrolled proliferation of cells, invasion into surrounding tissues, and the dispersal 
of secondary tumour metastases to sites around the body, which is ultimately fatal. 
The transformation of cells from healthy to neoplastic involves the accumulation of 
genetic lesions and mutations in genes which regulate and suppress growth, or which 
control cellular survival. These can arise from spontaneous mutations, germ line 
inheritance/viral-transmission of oncogenes, or from exposure to DNA-toxic 
carcinogens and radiation. Studies reveal that people carrying specific germ line 
mutations will not all develop the tumours they are predisposed toward. Similarly 
people exposed to comparable quantities of radiation, or mutagenic toxins will not all 
develop cancer, demonstrating that ultimately there are several checkpoints which a 
cell must overcome before it can proceed to unrestrained, or transformed growth. 
The immune system also plays a significant role in preventing the outgrowth of 




1.1 Ps20, SLPI, and elafin – WFDC family proteins with important roles in cancer. 
 
Whey-acidic protein (WAP) family members prostate stromal 20 (ps20), secretory 
leukocyte protease inhibitor (SLPI), elafin and are small secreted factors containing 
highly conserved WAP-four-disulphide-core (WFDC) domains. The main 
physiological role of this protein family seems to be as mucosal anti-microbials and 
serine-protease inhibitors, which assist in wound healing, suppression of tissue 
damage following injury, and as regulators of innate immunity (Clauss et al., 2005). 
However, it is being increasingly recognised that these factors have important roles 
in cancer and there is now abundant data linking ps20, SLPI, and elafin, to numerous 
human cancers in both protective and deleterious roles. It is becoming clear that the 
pleiotropic nature of these factors, including their anti-inflammatory, growth regulatory 
and more recently immunoregulatory functions may have overlapping or conflicting 
roles in the development and progression of tumours.  
 
1.1.1 Evolution of WFDC family proteins. 
 
The WFDC domain, with its characteristic 8 cysteine residues forming 4 disulphide 
bonds, has been highly conserved from mammals down to cnidarians and 
urochordates (Smith, 2011). There are 18 WFDC domain containing proteins in man 
(fig. 1.1), most of which have not been characterized beyond the gene level (Bingle 
and Vyakarnam, 2008). Due predominantly to studies of the function and expression 
of SLPI and elafin, WFDC domain containing proteins have become associated with 
the homeostatic regulation of inflammation (Sallenave et al., 1994) through a well-
characterized serine protease inhibitor function (Sallenave, 2010). However both 
SLPI and elafin possess well characterised anti-microbial functions, including anti-
bacterial, anti-viral and anti-fungal activity (Williams et al., 2006). Both SLPI and elafin 




Figure 1.1 Schematic representation of WFDC domain containing proteins in man 
WFDC domain containing proteins in man. 
Fig1.1 Schematic representation of WFDC domain containing proteins in man. The 
human genome contains 18 proteins containing the WFDC domain. 14 are on 
chromosome 20. WFDC1 is the only member on chromosome 16. All proteins contain a 
signal peptide for secretion. The position of the characterised domains is shown respective 





especially by neutrophil elastases, and have demonstrated specificity for inhibition of 
diverse proteases including neutrophil elastase, cathepsin-G and proteinase-3 
amongst other factors produced during the inflammatory response (Wilkinson et al., 
2011, Moreau et al., 2008). Ps20 was first characterised by its ability to inhibit growth 
of PC-3 prostate cancer cells and to date has no characterized protease inhibitory 
function (Rowley et al., 1995). Various studies have suggested pleiotropic functions, 
including regulation of ICAM-1 (Alvarez et al., 2011), induction of senescence (Madar 
et al., 2009), and induction of angiogenesis (McAlhany et al., 2003), though the 
predominant physiological function is still a subject of investigation (Larsen et al., 
1998). 
 
Of the 18 WFDC proteins in man, 14 are encoded on a single region on chromosome 
20, while the others are distributed throughout the genome. It has been noted that 
the genetic locus at chromosome 20 where the majority of human WFDC containing 
proteins are encoded is undergoing rapid divergence between humans and 
chimpanzees, a hallmark of proteins with innate immune functions (Hurle et al., 2007, 
Emes et al., 2003). Conversely, however, the ps20 aa sequence shows a remarkable 
level of conservation, with certain protein regions such as exon 3 being 100% 
conserved between human, chimpanzees chickens, all the way down to fish (fig 
1.2A). This lack of evolutionary divergence suggests that ps20 may possess a unique 
functional history, distinct from other WFDC family members which appear to be 
evolving rapidly (Bingle and Vyakarnam, 2008). Notably, WFDC1 is encoded on the 
16q23 locus, which was shown to be frequently under-expressed or down-regulated 
in prostate cancer relative to healthy controls, indicating a role as a potential tumour 
suppressor gene (Watson et al., 2004a).  
 
With the regards to the function of the WFDC domain itself, only the WFDC domain 




Figure 1.2 Amino acid sequence of ps20 and the WFDC domains of WFDC family proteins 
Figure 1.2 Amino acid sequence of ps20 and the WFDC domains of WFDC family 
proteins. A, The aligned AA sequence of ps20 in 6 species. Identical residues are 
presented as white on black, and conserved residues as white on grey. The 8 conserved 
cysteines of the WFDC domain are indicated by asterisks. B, A comparison of the AA 
sequences of the WFDC domain in all 18 human family members. The domain in SLPI 
and elafin blue) contains a three AA sequence which confers anti-proteinase activity. 




inhibitory function, and this has been attributed to a three AA sequence between the 
second and third cysteine residue of the WFDC region (Fig. 1.2B) (Bingle and 
Vyakarnam, 2008). As such despite a relatively high level of conservation in the 
spacing of the cysteines of WFDC domains throughout the family, it is unlikely that 
other WFDC proteins possess this anti-protease function. 
 
1.1.2 Expression of WFDC proteins. 
 
The first study looking at WFDC1 expression was performed on rat tissues, as ps20 
was originally purified as a growth inhibitory factor from rat urogenital sinus 
mesenchymal cells. This study also showed high expression of ps20 in the heart, with 
detectable but low expression in testis and prostate. However, immunohistochemical 
analysis of rat prostate tissue, revealed strong staining in smooth muscle in the 
stroma and vasculature (Larsen et al., 1998). This was the first suggestion that ps20 
is a stromally expressed protein. In a later study reporting cloning of the human 
WFDC1 gene, expression was shown in lung, cervix, prostate and uterus, with the 
highest being in the lung and prostate (Larsen et al., 1998). Subsequent reports 
including immunohistochemical analysis have also suggested that stromal smooth 
muscle is a key site of ps20 expression (McAlhany et al., 2003), and global BioPGS 
data largely support previous sites of WFDC1 expression, with the highest being in 
the prostate, placenta, lung, gut, retina and brain (fig. 1.3).  
 
More recently, one key function of WFDC1 has been uncovered by a study identifying 
the gene mutation causing multiple ocular defects (MOD) in cattle to the WFDC1 
locus. This condition comprises several developmental abnormalities in the eyes of 
Japanese cattle, revealing a significant role for WFDC1 in the development of these 
tissues (Abbasi et al., 2009). In the same report by Abbassi et al situ hybridization 
revealed significant expression of WFDC1 mRNA in the ocular tissues of cattle and 
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mice, and this was confirmed in mouse eyes using immunohistochemical analysis of 
ps20 expression. Ps20 was also present at the embryonic stages of development, 
suggesting a role during development of these tissues in animals other than cattle 
(Abbasi et al., 2009).  Interestingly, SLPI is also highly expressed in the retina (fig 
1.3) and has recently been reported to be a regulator of neuron repair following 
upregulation in response to cAMP signalling. Furthermore, exogenous SLPI was 
shown to enhance axonal regeneration (Hannila et al., 2013). Taken alongside the 
report citing WFDC1 mutations as the cause of MOD, it seems reasonable to 
conclude that expression of WFDC family proteins in nervous tissues may play an 
important role in either development, and/or neuronal repair mechanisms, in keeping 
with a broader role in wound repair, which has been previously characterised for both 
WFDC1 and SLPI (Ressler et al., 2014, Zhu et al., 2002). 
 
Another report demonstrated high levels of WFDC1 expression in the hind quarters 
of developing murine embryos, supporting a broader role for WFDC1 in development 
(Jukkola et al., 2006). However, WFDC1 null mice have been produced on the 
C57BL/6 background, and utilized in two reports to date (Ressler et al., 2014, Rogers 
et al., 2012). Authors of both studies report that the mice breed successfully and 
appear healthy, suggesting that WFDC1/ps20 is not a vital component of successful 
development, at least in mice. Curiously, in light of the reports of WFDC1 expression 
being crucial for successful bovine eye development, the mice do not appear to have 
reported abnormalities in the development of their eyes, or in their vision (Ressler et 
al., 2014). Our lab have recently taken receipt of WFDC1 null mice, kept in standard 
animal house conditions rather than the sterile environs utilised in previous reports. 




Figure 1.3 BioGPS expression pattern of WFDC1, SLPI, and elafin in human tissues 
Figure 1.3 BioGPS expression pattern of WFDC1, SLPI, and elafin in human tissues. 
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environment, have broad lack of wellbeing, and are not breeding (Vyakarnam. A, 
unpublished observation). Given the reported roles of SLPI, elafin and more recently 
WFDC1/ps20 in regulation of immunity, it is tempting to speculate that the lack of 
wellbeing in WFDC1 null mice is due to a higher propensity to infection in the non-
sterile conditions, however, there is currently no data to support this. 
 
Another notable site of WFDC1 expression is in CD4 T cells. Using qPCR to assess 
the level of WFDC1 expression, CD4 T cells were shown to express both the full-
length WFDC1 mRNA transcript and a novel species in which a region of exon 2 is 
absent (Alvarez et al., 2008). This report, published previously by the author’s 
laboratory, showed that the level of ps20 expression positively correlated with the 
ability of CD4 T cells to become infected with HIV and that this was linked to increased 
ICAM-1 expression. A subsequent report demonstrated conclusively that WFDC1 
expression regulates the adhesion characteristics of T cells, increasing the number 
of cell-to-cell conjugates formed and thereby the levels of HIV intercellular 
transmission (Alvarez et al., 2011). While these reports show no direct functional 
consequence of WFDC1 expression in CD4 T cells beyond the ICAM-1 dependent 
increase in permissiveness to HIV infection, unpublished data has shown that anti-
CD3/28 stimulation induced lower levels of IFNγ and IL-2 expression and reduced 
proliferation in WFDC1 expressing CD4 T cells relative to WFDC1 low/neg cells 
(Vyakarnam et al unpublished data), suggesting that WFDC1/ps20 may have effects 
on activation of CD4 T cells. 
 
Unlike WFDC1/ps20, the key sites of SLPI and elafin, appear to be epithelial rather 
than stromal, with significant protein secretion observed in inflammatory cells and 
mucosal surfaces, especially in the respiratory tract (Schalkwijk et al., 1999, Bingle 
et al., 2006, Sallenave et al., 1994). Elafin exhibits notably low baseline expression 
by measurement of global mRNA expression (fig.1.3), though studies have found 
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detectable elafin protein in cervico-vaginal lavage (Iqbal et al., 2009), and in bronchial 
lavage samples in health people (Tremblay et al., 1996, Sallenave and Silva, 1993) 
indicating a detectable level of constitutive expression in specific tissues. However, it 
is established that like SLPI, elafin is highly inducible and expression is increased in 
response to inflammatory stimulus. Epithelial cells have been shown to secrete elafin 
following stimulation with IL-1β and TNFα in vitro (Sallenave et al., 1994). The target 
of elafin's protease inhibitory activity, neutrophil elastase, was shown to induce 
expression of elafin mRNA, suggesting a feedback mechanism to regulate tissue 
damage by this inflammation associated protease (Williams et al., 2006). Notably, it 
was observed that bronchial alveolar cells in culture secreted negligible amounts of 
elafin until stimulation with inflammatory factors, which lend agreement to the low 
baseline expression levels presented here (fig 1.3). The inducible nature of elafin 
expression supports a role in the control of inflammation and infection in direct 
response to inflammation related stimuli, while the lack of constitutive expression 
implies that the molecule serves little homeostatic or regulatory role in normal 
conditions.  
 
This is in stark contrast to WFDC1 and SLPI which have highly levels of baseline 
expression in several tissues (fig 1.3). Moreover, there is a notable degree of overlap 
between the tissues which express both molecules; lung, colon, retina, testis and 
prostate are notable venues of WFDC1 expression which also express higher than 
average levels of SLPI. Notably, lung and colon are mucosal surfaces and the testis 
and prostate are secretory organs, which is in line with the proposed role of SLPI as 
a guardian against inflammation (Williams et al., 2006). However, with a far less 
clearly defined role for ps20, it is unknown what the function of ps20 is in these 
tissues. Unlike elafin and SLPI, work in our lab and others has to date not found any 
protease inhibitory function nor any anti-microbial activity for ps20 (Fish and 




Despite having high baseline expression in many tissues (fig 1.3) SLPI, like elafin has 
been shown to be induced in response to epidermal growth factor (EGF), neutrophil 
elastase, and α-defensins (Sallenave et al., 1994). However, SLPI induction in 
macrophages is more nuanced. SLPI is expressed in response to LPS stimulation, 
but not TNFα or IL-1β. Interestingly, it is induced with slow kinetics in response to IL-
6 and IL-10, suggesting it may in certain contexts be a component of an induced 
immunoregulatory response (Jin et al., 1998). However, it has been observed that 
SLPI expression can be inhibited in bronchial epithelial cells following TGFβ 
stimulation, again indicating that SLPI may have context and tissue specific 
immunoregulatory functions (Fleming et al., 2003). 
 
Unlike SLPI and elafin, there is no evidence to date that WFDC1 is induced, nor that 
ps20 is expressed in tissues in response to inflammation or inflammatory cytokines. 
It has been observed that WFDC1 was upregulated in placentas from women 
suffering pre-eclampsia, a hypertensive condition whose aetiology is little understood 
but during which global inflammation is enhanced (Rajakumar et al., 2011). In the 
named study no functional insights were drawn from this observation. However, in 
line with expression traits of SLPI and elafin, it is interesting to speculate that 
WFDC1/ps20 may be induced under certain inflammatory contexts, though to date 
the only observed induction of WFDC1 was shown in response to TGFβ stimulation 
in the PS-1 prostate stromal cell line, where northern blotting showed significantly 
increased mRNA signal following 50pM TGFβ stimulation (McAlhany et al., 2003).  
 
1.1.3 Biochemistry of ps20 and WFDC family proteins SLPI and elafin 
 
No studies to date have explored the biochemical characteristics of ps20. Indeed, 
beyond resolving ps20 on a western blot, no further in vitro elucidation of its 
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biochemical properties has been undertaken. However, numerous biochemical 
properties of other WAP family proteins are well elucidated, and these may provide 
an insight into characteristics common to the WFDC protein family. 
 
Ps20, SLPI, and elafin all contain a signal peptide and are secreted into the 
extracellular milieu, where SLPI and elafin have been shown to interact with 
transglutaminase (TG) and become cross-linked to extracellular matrix factors 
(Baranger et al., 2011, Guyot et al., 2005b). In addition to this there are a number of 
well characterized processing events involved in the functional regulation of WFDC 
proteins. The elafin precursor pre-elafin (also called Trappin-2) is secreted as an 
≈11kDa protein with an N-terminal cementoin domain containing a repeated 
transglutaminase motif (this motif is absent in SLPI and ps20). Pre-elafin is then 
cleaved to release a functional 6kDa elafin C-terminal region. The physiological 
protease responsible for this cleavage is unknown, but in vitro cathepsin L, cathepsin 
K, trypsin, tryptase and plasmin are able to cleave between Lys38 – Ala39 (Guyot et 
al., 2005a). SLPI is secreted as a 12kDa protein and has similarly been shown to be 
a substrate for cleavage by cathepsins, specifically L, B and S, yielding a 7.5kDa N-
terminal and a 4.5kDa C-terminal fragment (Taggart et al., 2001). Interestingly, pre-
elafin and cleaved-elafin have comparable serine protease inhibitory function, while 
the serine-protease inhibitory function of SLPI is inactivated by cathepsin cleavage 
which takes place within the active site of the C-terminal WFDC domain (Taggart et 
al., 2001). In contrast to SLPI and elafin, ps20 has no known serine-protease 
substrate and no protease capable of cleaving it has yet been identified. However, it 
is clear that there are multiple ps20 species present in ps20 CM (Alvarez et al., 2008, 
Larsen et al., 1998) and the ps20 species demonstrated to inhibit cellular proliferation 
of PC-3 cells resolved at a molecular weight well below the predicted 24kDa of the 
full length protein, which would suggest a cleavage of the full-length, or pre-protein, 
may be taking place (Rowley et al., 1995). Given the pluripotent functions of these 
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three molecules, it may be the case that the cleavage of these proteins is an important 
regulatory step; activating/abrogating the activity of their protease inhibitory functions 
and/or their other non-protease inhibitory functions in a cell and context specific 
manner, and allowing these proteins to function with a high degree of specificity in 
reaction to dynamic events such as immune activation, wound healing, angiogenesis, 
and tumourigenesis. Likewise, given that WFDC proteins can become cross-linked 
to ECM components such as Fibronectin (Guyot et al., 2005b, Baranger et al., 2011), 
it may also be the case that proteolytic cleavage of regions of the peptide chain may 
serve to liberate WFDC proteins, or WFDC protein fragments from the ECM, creating 
soluble mediators. In this respect, cathepsins have been shown to have an important 
role in cancer invasion and metastasis and are frequently upregulated in cancer (Turk 
et al., 2012). Cathepsins B and L specifically are responsible for ECM degradation 
and remodelling in the tumour microenvironment, leading to increased invasion by a 
number of tumour cell types (Turk et al., 2012). 
 
It is likely therefore that the biochemical regulation of WFDC protein functions is 
complex and tissue specific and involves a number of post-secretion processing 
events involving cleavage by various proteases and interactions with extracellular 
matrix components such as transglutaminase and fibronectin. As both SLPI and 
elafin are subjects of extensive translational research, it seems germane that a full 
understanding of how post-secretion processing of WFDC family proteins impacts 




1.2 Prostate Cancer 
 
More than 1.1 million cases of prostate cancer were recorded in 2012, accounting for 
around 8 per cent of all new cancer cases and 15 per cent in men (Ferlay et al., 
2015). Despite this, it remains the second leading cause of death in men. The vast 
majority of prostate tumours arise from epithelial tissues, resulting in 
adenocarcinomas. The accepted paradigm is that prostate carcinoma usually arises 
from lesions termed prostate intraepithelial neoplasia (PIN). This condition is 
characterised by many features reminiscent of early stage cancer, including loss of 
cellular polarity, nuclear atypia, and focal dysplasia, resulting in displaced cells lining 
the acinar and luminal spaces (Epstein, 2009).  
 
1.2.1 Anatomy of the prostate 
 
The prostate is a gland located at the base of the bladder, surrounding the urethra, 
with the average being slightly larger than a walnut, weighing between 11 and 16 
grams. The human prostate has been divided anatomically into different zones (fig. 
1.4A) which have discreet embryologic origins and manifest different histologies and 
biological functions (Lee et al., 2011). Most prostate cancers have been shown to 
arise in the peripheral zone, with some in the transitional zone, and almost none from 
the central zone (Lee et al., 2011, De Marzo et al., 2007). The prostate is a gland 
composed mainly of two tissue types; i) Epithelial tissue containing secretory 
glandular cells, non-secretory basal cells -- which are thought to be stem cells --, and 




Figure 1.4 Anatomy of the prostate 
Figure 1.4 Anatomy of the prostate. A) Schematic illustration of the prostate showing 
the zones of the prostate. a) Central zone, b) Fibromuscular zone, c) Transitional Zone, d) 
Peripheral Zone, and e) Periurethral gland region. Adapted from (De Marzo et al., 2007). 
B) Outlines the cell types present in the human prostate gland, adapted from (Barron and 







types including fibroblasts, myofibroblasts, lymphocytes, smooth muscle cells, neuro-
muscular cells and a complex network of extracellular-matrix (fig. 1.4B).  The cellular 
origins of prostate adenocarcinomas have long been thought to be luminal, i.e. 
secretory glandular epithelial cells. This is largely due to immunohistochemical 
diagnostic tests, wherein loss of basal epithelial tissue is a prognostic indicator of 
invasive cancer (Hameed and Humphrey, 2005). Despite this however, recent 
experiments - in which individual basal and luminal cell populations were isolated 
from human prostectomy samples by expression of different keratins and cell-type 
specific surface markers - have shown that only cells of basal origin were able to form 
tumours following grafting onto mice alongside stromal tissue. Luminal tissue, despite 
being subjected to oncogenic transformations, showed no tumour formation, and 
biopsies were indiscernible to those from mice grafted with stromal tissue alone 
(Goldstein et al., 2010).  
 
1.2.2 Molecular biology of prostate cancer. 
 
Since the sixties, it has been understood that prostate cancer growth is dependent 
on steroid hormones termed androgens, such as testosterone, and its major 
metabolite dihydrotestosterone. This is evident by the regression of prostate tumours 
in animals deprived  of androgen (Heinlein and Chang, 2002a). Androgens signal 
through the androgen receptor, a large intracellular hormone-activated transcription 
factor. Androgen receptor signalling regulates the growth and development of the 
prostate and maintains prostate homeostasis (Heinlein and Chang, 2002b). Both 
stromal and epithelial compartments rely on androgen signalling; stromal tissues 
respond to androgen signalling to modulate epithelial growth, survival and 
differentiation in a paracrine manner (Cunha et al., 2004), while epithelial tissues 
respond to androgen signalling to regulate production of secreted proteins (Yu et al., 
2009). It is now accepted that prostate tumours commonly result from outgrowth of 
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PIN legions, and are frequently characterised by disruption of a number of key 
signalling pathways. Studies have shown that 40% of primary prostate tumours, and 
70% of metastatic cases have genomic aberrations in the PI3K/Akt pathway. A 
significant proportion of these feature the loss or mutation of phosphatase and tensin 
homologue (PTEN), a tumour suppressor protein which limits AKT activation (El 
Sheikh et al., 2008, Reid et al., 2010). Indeed, homozygous PTEN deletion is 
sufficient to induce progressive, metastasising tumours in mice (Wang et al., 2003). 
Another genetic abnormality associated with large numbers of prostate cancers are 
chromosomal translocations between coding regions of ETS (E26 transformation 
specific) family transcription factors (typically ERG, and less commonly ETV1), and 
the promoter of the androgen responsive gene TMPRSS2 (Tomlins et al., 2005). 
Indeed, two recent studies have proposed that this genetic lesion is sufficient to 
induce PIN in otherwise healthy prostate epithelia, and can contribute to progression 
of neoplasias to invasive cancers (Carver et al., 2009, Tomlins et al., 2007). A number 
of studies have indicated that this gene rearrangement may be induced as a direct 
result of AR signalling (Lin et al., 2009). As well as ETS recombinations and PTEN 
mutations, more generic oncogenic alterations are also found in prostate cancer. For 
example, c-MYC overexpression is frequently observed (Taylor et al., 2010), and as 
with most cancer types p53 and pRb are frequently mutated or absent, though these 
are more common in metastatic cancer than in local disease (Taylor et al., 2010), 
corroborating the commonly held assumption that increasing genetic instability 
facilitates the progression and metastasis of tumours.  
 
Local prostate cancer is usually treated using radical prostectomy, or with radiation 
treatment. However, given the reliance of prostate tissue on AR signalling for growth, 
initial treatment of metastatic or recurrent disease, or where recurrence is predicted, 
patients are treated with androgen depravation therapy, which usually restrains 
growth of the cancer. However, in most cases PCa will progress to androgen 
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independence, a condition called castration resistant prostate cancer (CRPC), 
whereby tumours, through a variety of biological mechanisms still being elucidated, 
acquire the ability to grow unrestrained by the availability of androgen (Shafi et al., 
2013). Androgen independence can emerge through a number of known 
mechanisms. Androgen receptor mutations have been found in 20 to 50% of CRPCs 
(Gottlieb et al., 2004) and are reported broaden the ligand binding specificity of AR 
to non-androgynous ligands leading to more frequent AR activation (Shafi et al., 
2013). Another cause of androgen independence is amplification of the AR gene, 
leading to overexpression of the AR. This has been observed in up to 80% of CRPC 
cases (Liu et al., 2008b), and is rarely seen in non-castration resistant cases 
(Bubendorf et al., 1999). Alternatively, many studies have cited alternative splicing of 
the AR gene as the catalyst event for CRPC. While the relevance in clinical cases is 
controversial and difficult to study given the lack of available antibodies, it has been 
established that alternatively spliced forms of AR are extant which lack the ligand 
binding domain, and are thus constitutively active and growth inducing (Hu et al., 
2009). In addition to obtaining androgen independence, as tumours progress and 
become increasingly genetically unstable, multiple signalling pathways become 
dysregulated, leading to synergy between different pathways responding to 
androgens, growth factors and cytokines, adding extra levels of complexity to the 
causes of both tumour growth the and processes leading to androgen independence.  
 
1.2.3 Stromal-epithelial interactions: the Reactive Stroma in PCa. 
 
Cell-intrinsic changes in biochemistry are fundamentally important in the emergence 
of neoplastic cells, but it is now generally accepted that the reciprocal interactions 
between neoplastic epithelia and the surrounding stroma are critical in supporting 
growth and progression of emerging neoplasms. The stromal compartment within the 
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prostate surrounds the secretory epithelium and is separated from the luminal and 
basal epithelial layer by a robust matrix named the basal lamina (fig 1.4B). In health, 
the stromal response to androgen signalling is the expression of paracrine factors 
which regulate the growth, survival of the epithelium, as well as maintaining tissue 
differentiation (Lai et al., 2012). The stroma itself is a plastic tissue whose 
components vary temporally and spatially in response to micro-environmental cues. 
For example, stroma will respond to insult and injury with the appropriate wound 
healing response; or to the presence of microorganisms in the lumen of the prostate, 
with the appropriate inflammatory response. This coordinated mobilisation of stromal 
components, including the genotypic and phenotypic changes that accompany it, 
have been termed the reactive stroma (Tuxhorn et al., 2001). There is now a well-
established etiological link between chronic prostatic inflammation and the 
development of PCa (De Marzo et al., 2007), and the accepted paradigm is that the 
changes in the stroma which accompany the onset and development/resolution of 
inflammation are important in supporting prostate carcinogenesis. Indeed, it is 
thought that any response by the stroma to a damaged or disrupted epithelium, be it 
to chronic inflammation, wounding, benign prostatic hyperplasia, or the early stages 
of neoplastic growth, can induce a reactive stromal phenotype (Barron and Rowley, 
2012). 
 
Perhaps the main constituent of tissue stroma, including in the prostate, and a critical 
mediator of a reactive stromal phenotype are fibroblasts. These cells exhibit a 
phenotypic diversity depending on their micro-environmental stimuli, and are 








Figure 1.5 Stromal cell phenotypes are characterized by their expression of a series of stromally 
associated factors 
Figure 1.5  Stromal cell phenotypes are characterized by their expression of a series 
of stromally associated factors. Smooth muscle cells are defined by expression of 
Calponin and Smooth muscle actin. Fibroblasts express vimentin, Pro-collagen I and 
Tenascin-C. Myofibroblasts are considered to be plastic representing an intermediate 
phenotype with an expression prolife which includes factors specific to both smooth muscle 
and fibroblasts (Barron and Rowley, 2012). 
 
 
well documented that fibroblasts are phenotypically different when associated with 
prostate tumours than in healthy tissue. These cancer associated fibroblasts (CAF) 
or myofibroblasts show expression of both smooth muscle α-actin fibroblast 
associated factors, suggesting a shift toward a myofibroblast type phenotype 
(Tuxhorn et al., 2002). It’s commonly understood that myofibroblasts represent an 
activated fibroblast cell type; increasingly synthetic, contractile, with increased 
deposition of ECM, and have been shown to secrete growth factors which induce a 
microenvironment favourable to the survival of other cell types (Powell et al., 1999). 
The particular characteristics of myofibroblasts lend themselves to a wound healing 
environment where they can encourage tissue regeneration, and use their contractile 
properties and ECM deposition to suture the wound. However their dysregulation in 
the context of tumours, leads to enhanced tumour growth and the induction of a pro-




Experimentally it has been shown that tumours can actively change the surrounding 
stroma to support their own survival and growth. Using a mouse model of prostate 
cancer it was shown that the tumours can impose a p53 dependent growth 
suppression on the surrounding stroma. This results in a selection pressure from 
which emerges a p53 null stromal compartment, which manifests high proliferative 
potential and supports the growth of the surrounding stroma (Hill et al., 2005). A more 
recent study has suggested a role for p62 in the reprogramming of fibroblastic stroma 
to support tumour growth. p62 was found to be reduced in the reactive stroma of 
numerous tumour types, including prostate tumours, and a p62 KO mouse had 
increased tumour volumes relative to controls. It subsequently emerged that the loss 
of p62 from the murine prostate stroma induces metabolic reprograming, altered 
mTOR signalling, and an increase in IL-6 which induces PIN, and leads to the 
induction of carcinogenesis. p62 was shown to be reduced in stromal tissues of 
human tumours of the breast and prostate and this was shown to be linked to altered 
mTOR signalling (Valencia et al., 2014). 
 
Other studies have focused on the soluble mediators of CAF/myofibroblast biology, 
amongst the most important of which is transforming growth factor-β (TGFβ). The 
TGFβ family members have been shown to regulate a wide range of biological 
functions of relevance to prostate homeostasis, including i) the chemotaxis of 
immune cells into the organ, ii) regulation of the deposition of ECM, and iii) 
maintenance of tissue integrity by regulating the expression of matrix-
metalloproteases and their respective inhibitors  (Stover et al., 2007). TGFβ family 
members signal through type I and II trans membrane serine kinases (TGFβ 
receptors I-III), and signal transduction is followed by activation the SMAD family 
transcription factors, resulting in activation and repression of series of target genes 
(Massague, 2008). While the role of TGFβ family members is likely highly complex, 
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the commonly accepted function of stromally derived TGFβ is anti-proliferative and 
pro-apoptotic with respect to prostate epithelia (Siegel and Massague, 2003). During 
early stage prostate cancer, evidence suggests that TGFβ signalling through SMAD4 
transcription factor restrains tumour growth and prevents progression and 
metastasis. Indeed, in PTEN null mice, which develop poorly progressive tumours, 
deletion of SMAD4 was sufficient to induce lethal metastatic cancer in 100% of the 
mice (Ding et al., 2011). It was subsequently shown that the expression of 
transcription factor NR2F2, a member of the nuclear receptor superfamily, was 
sufficient to overcome the SMAD4 dependent barrier in PTEN KO induced tumour 
growth. NR2F2 is highly overexpressed in human and mouse prostate tumours, 
further supporting the evidence that TGFβ signalling is fundamental in restraining the 
progression and development of PCa (Qin et al., 2013). However there are numerous 
lines of evidence that TGFβ can also lead to PCa progression through SMAD4 
independent signalling pathways. Transformed PCa cells respond to TGFβ signalling 
by increased entry to the cell cycle and induction of epithelial-to-mesenchymal 
transition (EMT), a process where cells loose epithelial polarity and appropriate a 
mesenchymal morphology. This suggests that once the SMAD4 barrier has been 
overcome, TGFβ may signal through different pathways to mediate pro-tumourigenic 
functions (Ao et al., 2006).   
 
1.2.4 Role of ps20 in cancer 
 
Unlike elafin and SLPI the primary physiological function of ps20 has yet to be 
definitively elucidated. However, work published to date has implicated ps20 in range 
of processes including wound healing (Bouchard et al., 2006), ocular development 
(Abbasi et al., 2009), pre-eclampsia (Rajakumar et al., 2011), tumour suppression 
(Gratias et al., 2007), cellular senescence (Madar et al., 2009) and an increase in 
susceptibility of CD4 T cells to HIV through regulation of adhesion molecule ICAM-1 
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(Alvarez et al., 2011, Alvarez et al., 2008). However, the biochemical complexities of 
ps20 and the lack of known binding partners continue to significantly hamper efforts 
understand this protein’s physiological significance in health and disease. 
 
ps20 was originally purified as a 20kDa factor from the culture media of rat urogenital 
sinus cells and was shown to potently inhibit proliferation of the PC-3 Prostate cancer 
cell line (Rowley et al., 1995). Later, the same group cloned the WFDC1 gene (Larsen 
et al., 1998) and located it to chromosome 16q24, a region which is subject to 
frequent mutation and loss in various cancers (Larsen et al., 2000) (Harkonen et al., 
2005). This protein is strikingly well conserved which suggests an important 
physiological role, but what this is exactly remains elusive. Further investigation into 
the biology of ps20 in prostate cancer demonstrated two important but contradictory 
phenomena. In a mouse xenograft model of prostate cancer, tumours formed from 
PC-3 cells engineered to overexpress rat-ps20 showed significant increase in size, 
dry weight, and micro-vascular density compared to control tumours (McAlhany et 
al., 2003). Immunohistochemical analysis of this data showed significantly increased 
neo-vascularization in the ps20 tumour, suggesting a role in angiogenesis. Other 
experiments corroborated this, demonstrating that ps20 acts as a chemo-attractant, 
though not a growth factor, for endothelial cells and that ps20 expression was induced 
in prostate stromal cells by TGFβ (McAlhany et al., 2003), a known angiogenic factor. 
This evidence suggests that despite being associated with a region of the 
chromosome often absent or mutated in tumours, that ps20 may also exert pro-
tumourigenic characteristics under certain physiological conditions.  
 
In contrast, a subsequent study by the same group looked at ps20 expression in 
cancerous-prostate stromal and epithelial tissues from clinical samples using 
immunohistochemical analysis (McAlhany et al., 2004). Interestingly, a strong 
association was observed between increased gleason score and decreased stromal 
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expression of ps20, suggesting that tissue specific loss of expression was beneficial 
to tumour growth. Accompanying this however, was a highly localized increase in 
ps20 staining in the epithelial compartment, and this staining significantly correlated 
with reduced recurrence-free survival of patients with PCa (McAlhany et al., 2004).  
It is likely therefore that ps20 has both pro-tumourigenic and tumour-suppressive 
roles that are cell and tissue specific, which may be exhibited at different temporal 
and spatial points. 
 
A number of other studies have looked at ps20 expression in cancers and it has been 
shown to be down regulated in a number of tumour types (table 1.1) including 
bladder, brain, lung (Madar et al., 2009), melanoma (Liu et al., 2009), and prostate 
cancer (Madar et al., 2009, Watson et al., 2004b). However, no difference of 
expression was seen in either retinoblastoma or hepatic cancer (table 1.1) (Saffroy 
et al., 2002, Gratias et al., 2007) suggesting that its proposed tumour suppressive 
functions are restricted to specific tissues. In another study latexin was over 
expressed in gastric cancer cells and shown to induce ps20 expression. 
Subsequently, the growth of the gastric tumour cells was inhibited, which is consistent 
with data in other cancers and cell types (Li et al., 2011). However, in contrast to 
studies focusing on SLPI and elafin, no evidence of ps20 over expression in cancer 
has been observed, suggesting that it has predominantly anti-tumourigenic functions 
incompatible with the growth of tumours.  
 
One study observed that the WFDC1 locus was frequently subject to methylation in 
melanoma (Liu et al., 2009). To investigate the function of ps20 in melanoma, the 
group then overexpressed ps20 in melanoma cell lines, and observed reduced 
xenograft tumour growth in vivo. Interestingly, ps20 expressing cells were not growth 
inhibited in vitro suggesting the anti-tumourigenic properties were not related to 
cellular proliferation per se. It was observed that secreted factor Dickkopf1 was 
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upregulated in ps20 expressing cells, indicating that ps20’s growth inhibitory 
functions may be associated with indirect inhibition of the Wnt signalling pathway, 
which is important for growth in many tumour types (Katoh, 2005). Further mechanist 
insights have been garnered from a more recent study in melanoma where it was 
shown that experimental knockdown of membrane bound protein ABCB5 
upregulated WFDC1 gene expression. It was subsequently shown that IL-8 was 
directly down-regulated by ectopic expression of ps20, as were numerous proteins of 
the WNT family (Wilson et al., 2014). These two studies then, provide evidence that 
ps20 may have growth regulatory properties which are mediated through regulation 
of the WNT pathway, and other cytokines.  
 
The body of WFDC1/ps20 focused studies to date largely suggest a growth inhibitory 
role, where stromal ps20 expression is incompatible with tumour growth. However, it 
seems that when expression of WFDC1/ps20 is dysregulated, it may conform to pro-
tumourigenic phenotypes, involving increased epithelial expression and the 
promotion of angiogenesis.   
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1.2.5 Role of SLPI in Cancer 
 
A number of studies have investigated the role of SLPI in cancer, both at the level of 
expression, and, more recently a number of studies addressing function have been 
published. SLPI expression is shown to be both up and down-regulated depending 
on tumour type (table.1.1). In many cases elevated SLPI expression has been 
reported, such as in lung cancers (Ameshima et al., 2000, Bild et al., 2006), ovarian 
cancer (Israeli et al., 2005, Hough et al., 2001, Schwartz et al., 2002), pancreatic 
cancer (Iacobuzio-Donahue et al., 2003, Ryu et al., 2002) and in one report, breast 
cancer, showing an overexpression (>2.5 fold) expression of SLPI in a highly 
metastatic breast cancer line compared to a poorly metastatic line (Kluger et al., 
2005). These data are suggestive that in certain contexts SLPI may be advantageous 
to tumour growth. However, there are an almost equal number of cancers where 
decreased SLPI expression has been observed, such as in nasopharengeal 
carcinoma (Huang et al., 2012, Tse et al., 2012, Sriuranpong et al., 2004), melanoma 
(Jaeger et al., 2007, Martins et al., 2011), and prostate (Thompson et al., 2008), 
which is indicative of a potential tumour suppressor role in those tissues. In breast 
cancer, SLPI expression was shown to be down-regulated in one study (Hu et al., 
2004) and in another its expression was linked to increased survival from disease 
(Cimino et al., 2008). A further study showed that SLPI overexpression in breast 
cancer cell lines, increased apoptosis, and that intra-tumoural administration of SLPI 
in mice reduced tumour growth (Amiano et al., 2012). In addition, inoculation of mice 
with mammary tumour cells over expressing SLPI reduced subsequent tumour 
growth (Amiano et al., 2011). This contrasts with another study which shows mouse 
mammary tumour cells overexpressing SLPI have increased growth in vivo, but 
reduced invasiveness (Sugino et al., 2007). This study also highlighted a potential 
role for SLPI in enhancing blood borne metastasis, though it provided no mechanistic 
insight as to how this metastatic advantage was mediated. 
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Table 1.1 Expression of ps20, SLPI and elafin in cancer 
 
Ps20 mRNA/protein Expression References 
Prostate mRNA Downregulated (Madar et al., 2009) 




mRNA Downregulated (Madar et al., 2009) 
Melanoma mRNA Downregulated (Liu et al., 2009) 
Hepatic  mRNA Not regulated (Saffroy et al., 2002) 
SLPI mRNA/protein Expression References 
Thyroid, Stomach, 
Prostate, Kidney 
mRNA Not regulated (Devoogdt et al., 2004) 
Intestinal tract mRNA Upregulated (Devoogdt et al., 2004) 
Prostate mRNA/protein Downregulated (Thompson et al., 2008) 
Pancreas mRNA Not regulated (Devoogdt et al., 2004) 
 mRNA Upregulated (Iacobuzio-Donahue et al., 2003, 
Ryu et al., 2002) 
Lung mRNA Not regulated (Devoogdt et al., 2004) 
 mRNA Upregulated (Bild et al., 2006, Ameshima et al., 
2000) 
Breast mRNA Not regulated (Devoogdt et al., 2004) 
 mRNA Downregulated (Hu et al., 2004) 
 mRNA Upregulated (Bertucci et al., 2004, Kluger et al., 
2005) 
Ovarian mRNA Upregulated (Israeli et al., 2005, Hough et al., 
2001, Schwartz et al., 2002, Clauss 
et al., 2010) 
 protein Upregulated (Tsukishiro et al., 2005) 
Cervix Uteri mRNA Upregulated (Devoogdt et al., 2004) 
 promoter Upregulated (Rein et al., 2004) 
Uterus mRNA Upregulated (Devoogdt et al., 2004) 
 mRNA Downregulated (Tian et al., 2004) 
Nasopharyanx mRNA Downregulated (Sriuranpong et al., 2004) 
 mRNA/Protein Downregulated (Tse et al., 2012) 
  Downregulated (Huang et al., 2012) 
Endometrial 
epithelial carcinoma 
mRNA Upregulated (Zhang et al., 2002) 
Bladder mRNA Downregulated (Liang et al., 2002) 
Gastric Cancer mRNA/protein Upregulated (Cheng et al., 2008) 
    
elafin mRNA/protein Expression References 
Urothelium mRNA Upregulated (Smith et al., 2001) 
Skin mRNA/protein Upregulated (Alkemade et al., 1994) 
Oesophagus protein Upregulated (Alkemade et al., 1994) 
Head and Neck protein Upregulated (Westin et al., 2002) 
Bladder mRNA Downregulated (Liang et al., 2002) 
 mRNA Upregulated (Blaveri et al., 2005) 
Mouth protein Upregulated (Robinson et al., 1996) 
Lung protein Upregulated (Yoshida et al., 2002) 
Prostate mRNA Downregulated (Li and Sarkar, 2002) 
Breast mRNA Downregulated (Clauss et al., 2010, Zhang et al., 
1995) 
Ovarian  protein Upregulated (Clauss et al., 2010) 
Glioblastoma mRNA/protein Upregulated (Saidi et al., 2008) 
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Interestingly, SLPI was highly upregulated in a study looking at a rare and aggressive 
form of disease called inflammatory breast cancer which fits with the concept of SLPI 
as a molecule induced under inflammatory conditions. However this study does not 
indicate whether SLPI itself contributes directly to the development/growth of the 
breast tumours under these inflammatory conditions (Bertucci et al., 2004). SLPI 
expression has also been shown to correlate with more aggressive, metastatic gastric 
carcinoma, and experimental overexpression of SLPI in two gastric carcinoma cell 
lines enhanced cell growth, migration and invasion, once again demonstrating SLPI’s 
tumourigenic properties (Cheng et al., 2008). These studies taken together suggest 
that SLPI has a context dependent function in cancer, which is dependent on the 
specific micro-environmental conditions within tumours.  
 
A number of studies have investigated the role of SLPI in ovarian cancer, and up-
regulation of SLPI in this tumour type is well established (Israeli et al., 2005, Hough 
et al., 2001, Schwartz et al., 2002, Tsukishiro et al., 2005) leading to investigations 
as to its efficacy as a diagnostic biomarker (Havrilesky et al., 2008, Jacob et al., 
2009). Functional studies suggest that SLPI possesses direct tumourigenic effects: 
overexpression of different SLPI isoforms in ovarian cancer cells increased growth, 
colony formation and in vivo xenograft growth, and this function was shown to be 
independent of SLPIs protease inhibitor function (Devoogdt et al., 2009). A 
subsequent study by the same group showed that SLPI dependent enhancement of 
ovarian cancer cell growth is dependent on binding to progranulin, which protects the 
molecule from degradation by elastase (Simpkins et al., 2008). SLPI can also 
antagonize the effects of paclitaxel suggesting that under certain cellular conditions 
the presence of SLPI inhibits apoptosis (Rasool et al., 2010). It has also been 
observed that SLPI possesses a net pro-invasive effect in vivo in ovarian cancer 
xenografts by up-regulation of the collagenase MMP-9. This is despite the fact that 
SLPI’s protease inhibition activity has been demonstrated to antagonise the release 
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of MMP9 from the cell surface (Hoskins et al., 2011). Taken together these studies 
suggest that in ovarian cancer SLPI is clearly tumourigenic. However, its growth 
enhancing functions seem to be predominantly mediated indirectly through 
processing events upstream of other proteases or growth factors rather than in a cell-
intrinsic manner. It remains to be conclusively demonstrated that SLPI has direct cell-
intrinsic effects on signalling or transcription which could mediate pro- or anti-
tumourigenic functions, or whether its functional effects are mediated solely by 
regulation of the extracellular environment. 
 
The role of SLPI as a protease inhibitor and guardian against inflammatory damage 
by elastases in the lung is well characterized (Moreau et al., 2008). However, the 
function of SLPI in lung cancer remains poorly understood. SLPI is over expressed 
both in adenocarcinomas and in squamous cell carcinomas of the lung. Urethane 
induced tumour development in mice was abrogated in SLPI knockout animals 
(Nukiwa et al., 2008). Similarly, overexpression of SLPI in lewis lung carcinoma cells 
increased sub-cutaneous tumour growth without increasing proliferation of cells in 
vitro (Devoogdt et al., 2003), suggesting that this function relies on altered 
tumourigenic processes mediated by secondary factors, rather than direct increases 
in tumour cell proliferation and/or survival. Devoogdt et al showed that TNFα can 
promote tumour development in vivo by inducing SLPI expression. Knockdown of 
SLPI in 3LL lung carcinoma cells completely abrogated tumour formation (Devoogdt 
et al., 2006). However, in contrast to these studies, SLPI was elevated in non-
metastatic lung carcinoma lines relative to liver-metastatic lines, and SLPI expression 
in tumour cells curbed TNFα and NFϰB signalling and led to 80% fewer metastases 
in vivo (Wang et al., 2006a). This is strong evidence that SLPI can have a directly 
protective role in preventing tumour metastasis and serves to reinforce the pervading 




To date then, numerous studies suggest SLPI is capable of acting as a tumourigenic 
factor in certain tumour cell types, corroborating expression data showing SLPI up-
regulation in various solid tumours. However somewhat disparate evidence shows 
that SLPI is down-regulated in certain tumour types indicating that its role is complex 
and probably tissue and/or cell type specific. Interestingly, SLPI is involved in 
antimicrobial responses and the dampening of inflammatory processes at mucosal 
sites, especially in the lower respiratory tract and it is thought to perform similar 
functions in the stomach and intestinal mucosae (Taha et al., 2005). Development of 
cancer in the lungs and gastro intestinal tract is etiologically linked to chronic 
inflammation of these tissues (Hannelien et al., 2012). It is of note that SLPI 
expression was also upregulated in inflammatory breast cancer (Bertucci et al., 
2004). The enhanced expression of SLPI in these particular cancers may suggest 
that there are reciprocal effects of SLPI expression on increased tumour growth, and 
of the inflamed tumour microenvironment on SLPI expression, which may require 
interpretation through the complicated nexus of the inflammatory response. It has 
been clearly demonstrated that overexpressing SLPI can drive tumourigenesis 
(Simpkins et al., 2008, Devoogdt et al., 2009) and it may therefore be the case in 
tumours, especially at mucosal surfaces, that SLPI expression is induced as a result 
of local inflammatory signalling and subsequently has deleterious effects on tumour 
growth. Or alternatively it may be that the tumours themselves drive SLPI expression 
for their own growth advantage, and this induces subsequent effects on local 






1.2.6 Role of elafin in cancer. 
 
Like SLPI, elafin has been shown to be upregulated in numerous tumour types 
including mouth (Robinson et al., 1996), urothelium (Smith et al., 2001), breast 
(Larramendy et al., 2000) bladder (Blaveri et al., 2005), glioblastomas (Saidi et al., 
2008) and ovarian cancers (Tanner et al., 2000, Clauss et al., 2010) and it was shown 
to be over expressed specifically in highly differentiated squamous cell carcinomas 
of the lung (Yoshida et al., 2002), skin (Alkemade et al., 1994), and upper respiratory 
tract (Westin et al., 2002) (Table 1.1). However there is conflicting evidence from 
other tumour types where decreases in elafin expression have been observed, as in 
cancers of the  breast (Clauss et al., 2010, Zhang et al., 1995) and in primary samples 
from numerous squamous cell carcinomas (Clauss et al., 2010, Larramendy et al., 
2000). In one study of ovarian cancer, researchers found genomic gains of elafin’s 
chromosomal locus in various cell lines suggesting that elafin expression may provide 
an advantage in cellular growth. In addition, elafin expression in these cells was 
shown to be specifically induced by inflammatory conditions and NFϰB activation, 
suggesting that inflammatory conditions are conducive to elafin expression in ovarian 
tumour tissues (Clauss et al., 2010). In addition to being upregulated in ovarian 
cancer, a subsequent study showed knockdown of elafin in ovarian cancer cell lines 
in vitro increases the sensitivity to apoptosis induced by a number of commonly used 
agents including cisplatin, carboplatin, cyclophosphamide and 5-fluorouracil, which 
is further suggestive of a potentially advantageous role in tumour growth (Wei et al., 
2012). In contrast however, elafin was shown to be transcriptionally silenced in 
melanoma cells. Epigenetic suppression of the Foxa2 transcription factor was 
responsible for regulating elafin in melanoma cell lines and this could be reversed by 
a DNA methylation inhibitor which subsequently induced elafin specific growth 
suppression and apoptosis (Yu et al., 2011). Similarly, in a separate study, over 
expression of elafin in melanoma cell lines induced p53 dependent apoptosis (Yu et 
47 
 
al., 2010). Another study showed that elafin overexpression can supress breast 
cancer cell proliferation by halting the cells in G0-G1 phase of the cell cycle. However, 
in the absence of functional Rb protein elafin induces caspase3 dependent apoptosis 
(Caruso et al., 2010). So it seems elafin can function upstream of at least two 
pathways (p53 and Rb) to control cell death and function as a tumour suppressor 
protein when expressed in certain tumour cell types.  
 
Data suggests that the highest expression of elafin is seen in well differentiated 
tumours, and despite expression being elevated in cancer compared to healthy 
tissues, the expression does not seem to be associated with aggressive or invasive 
tumour types (Bouchard et al., 2006). This may be because elafin is capable of 
inhibiting various proteases within the tumour microenvironment which assist in 
tumour invasion. Lastly, in glioblastomas, elafin expression was increased and 
appears from histochemical analysis to be expressed at sites undergoing necrosis 
(Saidi et al., 2008). Subsequently, the same study showed elafin to be upregulated 
by hypoxia which supports a role for WFDC family proteins as potential regulators of 
angiogenesis during tumour development , as has been shown in a study of ps20 
(McAlhany et al., 2003). These contrasting data paint a familiar picture, wherein elafin 
expression, like SLPI, appears to have both advantageous and deleterious roles on 
tumour growth depending on the tumour type and cellular origin. Dissection of elafin’s 
function at the molecular level will likely be required to elucidate further the overall 
stage-by-stage role in tumourigenesis and the potentiality of utilizing or targeting 







1.3 Cancer and the Immune system 
 
Of fundamental importance to health is the ability of the body to recognise and 
eliminate cells as they become genetically unstable and begin to replicate 
uncontrollably. Myriad biological mechanisms service this end; intracellular proteins 
which recognise genetic lesions and induce cell-death, extracellular factors which 
regulate cellular growth and survival, and manipulate the extracellular environment; 
and the immune system, facets of which surveil tissues and eradicate cells which 
have begun to deviate from routine immune presentation. These systems, while 
highly effective, can malfunction, leading to outgrowth of transformed cells, 
neoplasms, and ultimately invasive tumours. Once cells have become transformed, 
the growth and persistence of tumours results from a failure of anti-tumour immunity 
at three key stages: (i) Immunosurveillance, (ii) activation of anti-tumour immunity 
and lastly, (iii) the failure of adaptive anti-tumour immunity to clear the tumour burden.   
 
Numerous lines of evidence both in vitro and in vivo suggest ps20 and WFDC family 
proteins SLPI and elafin possess immunomodulatory functions which may impact 
their effect within tumourous tissues, either when over-expressed, or when their 
expression is lost. In this section I will outline the facets of tumour immunobiology 
relevant to this study before reviewing the literature pertaining to the role 
immunoregulatory role of ps20, SLPI and elafin, and how this may impact 
tumourigenesis. 
 
1.3.1 Immunosurveillance  
 
The term immunosurveillance refers to a series of processes whereby the immune 
system spontaneously patrols for, recognises, and eradicates neoplastic cells before 
they become tumours. This phenomenon has been clearly demonstrated through 
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evidence of increased numbers of tumours in immune-deficient humans and mice 
(Dunn et al., 2004). Immunosurveillance is thought to be the principle function of an 
innate immune cell type called natural killer (NK) cells. Like certain T cells types, 
these cells are activated by the cytokines IL-2, IL-12, IL-15 and type 1 interferons, 
and migrate into tumourigenic environments in response to chemokines CCL2 and 
CCL5 (Bernardini et al., 2012, Zwirner and Domaica, 2010). NK cells are able to 
mediate cellular killing through i) the release of cytotoxic granules containing perforin 
and granzyme, ii) the ligation of death receptors such as TNF, FasL and TRAIL, to 
induce apoptosis, or iii) the expression of IFNγ, which halts tumour growth and 
induces the activation of other immune compartments (Zwirner and Domaica, 2010). 
Key to the function of NK cells is their ability to distinguish transformed cells from 
healthy cells. They do this through the recognition of a number of stress induced 
molecules on the surface of tumour cells which bind and activate a highly redundant 
series of receptors on the NK surface, most notably NKG2D (Long et al., 2013). NK 
cells require ligation of the inhibitory KIR receptor (Ly49 in mice) by MHC class 1 on 
the target cell surface to provide a ‘do not kill’ signal. In the presence of other 
stimulatory signals from the target cell, the failure to detect MHC class 1 leads to the 
activation of second pathway, and the tumour cell is perceived as non-self, and 
subsequently destroyed (Long et al., 2013). 
 
An increasing body of evidence in mice supports the concept of NK cells as the 
natural mediators of immunosurveillance. For example, RAG-/- mice, which lack 
adaptive immunity, developed far fewer tumours than RAG-/- and γc-/- mice, which 
lack both adaptive immunity and NK cells (O'Sullivan et al., 2012). Further evidence 
comes from the transgenic adenocarcinoma of the mouse prostate (TRAMP) model 
of prostate cancer. TRAMP mice spontaneously develop prostate adenocarcinoma 
at puberty due to the transgenic expression of the SV40 large T antigen under control 
of the prostate specific probasin promoter (Hurwitz et al., 2001). Augmented tumour 
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growth was observed in TRAMP mice which were also deficient for the NK cell 
activating NKG2D receptor, suggesting activation of NK cells restrains TRAMP 
tumour growth (Guerra et al., 2008). In humans, evidence for the role of NK cells in 
immune surveillance comes from a longitudinal study in which the blood of a large 
cohort of 3625 subjects was investigated for its natural cytotoxicity against the 
cancerous K562 myeloid progenitor cell line. Over the 11 years of follow up, those 
subjects whose blood exhibited low natural cytotoxicity had a statistically increased 
risk of developing tumours. Certain haplotypes of the NKG2D gene were found to be 
a key risk factor in subjects developing cancer, and were associated with the level of 
NK cell cytotoxicity observed in the original study (Hayashi et al., 2006, Imai et al., 
2000), again highlighting the importance of NK cell recognition of transformed cells 
in defence against neoplasms.  
 
The concept of immunosurveillance logically leads to the concept of immunoediting. 
Simply stated, this is the process whereby neoplastic cells are constantly eradicated, 
placing nascent neoplasms under a selective pressure to escape recognition by the 
immune system. It is described in three stages, i) elimination, where immunogenic 
tumour cells are cleared, ii) equilibrium, where surviving tumour cells remain dormant 
and coexist with the active machinery of immune surveillance (Koebel et al., 2007), 
ultimately progressing to, iii), immune escape, whereby the surviving malignancy has 
become poorly immunogenic and is no longer recognised by the immune system 
(Dunn et al., 2002).  
 
1.3.2 Induction of anti-tumour immune response. 
 
Once a tumour has escaped immune surveillance, other physiological mechanisms 
are required to recognise the neoplasm and instigate an immune response against 
it. However, the immune system has evolved primarily to protect the host from 
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infectious pathogens. Innate immune cells which patrol tissues such as macrophages 
(MФ) and dendritic cells (DCs), are activated through a broad family of cellular 
receptors known as pattern recognition receptors (PRRs). These PPRs, are activated 
by highly conserved pathogen-associated molecular patterns (PAMPs) associated 
with viruses, bacteria, fungi and other pathogens (Reis e Sousa, 2001). Once 
activated MФ, and DCs act as antigen presenting cells (APCs), presenting self and 
foreign peptides to the adaptive arm of the immune system to invoke a specific and 
robust response against the pathogen. Because tumours are sterile and derived from 
host cells, these PAMPs are not present, and despite the presence of APCs and other 
leukocytes in the tumour microenvironment, PRRs do not become activated and 
there is a failure to illicit an adaptive immune response.  
 
APCs express high levels of MHC class II, which when loaded with pathogen derived 
antigen (e.g. from phagocytosis) can interact with the CD4 receptor and the cognate 
T cell Receptor (TCR) on CD4 T cells. When combined with the appropriate 
secondary activation signal, this interaction results in the activation of the CD4 T cell. 
Alternatively, endogenous antigen resulting from viral infection, or (via cross 
presentation) exogenous antigen, can be presented in the context of the MHC class 
I molecule, which interacts with CD8 and the cognate TCR on a CD8 T cell. This 
results in the activation of CD8+ cytotoxic T cells (CTL).  As host cells bear MHC 
class I at their surface, activated CTLs are highly specialised to bind to and kill 
infected self-cells in an antigen specific manner (Berke, 1994).  
 
In the context of cancer, immunity has to be initiated against cells expressing tumour-
associated antigens (TAA); peptides derived from self-proteins commonly associated 
with specific tumour types, and which are presented in the context of MHC cIass 1 
molecules at the surface of tumour cells. As in the case of a viral infection, a robust 
response by CTLs is desirable to destroy tumour cells (Savage et al., 2002, Ikuta et 
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al., 2000). However, due to the lack of PAMPs and therefore of immune activation of 
APCs, there is frequently a failure to elicit robust TAA-specific CTL immunity. 
 
There are however mechanisms through which sterile inflammation, i.e. in the 
absence of pathogens, can result in anti-tumour adaptive immunity. These rely on 
the presence of danger-associated molecule patterns (DAMPs), a series of molecular 
signals, including inflammatory mediators, nucleotides such as ATP, and lipids, which 
are shed or purposefully released from dying cells (Ghiringhelli et al., 2009). Though 
these processes are still not well understood, it has been shown that DAMPs attract 
and signal to innate immune cells, predominantly MФ. During tumourigenesis 
numerous cell-intrinsic processes such as oncogenic stress and oxidative stress can 
lead to cell death, either by apoptosis or necrosis. These highly conserved processes 
can result in the production of DAMPs which interact with MФ as they scavenge 
apoptotic cell corpses and other cellular debris. The recognition of DAMPs results in 
the activation of the MФ and the release of IL-1β, resulting in further downstream 
immune activation (Ghiringhelli et al., 2009). The presence of ATP in the milieu of 
cellular debris has also been shown to result in the activation of the NLRP3 
inflammosome in DC cells and the secretion of IL-1β which in turn lead to the priming 
and activation of tumour specific, IFNγ secreting CTLs, and activation of γδ T cells, 
essentially turning the dying tumour cells into an anti-tumour vaccine (Eisenbarth and 
Flavell, 2009). 
 
How the recognition of tumours and activation of immune pathways leading to 
adaptive responses occurs in vivo is still not well understood, but the existence of 
such processes is clear by the existence of adaptive responses which have been 




1.3.3. Stromal suppression of anti-tumour immunity. 
 
As we have seen, the growth of tumours, including in the prostate, is accompanied 
by reciprocal cellular and molecular changes within the surrounding stroma, which 
facilitate and support the growth of the tumour. It is now known that as well as 
supporting the growth of the tumour through reciprocal interactions which facilitate 
cellular proliferation and vascularization of the tumour, the tumour stroma also 
mediates potent immune suppression, preventing established anti-tumour adaptive 
immunity from taking effect. Kraman et al have recently demonstrated that expression 
of the fibroblast activation protein (FAP) on the surface of cancer-associated 
fibroblasts delineated a highly immune-suppressive tumour-stromal cell 
compartment. Coupling the expression of FAP to the transgenic expression of the 
diphtheria toxin receptor in mice, they demonstrate that elimination of the FAP+ cell 
compartment throughout the animal is sufficient to restore robust  T cell mediated 
anti-tumour immunity and instigate regression of the tumour (Kraman et al., 2010). 
FAP+ fibroblasts mediate suppression through expression of immunosuppressive 
proteins such as stromal derived factor-1 (SDF-1) and transforming growth factor-β 
(TGF-β). Such cytokines prevent the activation of effector T cells and facilitate the 
development and function of T regulatory cells (Tregs) which themselves suppress 
immune responses.  
 
There are however myriad ways in which the tumour can co-opt extant immune 
suppressive mechanisms to escape and inhibit anti-tumour immunity. For example, 
the recruitment of MMP9 expressing neutrophils has been shown to have similar 
suppressive effect to FAP+ fibroblasts, by liberating cell associated TGFβ, and 
contributing to fibroblast activation (Seung et al., 1995). There is also evidence from 
a number of studies that tumours can recruit myeloid-derived suppressor cells to the 
stroma which are potently suppressive of T cell responses through numerous 
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mechanisms including production of IDO (Meyer et al., 2011, Prendergast et al., 
2014), and tumour cells and cancer associated fibroblasts secrete high levels of 
chemokines such as CCL2, CCL5, which have been shown to induce TH17 cell 
migration into the tumour, a T cell subset which evidence shows are likely pro-
tumourigenic and deleterious to anti-tumour immunity (discussed below) (Su et al., 
2010). So while there is accumulating evidence that the immune system recognises 
and attacks tumours, it is now accepted that tumours are able to survive, in part at 
least, by regulating tumour the microenvironment to suppress these immune 
responses directed against them. 
 
1.3.4 T cells in cancer. 
 
T cells are the fundamental mediators of adaptive, specific immune responses, and 
it has been shown in animal models that T cell mediated anti-tumour responses can 
mediate the eradication of solid tumours (Kraman et al., 2010). It has been 
demonstrated that the frequency and location of tumour infiltrating T cells within 
tumours can be a better predictor of progression and survival than established 
histopathological methods used for tumour staging (Galon et al., 2006), suggesting 
an active role for T cells in the restriction of tumour growth.  
 
T cells are characterized by the expression of a unique T cell receptor (TCR) that 
recognises specific molecular targets through interaction between their TCR and 
target cell surface MHC-cognate antigen complexes. Following migration from the 
bone marrow, T cells mature in the thymus, where their unique TCR interacts with 
self-antigen. The T cell clone is then selected for survival or deletion based on the 
affinity with which its TCR-recognises self-derived peptides. Each surviving T cell will 
bear one of either CD4 or the CD8, the co-stimulatory molecules which will delineate 
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the cells ability to interact with MHC class II or MHC class I molecules respectively 
(Lo and Allen, 2014).   
 
Following the priming and co-stimulation of T cells by APCs in the spleen or lymph 
node, naïve T cells will undergo expansion and differentiation to become antigen 
specific effector cells. Depending on the innate response elicited, CD4 T cells will be 
induced to become TH1, TH2, TH17 or T regulatory cells (Raphael et al., 2014). These 
subsets are primarily delineated by the cytokines they produce and the functional 
effects they elicit. CD8 T cells will become activated to become CTLs. Besides CTLs, 
TH1 cells are the cells of primary interest in anti-tumour responses as their 
predominant role is the co-stimulation and activation of CTLs, and their activation and 
recruitment leads to more effective target cell lysis, and the production of cytokines 
IFNγ and TNFα, which is desirable during infection with intracellular pathogens, or in 
cancer (Shankaran et al., 2001).  
 
Though the mechanisms are not well elucidated, tumours do induce specific T cell 
responses. These can be to i) self-antigens restricted to highly specific tissues, e.g. 
the testis, and which have become expressed on the tumour, ii) self-antigens 
associated with specific differentiated tissues, such as prostate acid phosphatase in 
the prostate (Westdorp et al., 2014), iii) or self-antigens that have been highly 
upregulated by tumours. However, there are also examples of specific T cell 
responses to neo-antigens resulting from mutations within the tumour, or from 
tumour-induced changes to the post-translational modifications of certain proteins 
(Vigneron et al., 2013). Early evidence of MHC restricted tumour specific CD8 T cells 
came when it was demonstrated that tumour infiltrating lymphocytes (TILs) from 
resected melanomas could specifically lyse autologous melanoma cells (Yee et al., 
1999). CTLs capable of lysing tumour cells had high avidity for specific MHC-tumour 
associated antigen (TAA) complexes, while those cells with low avidity could not (Yee 
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et al., 1999) demonstrating the importance of MHC-TAA complexes in the induction 
of CTL responses. However, while a number of studies have demonstrated the 
presence of infiltrating TAA specific CTLs within tumours, other studies have 
suggested that the proportion of these cells within tumours may be very low, in the 
region of 1-5% (Savage et al., 2008, van Rooij et al., 2013, Andersen et al., 2012). 
Indeed, that these cells were derived from growing tumours demonstrates that they 
are not having the desired effects of lysing tumour cells in vivo. Toward elucidating 
what T cells make up the other 95% of TIL, studies have suggested that it includes T 
regulatory cells (Tregs)(both thymically and locally induced), CD8 T suppressor cells, 
derived from tolerized CTLs, and  non-specific T cells migrating to inflammatory cues 
(Savage et al., 2014). 
 
Numerous studies have investigated the role of Tregs in cancer, and it is now 
established that tumours are frequently infiltrated by tumour specific Tregs which 
actively suppress immune responses and induce tolerance (Wang et al., 2005a). 
Tregs are CD4 T cells characterized by high levels of CD25 expression and 
expression of the FoxP3 transcription factor, and are able to mediate suppression of 
effector T cell responses through cell-to-cell contact and through secretion of soluble 
mediators such as IL-10 and TGFβ. Increased proportions of Treg in the total CD4 T 
cell populations have been observed in lung, breast and ovarian tumours (Woo et al., 
2001, Wang et al., 2006b). These cells present a significant challenge to anti-cancer 
therapies, and understanding the mechanisms which drive suppressive immunity 
within tumours is one of the fundamental aims of tumour-immunological research.  
 
Pertinent to the concept of Treg function are the concepts of recessive and dominant 
immune tolerance. Recessive tolerance stems from the thymic deletion of auto-
reactive CD4 and CD8 T cells. While fundamental in preventing autoimmunity, this 
mechanism leaves the T cell repertoire devoid of T cells which strongly recognise 
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self-antigen, from which  tumour associated antigens ultimately derive (Rizzuto et al., 
2009). Dominant tolerance is more local to the tumour. Tumours employ numerous 
mechanisms, including the co-opting of regulatory T cells, to suppress tumour 
specific T cell responses and in this way tolerizes the adaptive immune system to its 
presence (Savage et al., 2014).  Numerous lines of evidence suggest that natural 
Tregs (nTregs) arise in the thymus in response to recognition of self-antigen, though 
none of these antigens have been elucidated (Jordan et al., 2001, Apostolou et al., 
2002). Induced Tregs (iTregs), in contrast are thought to be naïve T cells which 
differentiate in extra-thymic sites in response to antigens present in commensal 
bacteria and food. It has also been proposed that iTregs may be conditioned in 
tumours in response to neo-antigens (Yang et al., 2010) and there is evidence to 
suggest the antigen specific CD4 T cells within tumours up-regulate FoxP3 upon 
transfer into tumours (Getnet et al., 2009). However, other studies looking at the TCR 
repertoire of Tregs found in prostate and other tumour types concluded that the 
contribution of locally induced Tregs to immune suppression was negligible (Malchow 
et al., 2013, Hindley et al., 2011). They demonstrated repeated recruitment of distinct 
Treg specificities, supporting the hypothesis that thymic selection of tolerogenic 
Tregs results in specific clones which become expanded within tumours, and mediate 
suppression which contributes to suppressing TAA specific effector T cells. 
 
There is now a great deal of evidence supporting the notion that infiltrating Tregs, 
actively suppress anti-tumour response. Specifically, Yu et al demonstrated that 
CD4+ CD25+ Tregs within the tumour inhibited proliferation and activation of anti-
tumour CTL and blocked the production of IFNγ. Subsequently, blockade of Treg 
derived immunosuppressive cytokines IL-10 and TGFβ partially restored anti-tumour 
immunity, however depletion of Tregs from the tumour was necessary and sufficient 
to mitigate the complete eradication of well established, highly aggressive tumours 
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(Yu et al., 2005). Further evidence has come from studies focused on prostate 
tumours and will be discussed in the following section. 
 
The discovery of IL-17 producing TH17 cells changed the classical TH1/TH2 dichotomy 
of T helper cell differentiation (Harrington et al., 2005, Park et al., 2005). These cells 
differentiate from naïve CD4 T cells activated in the presence of IL-1, IL-6 and IL-23 
(Wilson et al., 2007). While these cells are classically thought to be pro-inflammatory, 
their physiological roles are still being characterized. It has however emerged that 
TH17 cells are abundant in most common cancers (Ye et al., 2013), including prostate 
cancer (Sfanos et al., 2008, Derhovanessian et al., 2009). Indeed, many tumour 
microenvironments produce IL-1, IL-6, IL-23 and TGFβ, providing optimal conditions 
for the differentiation and expansion of TH17 cells (Su et al., 2010, Kryczek et al., 
2009, Miyahara et al., 2008). It has also been shown that chronic inflammation within 
tumours can lead to activation of NOD2 and TLR signalling, which stimulated IL-1β, 
IL-6, IL-23 and TGFβ expression and induced TH17 differentiation (Su et al., 2010). 
It seems likely then, that the induction of TH17 cells is in part due to inflammation 
associated with tumours, but also that the presence of TH17 within tumours 
contributes to and prevents the resolution of that self-same inflammation. The pro-
tumourigenic function of TH17 cells has been demonstrated in mice and numerous 
human studies and have shown IL-17 to be pro-tumourigenic, most likely through its 
pro-angiogenic functions (Tartour et al., 1999, Numasaki et al., 2003). However, 
studies disagree on the prognostic value of TH17 cells in prostate cancer. One found 
increased TH17 number to correlate with slower PCa progression (Sfanos et al., 
2008), whereas these results were contradicted by another group investigating 
castration resistant cancer (Derhovanessian et al., 2009)  indicating that these cells 
may have variable context specific roles. The function of TH17 in tumours remains 
controversial, and elucidating this will rely on understanding the origin of these cells 
within tumours. TH17 cells, unlike TH1 and TH2 cells, are in their nature highly plastic 
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and can differentiate into TH1 or iTreg cells (Koenen et al., 2008). It is not yet 
understood whether tumour associated TH17 cells are i) induced de novo within the 
tumour from naïve cells, ii) recruited to the tumour site, or iii) arise as a result of 
reprogrammed Treg cells (Alizadeh et al., 2013). Determining the origin of these cells 
is important in helping to understand their role with in the microenvironment. 
 
Adding another layer of complexity to the activity of T cells within tumours, is the 
recently discovered subset of CTL, termed suppressors of regulatory T cells (srT 
cells). These are naturally occurring thymically selected CD8 T cells which have 
specificity for antigens expressed by regulatory components of the immune system, 
such as Tregs or other suppressive facets of the tumour microenvironments. CTLs 
have been isolated in cancer patients and from healthy donors which have specificity 
for FoxP3 expressing Tregs, through recognition of HLA-A2 restricted FoxP3 derived 
antigen (Larsen et al., 2013); cells expressing the regulatory receptor PD-L1 (Munir 
et al., 2013b, Munir et al., 2013a); and cells expressing the tryptophan depleting 
immune-suppressive enzyme IDO (Sorensen et al., 2011b, Sorensen et al., 2011a).  
These CTLs target the cell baring the relevant cognate antigen and eliminate them, 
thereby reducing the suppressive component within the tissue. The role of these cells 
in health, and their effectiveness in targeting suppressive elements during disease is 
not yet established, but they represent an interesting immunological subset, which 
may be of use therapeutically. 
 
While T cells are likely fundamental to any successful anti-tumour immune response, 
tumours employ various mechanisms to overcome active anti-tumour immunity, and 
to skew the immune milieu away from a CTL and TH1 response, towards a pro-
angiogenic TH17 cell based infiltrate. Equally, the predisposition for TAAs to restrict 
nTregs results in a suppressive regulatory infiltrate which further abrogates any active 




1.3.5 Immunity of Prostate cancer 
 
As we have seen, innate immune activation during tumourigenesis can result in the 
generation of anti-tumour immune responses. These responses are then suppressed 
by immune and stromal components associated with the tumour. Despite this 
standard narrative, immune responses are context specific, and as such, have unique 
characteristics in different tumour types. The failure of the immune system to prevent 
and eradicate prostate tumours suggests that one of two things has occurred, i) anti-
tumour adaptive immunity has not been induced, or ii) the adaptive immunity is being 
modulated by the prostate tumour microenvironment to adopt a 
regulatory/suppressive phenotype. Here I will discuss the literature pertaining to 
immunity within the prostate, and to prostate tumours. 
 
A number of studies have tried to define the immune infiltrate of prostate tumours. 
Both CD4 and CD8 T cells have been shown to be present within the organ, including 
IFNγ producing TH1, IL-4 producing TH2 cells, IL-17 producing TH17 cells and FoxP3 
positive Tregs. (Kiniwa et al., 2007, Sfanos et al., 2008). It has also been observed 
that IFNγ positive cells were increased in prostates with a gleason score of 7-9 (with 
increased gleason score reflecting the severity of the tumour) compared to those with 
scores <6. Conversely, numbers of IL-17 producing cells showed an inverse 
correlation with severity. No difference in numbers of TH2 or Tregs was observed 
(Sfanos et al., 2008). Another recent study has provided evidence of TAA specific T 
cells in patients with PCa. Peripheral blood derived T cells from PCa patients had 
significantly higher reactivity to prostate specific antigens than patients with either 
benign prostate hyperplasia, or healthy patients. These cells responded with far 
higher frequency once Tregs had been depleted (Hadaschik et al., 2012). The 
induction of a tolerogenic T cell phenotype has also been demonstrated in the 
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TRAMP mouse modal of PCa. TRAMP tumours were shown to induce large T-
antigen (TAG) specific T cell and B cell responses, but TAG specific CTLs were 
unable to kill target tumour cells, demonstrating that while the tumours do not escape 
immune recognition by CTLs, these cells are subject to suppressive mechanisms 
which prevent them from killing target cells (Willimsky et al., 2008, Willimsky and 
Blankenstein, 2005).  
 
One study investigated both CD4 and CD8 Regulatory cells in prostate cancer.  The 
study demonstrated proportionally high numbers of CD4CD25+ Tregs in prostate 
tumours, suggesting a potential skewing of the immune infiltrate towards a regulatory 
phenotype. However, it was also found that both CD4 and CD8 T cells derived from 
tumours were potent suppressors of naïve T cell responses ex-vivo, suggesting that 
prostate tumours are capable of inducing potent immune suppressive phenotypes in 
infiltrating lymphocytes including the induction of FoxP3+ regulatory CD8 cells, often 
called T suppressor cells (Kiniwa et al., 2007).  Other studies have also demonstrated 
the presence and function of this cell type (Arruvito et al., 2014). Like CD4 Tregs 
these cells feature a FoxP3 regulated transcription programme, and can suppress T-
effector responses through contact dependent and independent mechanisms. 
Indeed, Olsen et al showed CD8+ Tregs elicited antigen specific suppression of T 
cell responses, and that this suppression was mediated through both surface CTLA-
4 expression, and through the secretion of IL-35. Experimental blockade of either 
mechanism relieved the suppressive phenotype (Olson et al., 2012). In a different 
study, CTLA-4 and PD-L1 blockade abrogated CD4 Treg and CD8 Treg suppression 
of IL-15 induced CTL immunity against TRAMP tumours in mice (Yu et al., 2012). 
 
Despite T cell mediated immune-suppression being clearly pertinent to the 
suppression of anti-tumour immunity, another study has suggested that tumour 
suppression of CTL killing of PCa is dependent on intra-tumoural TGFβ signalling. 
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The authors demonstrated that transfer of CD8 T cells specific for the tumour, but 
deficient of TGFβ signalling, induced elimination of the tumour, in contrast to the 
transfer of CD8 cells in which TGFβ signalling was intact, which were suppressed 
(Zhang et al., 2006). Supporting this was evidence that tumour specific CTLs 
adoptively transferred to tumour bearing mice became tolerogenic upon infiltration 
into the tumour. Blocking TGFβ in these mice partially reversed the tolerogenic 
phenotype of these cells, providing further evidence that processes mediating 
suppression of T cell responses are based on the presence of secreted factors local 
to the tumour microenvironment (Shafer-Weaver et al., 2009).  Interestingly, one 
study has proposed a role for T-effector cell-intrinsic TGFβ signalling in the 
generation of tolerogenic immune responses in the TRAMP mouse. Inhibition of 
SMAD signalling in T cells induced CTL activity against TRAMP tumours leading to 
tumour regression. However, inhibition of SMAD signalling in Treg cells had no effect, 
highlighting, i) that it is possible to reverse tolerogenic phenotype through inhibition 
of specific signalling pathways and ii) that there are numerous different mechanisms 
by which tumours can induce immune tolerance (Donkor et al., 2011).  
 
1.3.6 Role of WFDC family proteins in immunity. 
 
The above observation that TGFβ can directly induce tolerance in anti-tumour 
immune contexts is pertinent to the hypothesis that soluble mediators within tumours 
are capable of enhancing or abrogating vital anti-tumour immune responses. There 
is amassing evidence that WFDC family proteins especially SLPI, elafin, and ps20 
possess immuno-modulatory functions which may have important implications within 
the tumour microenvironment. It is now well understood that tumours and the 
associated stromal tissues manipulate their environment to suppress the host anti-
tumour immune response leading to a failure of anti-tumour immunity and 
progressive disease (Ganss and Hanahan, 1998, Yigit et al., 2010, Belladonna et al., 
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2008). Furthermore we have seen that ps20 and WFDC proteins are indeed 
commonly dysregulated in tumours. Here we will discuss the known 
immunomodulatory functions of SLPI, elafin and ps20 and the possible implications 
in the context of tumours. 
 
There is emerging evidence that ps20 may possess intrinsic immuno-modulatory 
properties. In man, ps20 is expressed in CD4 T cells and increased ps20 expression 
correlates with ICAM-1 expression and increased propensity to form cell-to-cell 
conjugates (Alvarez et al., 2008). Observations from our laboratory also suggest that 
ps20 expression In CD4 T cell clones  is inversely correlated with the ability of those 
cells to produce IFNγ upon CD3/CD28 induced IFNγ expression (Reading and 
Vyakarnam, unpublished data), which is suggestive that ps20 it may possess 
adaptive immune modulatory properties and may be a T cell-intrinsic regulator of 
immune activation. Further insights have been gleaned from the development of the 
WFDC1 null mouse. It was shown that ps20-/- animals were more susceptible to 
neutrophil invasion into the lung upon challenge by Murine Hepatitis Virus, and these 
mice showed significantly elevated chemokines CXCL1 and CXCL2 (Rogers et al., 
2012). Ultimately, the infected ps20 null mice displayed higher titres of virus than did 
the control animals. In contrast, ps20 null mice subjected to influenza virus infection 
showed significantly increased viral titres at day 4 and macrophage infiltration into 
the lung was greatly increased (Ressler et al., 2014). In addition, this study 
demonstrated that embryonic fibroblasts taken from ps20 null mice expressed higher 
levels of the pro-inflammatory proteins MMP9 and Osteopontin. This response 
indicates that ps20 may play a protective role in some viral infections, possibly 
through the induction of certain inflammatory factors. Taken together then, these two 
studies suggest that ps20 has innate immune functions which can act in a context 
specific manner to regulate responses to viral responses, including the regulation of 
chemokines and the infiltration of immune cells.  However, to date there is not enough 
64 
 
evidence to suggest a role for ps20 in modulating anti-tumour immunity. But it seems 
reasonable to speculate that ps20 has specific innate and possibly adaptive immune 
regulatory functions which may be pertinent to tumour biology. 
 
Two recent papers have indicated that SLPI possesses the ability to modulate 
adoptive immune functions in the maintenance of mucosal tolerance (Samsom et al., 
2007, Xu et al., 2007).  Specifically, DCs from SLPI-/- knockout mice released more 
inflammatory cytokines and directed increased T cell proliferation following 
stimulation with LPS. Importantly, NFϰB activation was lower in SLPI positive DCs. 
This is pertinent given the control the NFϰB transcriptional program has on the innate 
immune response and subsequent adaptive immune interactions (Doyle and O'Neill, 
2006). Suppression of an inflammatory program may have knock-on effects on 
natural killer cell and T cell activation and consequently the killing of tumour cells. 
Therefore SLPI expression at cancer sites may suppress immune activation as it 
does at mucosal surfaces, and contribute to immune tolerance of the tumour. It is 
understood that factors produced by the tumour can affect the maturation of antigen 
presenting cells, resulting in poor T cell activation and proliferation (Gabrilovich et al., 
1996, Zou et al., 2001). In one study, CM from SLPI treated monocytes was shown 
to inhibit CD4 T cell proliferation. Interestingly, a cohort of Columbian HIV-1 
controllers who showed reduced expression of immune activation markers and higher 
T cell count also produced more SLPI, suggesting a correlation of SLPI expression 
with reduced adaptive immune activation (Taborda et al., 2012). Consequently, it 
holds that SLPI may contribute to the immunosuppressive milieu within the tumour 
microenvironment, and which may be advantageous for tumour growth in certain 
tumour types.  
 
The role of elafin in innate and adaptive immunity is somewhat harder to dissect. 
Contrary to the proposed anti-inflammatory role of SLPI, a number of studies have 
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shown an increased inflammatory response; increased recruitment of neutrophils and 
other immune cell types; and increased clearance of infectious agents when human 
elafin is over expressed in murine models. But these studies are extremely difficult to 
interpret given the lack of an elafin gene in mice (Simpson et al., 2001a, Simpson et 
al., 2001b, Sallenave et al., 1994, Roghanian et al., 2006, Wilkinson et al., 2009). 
Evidence in man shows that elafin expression is correlated with inflammatory cell 
numbers and is increased in suffers of farmers lung and psoriasis, two conditions 
which provoke an inflammatory TH1 skewed immune responses (Tremblay et al., 
1996, Schalkwijk et al., 1993). It is not clear however whether the increased elafin 
levels in these contexts serves to augment the TH1 response or is simply concomitant 
with the inflammatory response, perhaps induced as a homeostatic mechanism. 
There is recent evidence to suggest that elafin may regulate NFϰB signalling in 
similar ways to SLPI. One recent study showed that adenoviral elafin transduction 
reduced NFϰB activation and the subsequent activation of downstream intracellular 
pathogen recognition factors (Drannik et al., 2012). This manipulation of NFϰB 
activation may have effects in the tumour environment as we have discussed, 
however, until direct evidence in man of an immune modulatory function for elafin is 
demonstrated its potential to regulate anti-tumour immune responses when 
expressed in that context remains ambiguous.  
 
To date then, work has shown that WFDC family proteins have the ability to regulate 
and inhibit facets of the innate and adaptive immune response which may be 
pertinent in the context of intra-tumoural immune-suppression and immune escape. 
Therefore it seems at the very least plausible that the expression of WFDC family 
proteins within the tumour microenvironment may be contributing to the 
immunosuppressive phenotype observed in many cancerous tissues, and that the 
pro-tumourigenic role exerted by WFDC proteins in the tumours discussed in the 
previous paragraphs may be linked to these immune modulatory functions. 
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Consequently, further studies to assess the contribution of these factors to the 








Many studies have now shown that WFDC family proteins SLPI, elafin and ps20 are 
differently expressed in cancers  relative to healthy tissue, and that in some cases, 
have tumourigenic functions which can lead to enhanced tumour growth, 
invasiveness and metastasis. However the biochemical regulation of these proteins 
is complex and their interactions with proteases and the ECM within tissues is likely 
to add a further level of complexity to the function of these proteins in health and 
disease. In addition, it has also become apparent that the WFDC family of protein are 
capable of manipulating innate-immune signalling processes and cellular immune 
responses, suggesting that within tumours they may have deleterious roles which 
lead to enhanced intra-tumoural immune suppression and evasion. If this is the case, 
WFDC family proteins may be targets for therapeutic intervention. Given the highly 
specific properties of individual tumours and tissues, the next generation of cancer 
therapies will likely be targeted at the molecular level to molecules of known detriment 
to host clearance of the tumour challenge. In certain tumours, blockade of WFDC 
family molecules may serve a dual purpose, to abrogate the directly tumourigenic 
functions of the protein, and to block the anti-immune functions, which potentially act 
upon innate and adaptive immune cell types within the tumour microenvironment. As 
such, a better understanding of these complicated but important molecules may shed 







Work undertaken in this thesis intends to examine and elucidate the properties and 
functions of ps20, with particular focus on the role of ps20 in the prostate, such that 
its frequent down regulation in tumours of that organ may be better understood. The 
use of ps20 as a component of a locally delivered cytotopic therapy has been 
suggested due to its previously described growth inhibitory properties on prostate 
cancer cells (Larsen et al., 1998). However a far greater understanding of the 
biochemical properties of ps20 is required before this molecule could be utilized 
therapeutically. Previous attempts to purify ps20 have relied on the production of 
large volumes of conditioned media (CM) from urogenital sinus mesenchyme cells, 
followed by a complex and laborious protocol involving numerous fast protein liquid 
chromatography, and high pressure liquid chromatography steps. In addition, the use 
of C-terminal tags (e.g. HIS tag purification by Nickel chelate) has resulted in pure 
but non-functional protein.  
 
As such our first aim is to investigate the use of immune-affinity chromatography 
using an anti-ps20 antibody-conjugated column to purify ps20 as it is expressed both 
natively, for example by HeLa cells, and from a recombinant plasmid. These studies 
will use the range of ps20 specific antibodies available to us to perform a series of 
western blotting and ELISA based assays to characterise the protein produced by 
purification studies and to assay the results of subsequent downstream investigation. 
We will then undertake a characterization of the biochemical characteristics of ps20, 
with special focus on characteristics previously observed in fellow WFDC family 
proteins. For example, interactions with ECM proteins, transglutaminase, 
glycosaminoglycans and cathepsin family proteases will be investigated and we will 
interrogate the functional consequences of such interactions.  Using CM and purified 
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ps20 protein, we will investigate the binding of ps20 to heparin and physiologically 
relevant glycosaminoglycans heparin sulphate, and chondroitin sulphate A and C.  
In the second part of this thesis we will attempt to further elucidate the function of 
ps20 using models of ps20 expression in vitro. Using commonly studied healthy and 
tumour derived prostate cell lines we aim to follow the work of Rowley et al and others 
in studying the effect of ps20 expression on the growth of these cell lines. We will 
clone and express WFDC1 mRNA species in numerous prostate cancer cell lines of 
both epithelial tumour, and prostate stromal origin. Subsequently we aim to 
characterize the effects of ps20 and attempt to investigate the mechanisms of ps20 
dependent effects.  
 
Subsequently we aim to study the effect of ps20 expression on gene expression in 
the aforementioned cells. Using a combination of transcriptome microarray and 
multiplex ELISA technology we can interrogate ps20 induced changes in the 
expression of cellular and secreted factors. Further to this, we will investigate the 
effect of ps20 expression in trans, using CM from ps20 expressing cells as a model 
of stromally expressed ps20, and its effect on neighbouring epithelial/tumour tissues. 
 
Lastly, this thesis will attempt to use a cellular in vitro model of stromally expressed 
ps20 to investigate the role of ps20 expression on immunity within the tumour. The 
rational for this experimental approach is twofold: i) SLPI has been shown to have 
potent anti-proliferative effects on T cells, and ii) T cell responses are required for 
effective anti-tumour immunity. Our aim therefore is to assay the effect of ps20 
expression in prostate stromal cells on T cell responses, using readouts of T cell 
proliferation, activation and cytokine secretion to characterize the immune regulatory 




Our overall aim is to investigate and clarify the biochemical properties and functional 
effects of ps20 when expressed in the prostate in order guide future studies which 
may seek to utilise ps20 therapeutically for its growth suppressive and 




 Materials and Methods 
 




6, 12, 24, 48, 96 -well tissue culture plate (Costar corning). 
96-well U-bottom tissue culture plate (Costar corning). 
25cm2 / 75cm2 tissue culture flasks (Costar corning). 
10cm culture dishes (Costar corning).  
1.5ml Cyrovials™ (Costar corning). 
5ml, 10ml and 25ml serological pipettes (Costar corning). 
5ml FACs tubes (Beckton Dickenson). 
Syringe filters 0.22μm/0.4μm (Triple Red). 
ART filter tips, 1000, 250, 20ul (Thermo scientific). 
Glasstic Slides (Hycor KOVA, distributed by Fisher Scientific, USA). 
Vacutainer™ tubes (BD, Biosciences, San Jose, CA). 
1.5ml micro-centrifuge (Eppendorf) tubes (VWR, UK). 
15ml and 50ml Falcon tubes (Costar corning). 
96-well flat bottom ELISA NUNC-IMMUNO PLATE F96 MAXISORP (NUNC, Thermo 
Fischer Scientific, USA). 
 
2.1.2  Molecular Biology Reagents 
 
Agarose (molecular biology grade) (Sigma-Aldrich). 
Ampicillin (Sigma-Aldrich). 





DNA ladder 100bp-1000bp (New England Biolabs). 
Ethidium Bromide (Sigma-Aldrich). 
LB broth (Sigma-Aldrich). 
LB agar (Sigma-Aldrich). 
Nuclease Free water (Qiagen). 
All Primers (MWG Biotech). 
RNeasy RNA isolation kit (Qiagen). 
T4 DNA Ligase (New England Biolabs). 
EDTA (Sigma-Aldrich). 
Tris-(hydroxymethyl)-aminomethane (TRIS) (Sigma-Aldrich). 
Agarose (Invitrogen Life Technologies). 
E.coli stain JM109 competent cells (Promega). 
SOP media (Life Technologies). 
XhoI Restriction Enzyme (New England Biosciences). 
EcoRI Restriction Enzyme (New England Biosciences). 
RNeasy Extraction Kit (Qiagen). 
Gel Extraction Kit (Qiagen). 
One-step RT-PCR kit (Qiagen). 
Taqman PCR mix (Applied Biosystems, Life Technologies). 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
2.0 mil polyester sealing film, non-sterile (Elkay). 
Ethydium Bromide (Sigma Aldrich). 
 




Dulbeco’s modified eagle medium (DMEM) + GlutaMAX™(Gibco, Invitrogen Life 
Technologies, Paisley) 
RPMI1640 GlutaMAX™ + 1.25mM HEPES (Gibco, Invitrogen Life Technologies, 
Paisley) 
X-vivo™ 15 medium (Lonza, Walkersville, MD, USA) 
Gentomycin (Sigma-Aldrich). 
Fungazone™ (Gibco, Invitrogen Life Technologies). 
Phosphate Buffered Saline (Gibco, Invitrogen Life Technologies). 
Optimem™ (Gibco, Invitrogen Life technologies) 
Trypan Blue (Sigma-Aldrich). 
TrypLE express (Gibco, Invitrogen Life Technologies). 
Foetal Calf Serum (Gibco, Invitrogen Life Technologies). 
Human Serum (Lonza) 
BD Matrigel™ Basement Membrane Matrix (BD Biosciences) 
Cell Proliferation Dye eFluor® 670 (eBioscience) 
CellTrace™ CFSE Cell Proliferation Kit (Invitrogen Life Technologies). 
Lipofectamine 2000 (Invitrogen Life Technologies) 
Celltitre96® Aqueous One step solution cell proliferation reagent (Promega). 
Dynabeads® Untouched™ Human CD4 T Cells Kit (Invitrogen, Life Technologies). 
Propidium Iodide (Sigma Aldrich). 
RNase A (Applichem GmbH, distributed by VWR. UK). 
CD3/CD28 T cell activator Dynabeads (Life Technologies) 
Brefeldin A (Sigma-Aldrich) 
Formalin (37% Formaldehyde), (Sigma-Aldrich). 
GeneIn® Transfection Reagent (AMS Biotechnology Ltd, Europe) 




2.1.4  Antibodies and Proteins 
 
Human ps20-GST fusion protein (Proteintech). 
Tissue Transglutaminase from Guinea Pig Liver (Sigma-Aldrich). 
Human Cathepsin L (R&D Systems). 
Human Cathepsin B (R&D Systems). 
Anti-V5-HRP antibody (Invitrogen Life Technologies). 
AnnexinV-PE (eBiosceince). 
Neutralising anti-SerpinF1/PEDF Clone H-125 (Santa Cruz Biotechnology). 
Neutralising anti-Human IL-6 MAb Clone 1936 (R&D Systems Europe). 
Neutralising anti-TGFβ (R&D Systems Europe). 
Fibronectin from human plasma (Sigma-Aldrich). 
Polyclonal antibody, anti-rabbit IgG HRP-conjugated, host goat (AbD Serotec). 
Polyclonal antibody, anti-mouse IgG HRP-conjugated, host rabbit (AbD Serotec). 
Monoclonal antibody, Mouse IgG1, clone NCG01 (Fisher Scientific). 
Antibodies used in fluorescence-associated cell sorting (FACS) experiments are 
listed in Table 2.1. 
Anti-ps20 antibodies 650, 651, 5B9, 1G7, and 254. 
 
Table 2.1 Antibodies used for FACS staining experiments 
Antigen Fluorophore Clone Manufacturer 
CD3 PE HIT3α Biolegend 
CD8 PE-CY7 OKT8 Biolegend 
CD3 FITC HIT3α SCBT 
CD4 APC RPA-T4 Biolegend 
IL-2 PERCP-CY5.5 MQ1-17H12 Biolegend 
IFNγ PE-CY7 48.B3 Biolegend 
CD69 PE-CY7 FN50 Biolegend 
CD25 APC M-A251 Biolegend 




2.1.5  Biochemistry reagents 
 
Phosphate buffered saline x 1 sterile (PBS) Gibco, Invitrogen Life Technologies) 
Phosphate buffered saline x 10 sterile (PBS) Gibco, Invitrogen Life Technologies) 
NHS activated columns (GE healthcare) 
HiTrap Heparin columns 1ml (GE Healthcare). 
Glycine (Sigma-Aldrich). 
Heparan-sulphate from shark cartilage (Sigma Aldrich). 
Chondroitin sulfate C sodium salt from shark cartilage (Sigma Aldrich). 
Chondroitin sulfate A sodium salt from bovine trachea (Sigma Aldrich) 
Calcium chloride (CaCl2) (Sigma Aldrich). 
Dithiothreitol (DTT) (Sigma Aldrich). 
Lumitein protein stain (Biotium, UK) 
NuPage protein gels, Bis-Tris 12%, 1.5mm thickness 10/12 and 15 well formats (Life 
Technologies). 
Tween20 (Sigma-Aldrich) 
Bovine Serum Albumin (BSA) (Sigma-Aldrich). 
NuPage LDS reducing buffer (Invitrogen Life Technologies). 
1-Step Ultra TMB-Blotting Solution (HRP substrate) (Thermo-Fisher, UK) 
1-Step Ultra TMB-ELISA Substrate Solution (HRP substrate) (Thermo Fisher, UK) 
Sodium Chloride (NaCl) (Sigma-Aldrich). 
Sulphuric acid (Sigma-Aldrich). 
NuPage MOPS buffer x 20 (Invitrogen, Life Technologies)  
Bench Mark pre-stained protein ladder (Invitrogen, Life Technologies). 
Protran nitrocellulose membranes (Whatman, GE Healthcare) 





2.1.6  Plasmids 
 
pBK-CMV expression vector.  
Expresses the native untagged cDNA of WFDC1 in mammalian cells (A kind gift of 
David Rowley, Stratagene, USA) 
 
pMIGR1-eGFP  
Retroviral plasmid pMIGR1-eGFP encodes a multiple cloning site (MCS) upstream 
of enhanced green fluorescent protein (eGFP) separated by an internal ribosome 
entry site (IRES). The gene of interest is cloned into the MCS and the IRES ensures 
bicistronic expression of the eGFP reporter gene independently of the gene of 
interest. 
 
Figure 2.1 plasmid maps of pBK-CMV and MIGR1 
 
2.1.7  Commercial Kits 
 
QIAquick™ gel extraction kit (Qiagen) 
Miniprep™ kit (Qiagen) 
Endofree Maxiprep™ kit (Qiagen) 
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Quantitect™ RT-PCR kit (Qiagen) 
RNeasy™ extraction kit (Qiagen) 
One-step RT-PCR kit (Qiagen) 
IL-6 duoset™ ELISA kit (Rnd Systems) 
Multiplex (eBiosciences). 
SilverXpress® Silver Staining Kit (Invitrogen Life Technologies). 
Untouched CD4 T cell isolation kit (Life Technologies). 
FoxP3 intracellular staining kit (eBiosciences) 
 
2.1.8 Buffers 




Running Buffer - 1x NuPage MOPs buffer (2.5mM MOPS, 2.5mM TRIS base, 0.01% 
SDS, 0.05mM EDTA in ddH2O, pH 7.7) 
Transfer Buffer - 200mM Glycine, 25mM Tris Base, 10% Methanol, 0.1% SDS in 
ddH2O. 
Wash Buffer - 1% BSA W/V, 0.2% Tween 20 W/V in PBS.  
 
Ps20 ELISA 
Wash buffer - 0.2% Tween in PBS 
Blocking buffer - 1% BSA W/V in PBS 
Antibody binding buffer - 0.4% Tween in PBS + 1% BSA 
 
FACS staining 
Cell staining buffer +2% FCS, 2mM EDTA, +0.01 NaN3 in PBS. 
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Fixing Buffer - 4% v/v formalin in PBS. 
 
Agarose Gel running buffer 
40mM Tris acetate, 1mM EDTA in ddH2O, pH 8.3 
 
Affinity chromatography 
Binding buffer - 50mM Tris in ddH2O 
Heparin column elution buffer - 50mM Tris, 1M NaCl in ddH2O. 
1G7 column elution buffer - 50mM Tris, 200mM Glycine in ddH2O, pH 2. 
 
2.1.9  Cell Culture Media and Serum 
 
Media used in day-to-day culture of cell lines and primary human cells are described 
below and specific ingredients are prepared as described. Components are 
expressed either as a percentage (v/v) or by concentration (e.g. μg/ml).  
 
Foetal Calf Serum (FCS): Fetal Calf Serum was heat inactivated (HI) by agitated 
incubation at 56⁰C for 1h in a water bath followed by storage in appropriately sized 
aliquots at -20⁰C.  
 
Human AB serum: Serum was purchased from PAA laboratories (Yeovil), heat 
inactivated by agitated incubation at 56⁰C for 1h in a water bath followed by storage 
in appropriately sized aliquots at -20⁰C. Human serum is abbreviated to HS 
henceforth. 
 
DMEM complete medium: Dulbeco’s modified eagle medium + GlutaMAX™ 
containing 4.5g/L D-glucose and pyruvate was supplemented with 250μg/ml 




RPMI complete medium: RPMI1640 GlutaMAX™ containing 1.25mM HEPES, 
(Invitrogen Life Technologies) supplemented with 250μg/ml Gentomycin and 10% HI 
FCS. 
 
X-vivo medium: X-vivo™ 15 medium was supplemented with 250μg/ml Gentomycin. 
 
2.1.10 Immortalised/Established Cell lines. 
 
PC-3 A cell line derived from bone metastases of a 62yr old male with grade IV 
prostate adenocarcinoma. This cell line is used in studies relating to prostate 
tumourigenesis. This androgen independent cell line was first established in 1979 
and is one of the most commonly used cell lines for in studies relating to prostate 
tumourigenesis (Kaighn et al., 1979).  PC-3 cells were grown in 10cm dishes in 
≈12mls of RPMI complete media with 10% (v/v) FCS. Cells were frozen and thawed 
as described and cultured for 3-4 days up to a maximum of 10 passages. Obtained 
from ATCC. 
 
LNCaP Cells were originally isolated from the left supraclavicular lymph node of a 50 
year old caucasian male with prostate carcinoma. This is an androgen dependent cell 
line established in 1977 is a standard tool for studies relating to prostate 
tumourigenesis and growth (Horoszewicz et al., 1980). LNCaP cells were grown in 
10cm dishes in ≈12mls of RPMI complete media with 10% (v/v) FCS. Cells were 
frozen and thawed as described and cultured for 3-5 days up to a maximum of 10 
passages. Obtained from ATCC. 
 
WPMY-1 A prostate stromal myofibroblast cell line isolated from a histologically 
normal 54 year old man and immortalised with SV40 (Webber et al., 1999). This cells 
80 
 
line is taken from the peripheral zone of the prostate and is useful in studying 
paracrine stromal-epithelial interactions. WPMY-1 cells are cultured in 10cm dishes 
in ≈12mls DMEM complete media + 10% (v/v) FCS. Cells are frozen and thawed as 
described, cultured for 3-4 days up to a maximum of 10 passages. Obtained from 
ATCC. 
 
PNT2 Established by immortalisation of normal adult prostatic epithelial cells by 
transfection with a plasmid containing SV40 genome with a defective replication 
origin. The primary culture was obtained from a prostate of a 33 year old male at post 
mortem. PNT2 cells contain the SV40 genome and express large T protein.  Obtained 
from ATCC. 
 
HeLa A commonly used cell line and the first cell line successfully grown in the 
laboratory. Originally isolated in the 1951 (Scherer et al., 1953) from an unusually 
aggressive cervical carcinoma. This cell line is used as model in a number of 
branches of cellular biology due to their rapid proliferation rate and ease of culture 
and transfection efficiency. They display a strange morphology. A kind gift of 
Professor Michael Malim. 
 
293T An immortalised Human embryonic kidney cell line stably expressing the SV40 
Large T antigen. This cell line is commonly used experiments involving transient 
expression of transfected cDNAs due to the cells high transfection efficiency. A kind 





2.2  Methods 
 
2.2.1  Cell culture 
 
2.2.1.1 Thawing of cryopreserved cells. 
 
Vials were taken from -80⁰C freezer or liquid nitrogen and transferred to a 37⁰C water 
bath until defrosted. Cells were then taken into 5-10mls of appropriate complete 
media+10% FCS in a 15ml falcon tube to dilute out DMSO, and centrifuged at 200xg 
for 5 mins to pellet cells. Cells were then resuspended in complete media and 
transferred to culture vessels. Cells were cultured for at least 48h before being used 
in assays. 
 
2.2.1.2 Culture of adherent cell lines. 
 
All adherent cell lines were grown routinely in 10cm dishes or 75cm2 flasks depending 
on the number of cells needed for a given series of experiments. Cells were usually 
seeded at 106 cells in 12mls or 25mls of complete media+10% FCS depending on 
the culture vessel. Cells were grown at 37⁰C in a 5% CO2 humidified incubator 
(hereon referred to as 37⁰C/5%) for the indicated time or until 90-100% confluent. If 
cultured from a low density for an extended period (such as following thawing of 
limited number of cells) culture medium was changed every 3-4 days. Once cells 
reached an appropriately level of confluency they were passaged by removing media 
and incubating cells with 2-5mls of TrypLE™ express detachment reagent (preheated 
to 37⁰C) for ≈5 mins or until cells were detached. Cells were then washed in complete 
media to neutralise the trypsin analogue reagent. Following centrifugation cells were 




2.2.1.3 Cryopreservation of cell lines.  
 
For long term storage, cells were resuspended in ice-cold FCS + 10% dimethyl 
sulfoxide (DMSO) at a cell density between 106-107/ml. The resulting cell suspension 
(0.5ml-1ml) was transferred to cryovials™ (Corning) which were immediately placed 
on ice until transferred to the -80⁰C freezer. Vials were then stored at -80⁰C or for 
extended periods >6 months in liquid nitrogen. 
 
2.2.1.4 Peripheral blood mononuclear cell (PBMC) isolation.  
 
Blood samples were drawn from healthy donors from within KCL into 9ml heparinised 
Vacutainer™ tubes. Samples were diluted 1:1 with Hanks Balanced Salt solution 
(HBSS, GIbco, Invitrogen Life Sciences). PBMCs were isolated using high speed 
density centrifugation. Blood /HBSS was then layered gently on top of Lymphoprep™ 
(d=1077g/cm3), at a 1:2 Lymphoprep to Blood/HBSS ratio. Tubes were then 
centrifuged for 20 mins at 1000G with a minimal rate of deceleration. PBMCs were 
extracted from the resulting interphase buffy coat using a 5ml Pasteur pipette and 
washed 1:3 in RPMI complete media +10% human serum to dilute remaining 
lymphoprep.  Washing was performed twice (i) at 200xg for 5 mins to remove low 
weight platelets and (ii) at 300xg to remove all remove remaining traces of 
lymphoprep™. Cells were resuspended in RPMI complete media+10% human serum 
and used immediately (within 4 h) or cryopreserved as described. All steps were 
performed in sterile conditions at room temperature.  
 
2.2.1.5 CD4+ T cell isolation 
 
CD4+ T cells were negatively isolated from whole PBMCs using the Dynabeads® 
Untouched™ Human CD4 T Cells isolation kit (Invitrogen Life Sciences). This 
83 
 
process uses supermagnetic polymer beads (1μm diameter) coated with human anti-
mouse IgG Fc-specific antibodies. PBMCs are ligated to a mixture of mouse IgG 
antibodies: CD8, CD14, CD16 (for CD16a and CD16b) CD19, CD36, CD56, 
CDw123, and CD235a, which bind to target cells expressing these antigens. These 
cells are then removed from the milieu by incubation with the magnetic beads. The 
supernatant remaining therefore contains only CD4+ T cells, which lack the specific 
cellular markers listed. 
 
Prior to the isolation procedure all reagents with the exception of the PBMCs were 
chilled on ice. Freshly isolated PBMCs are resuspended in PBS+1% HS, 500μl for 
every 107 PBMCs used and transferred to 15ml falcon tube. 100μl of antibody mix 
and 100μl of HS are then added for every 107 PBMCs and the mixture is incubated 
with gentle rotation for 20-30 mins at 4⁰C to allow the antibodies to ligate to their 
respective cell surface antigens. Following ligation of the antibody mixture, cells are 
washed once with 5mls of ice cold PBS+1%HS and pelleted by centrifugation in order 
to remove un-ligated antibodies. Cells were resuspended in 1ml PBS+1%HS for 
every 107 cells. 1ml Dynabeads® were washed twice by adding 5 volumes of 
PBS+1%HS and holding against a magnet for 2 mins until beads had adhered to the 
tube wall. The remaining supernatant was and following removal of the magnet 
washing was repeated. Washed beads were then resuspended to the original volume 
with PBS+1%HS. These beads are then added to the washed and resuspended 
PBMC/ligated antibody mix and incubated at room temperature for 20 mins with 
gentle rotation to allow antibody-bead ligation to take place. Following the ligation of 
the beads to the antibody coated cell surface, negative isolation of CD4 T cells was 
performed by holding the resulting solution to a magnet for 5 mins. Once the beads 
and adjoining cell mixture was adhered to the side of the tube the supernatant was 
removed. This resulting suspension was counted and resuspended in RPMI complete 
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media+10% HS. Staining for purity of CD4+ve T cells was subsequently performed 
and consistently found to be ≈95%. 
 
2.2.1.6 Harvesting conditioned media from WPMY-1 cells. 
 
Batches of WPMY-1 transduced cell CM were collected from cells seeded in 75cm2 
flasks in a volume of 25mls of complete media. 106 cells were seeded, and CM was 
collected 72h after seeding. Where CM was required in multiple conditions, e.g. 
developed in the presence of a COX-2 inhibitor, cells seeded in multiwell plates and 
the ratios of cell number seeded, surface area and volume of media were kept the 
same as with 75cm2 flasks. Following collection of CM, media was clarified by 
centrifugation at 1000g for 10 mins, aliquoted in 1.5 ml Eppendorf tubes and stored 
at -80⁰C. 
 
2.2.2  Cellular Assays 
 
2.2.2.1 Viability/MTS assay.  
 
Proliferation and cell viability can be measured by using reagents which undergo a 
colourimetric catalysis through cell-metabolic processes. MTS is one such reagent. 
The Celltitre96® Aqueous One step solution cell proliferation reagent (Promega) 
contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an 
electron coupling reagent (phenazine ethosulfate; PES) which when cultured with 
metabolically active cells results in the generation of a formazan product which 
absorbs light at a wavelength of 490nm. The absorbance in any given well following 
incubation with the reagent is directly proportional to the number of living cells in 
culture. The reagent was thawed and aliquoted into 1ml aliquots to reduce the 
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number of freeze thaw cycles the reagent would be subjected to. Before each 
experiment an aliquot was thawed in a 37⁰C water bath and kept in the dark at RT 
until use. 
 
For individual experiments, cells were seeded at 2000-5000 cells/well in 100μl of 
complete media +/-FCS in 96 wells plates for the indicated time period. After this time 
15μl of Celltitre® reagent was added and the plate was incubated at 37⁰C/5% and 
readings were taken at specific time points, usually 1, 2 or 4h, using a colorimetric 
plate reader (Biorad, USA).  
 
2.2.2.2 Cell Cycle Staining/Analysis.  
 
Propidium iodide (PI) staining of nuclear chromatin was used to quantify the number 
of cells from a given population in each respective phase of the cell cycle.  5x104 cells 
were seeded in 12 well plates usually in triplicate. After treatment cells were cultured 
for 48/72h as indicated and harvested with TrypLE™. Cells were transferred to FACs 
tubes containing PBS+2% FCS to neutralise the TrypLE™ and centrifuged at 1000xg 
for 5 mins. Media was removed by flicking and cells were resuspended by running 
individual FACS tubes across a draining board grate. Tubes were then individually 
vortexed as 400μl of 70% ethanol in ddH2O was added to prevent cell clumping. Cell 
fixing was for 30 mins at RT or for <1 week at 4⁰C.  
 
For staining cells were once again centrifuged at 1000xg for 5 mins and fixing buffer 
was flicked off. Cells were resuspended as described. Staining solution was 0.05% 
Triton-X in PBS + 50μg/ml PI+100μglml RNase A (Both Sigma-Aldrich). 500μl of 
staining solution was added to each tube and incubated in the dark at 37⁰C for 45 
mins. In this time RNaseA digests the cells’ RNA content which is necessary as PI 
binds to both DNA and RNA and intact RNA remaining in the sample will invalidate 
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the result. Following staining cells are centrifuged once more and remaining staining 
buffer flicked off and cells resuspended. Cells are then acquired using the FACS 
canto II. Data was analysed using the 1D cell cycle analysis feature in FlowJo 7.6.4.  
 
2.2.2.3 Annexin V staining for apoptosis.  
 
Induction of apoptosis was investigated using annexin V conjugated to FITC. 3-6x104 
cells were seeded in 12 well plates in complete medium + 10% FCS. Cells were 
treated for the appropriate time (e.g. 24-72h) and harvested with trypsin as discussed. 
Cells were transferred to 5ml polystyrene tubes (BD biosciences) and centrifuged at 
2000xg for 5 mins. Media was poured away and cells were washed once in 500μl 
Annexin V binding buffer (BD Biosciences) and again centrifuged.  Excess buffer was 
poured off, and cells were resuspended in remaining buffer (≈100μl). 2μl of Annexin 
V-FITC were added and 4μl of PI solution (50mg/ml stock) and cells were incubated 
for 20 mins on ice in the dark before adding a further 100ul of PBS and acquiring 
using a FACS Canto II. 
 
2.2.2.4 Purified T cell CFSE proliferation assay.  
 
Purified CD4 T cells were purified as described and resuspended in 107 cells/ml in 
PBS. CFSE was added at 5μM and incubated for 5-10 mins at 37⁰C. Cells were then 
washed in complete RPMI media and resuspended at 2x106 cells/ml in x-vivo. Cells 
were plated at 105/well in 96 well U-bottom plates in the relevant conditions and 
stimulated with 0.06μl of anti-CD3/28 dynobeads™ (Invitrogen Life Sciences).  
Following 6 days of proliferation cells were transferred to FACS tubes and assayed 




2.2.2.5 T cell proliferation assay using whole PBMCs.  
 
PBMCs were purified as described and resuspended in 107 cells/ml in PBS. Either 
CFSE or eFluor605 reagent (eBioscience, UK) was added at 5μM and incubated for 
5-10 mins at 37⁰C. Cells were then washed in complete RPMI media and 
resuspended at 2x106 cells/ml in x-vivo. Cells were plated at 5x104/well in 96 well U-
bottom plates in the relevant conditions and stimulated with a variable concentration 
of anti-CD3/28 dynobeads™ (Invitrogen Life Sciences). Following 6 days of 
proliferation cells were stained for CD3 and CD8 as described and transferred to 
FACS tubes and assayed for CFSE dilution in the FITC channel of a FACS CantoII. 
 
2.2.2.6 Analysis of T cell activation 
 
Whole PBMCs were purified and seeded 2x105 cells in round well 96 well plates. 
Conditioned media or purified protein was added and the final volume made to 200μl 
with x-vivo media. Cells were incubated for the indicated time and then stimulated 
with anti-CD3/28 beads at a bead to cell ratio of 1 bead to 5 cells. Cells were then 
stained for CD3, CD8, CD69 and CD25 and fixed as described and analysed on the 
FACS canto II. 
 
2.2.2.7 Cell staining.  
 
Cells were transferred to FACS tubes and washed with 2mls of wash buffer (PBS + 
2% FCS + 0.05% sodium azide) and centrifuged (5 mins at 1000g). Cells were 
resuspended by agitation and the relevant Ab cocktail was added from the list given 
in table 2.1. Cells were incubated in the dark for 30 mins and washed and centrifuged 
again. Excess buffer was removed and cells were resuspended by agitation. Cells 
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were then acquired by FACS or fixed by addition of an equal volume of 4% 
paraformaldehyde and stored in the dark at 4⁰C until acquisition. 
 
2.2.2.8 Intracellular FACS staining. 
 
IC staining was performed using the FoxP3 staining kit (eBiosciences). Whole 
PBMCs were isolated and seeded at 5x105 in 48 well plates in x vivo media and 50% 
WPMY-1 CM. Cells were treated with 1:2 anti-CD3/28 dynabeads™ (Life 
technologies) for 48h and 5μg/ml brefeldin A (Sigma Aldrich) was added 16h prior to 
harvesting. Cells were washed with FACS wash buffer and stained with CD3 and 
either CD4 or CD8 antibody. Cells were washed and then fixed. Cells were washed 
in permeabilisation buffer and the excess removed. Antibodies to the relevant 
cytokines were added and incubated at room temperature for 30 mins. Cells were 
again washed with FACS buffer and 200μls of fix buffer was added. Cells were stored 
at 4⁰C in the dark until acquisition on a FACS canto II (BD biosciences). 
 
2.2.2.9 Cell Transfection. 
 
For ps20 purification:  
Transfection of 293F cells in 30ml conical flasks 1µg of pBK-WFDC1 was combined 
with 1ug of PEI or Lipofectamine in 100µl of optimum™  and incubated for 20mins. 
1µg of DNA was used per 106 cells. The mixture was added to cells drop wise and 
cells were cultured for different time points to express protein as required. 
 
Alternatively, 293T cells were transfected in 72cm2 plates. 1ug DNA /106 cells was 
used and media was changed to DMEM/F-12 after 6 hrs. Cells were cultured to 
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express protein for maximum 48h as 293T cell viability decreases rapidly in serum 
free media. 
 
For the transient expression of ps20 protein species in 293T cells to generate 
conditioned media (CM) a multiwell transfection assay was optimised using the 
GeneIn® reagent. The afternoon prior to the day of transfection cells were seeded in 
6 well plates at 4x105/well. The following day, media was replaced. The transfection 
reagents were prepared for each well according to the schema presented in table 2.2 
and incubated together at room temperature for 15 mins. 200μl of each mixture was 
then added dropwise to 293T cells. CM was collected after 48h, clarified, filtered and 
stored at -80⁰C. Where cells where transfected in larger vessels all experimental 
components including, volume of media added, number of cells seeded, and 
quantities of transfection agents used, were scaled up in proportion to the surface 
area of the vessel used. 
 
Table 2.2 Preparation of GeneIn™ for transfection 
optimum to 200μl 
plasmid DNA 2μg 
Blue reagent 8μl 
Red reagent 4μl 
 
2.2.2.10 β-galactosidase activity staining 
 
Cells seeded in 24 well plates were first fixed using 4% PA. The x-gal substrate is 
then added for 24h at 37ᴼC without CO2 before photographing cells using a camera 




2.2.3 Assays using bacterial cells 
 
2.2.3.1 Transformation of Competent Bacteria  
 
Bacteria were thawed on ice and 20μl per condition was added to pre-chilled tubes. 
1-100ng of DNA was added and incubated on ice for 30 mins. Tubes were heat 
shocked for 1 minute at 37⁰C and returned to ice for a further 5 mins. 200μl of SOC 
media was added and bacteria were incubated with agitation at 37⁰C for 1 hour before 
spreading onto agar plates.  
 
2.2.3.2 Bacterial culture  
 
Transformed bacteria were selected by overnight growth on agar plates. Agar plates 
were produced by adding 0.035% (w/v) LB agar to ddH2O water in sterile bottles, 
followed by autoclaving. While still warm, ampicillin was added to a final concentration 
of 100μg/ml. 25mls of molten agar was then added to 10cm dishes, left to solidify, 
and stored at 4⁰C for no more than 2 weeks. Streaking bacteria was performed by 
adding 200ml of bacteria in SOP media to the centre of an agar plate and then 
spreading evenly across the surface using a glass rod. These plates were then 
inverted and incubated over night at 37⁰C. Individual colonies were picked by 
touching with a sterile pipette tip and then placing into a 30ml universal tube 
containing 5mls of LB broth containing 100μg/ml ampicillin. Clones were cultured for 
4-6hours at 37⁰C in a shaker, and then 1ml of selected cultures was transferred to a 
sterile culture flask containing 200mls of LB broth +100μg/ml ampicillin. These flasks 
were cultured overnight. Bacteria was pelleted by centrifugation at 1000g for 20 mins 




2.2.4  Molecular Biology techniques 
 
2.2.4.1 RNA purification 
 
Total RNA was isolated from cell cultures using Qiagen™ RNeasy mini 
(1x105<5x106) kit. Pelleted cells were resuspended in 350ul RLT lysis buffer and 
homogenised using the Qiashredder™ spin column (Qiagen) and DNA removed by 
use of the RNAse-free DNAse set (Qiagen) according to the manufacturer’s 
instructions. Eluted RNA was quantified using a Nanodrop™ spectrophotometer and 
protein contamination determined via the 230:280nm ratio. RNA was either reverse 
transcribed immediately or stored at -80ºC. 
 
2.2.4.2 One step RT-PCR 
 
Following RNA isolation, RT-PCR was performed using the one-step RT-PCR kit 
(Qiagen, UK). The assay used 0.2μg of template RNA and 0.6μM of the relevant 
primer (WFDC1 or GAPDH, MWG Biotech, UK). Q solution supplied with the kit was 
added (10% of total volume) to remove secondary structure in the GC-rich target 
sequence. Primers used to amplify WFDC1 or GAPGH control sequences are shown 
in Table 2.3. Reactions were made up to 50μl with nuclease free water. Amplification 
was performed in an Eppendorf gradient thermocycler (Eppendorf, UK) as follows 
Hotstar Taq initiation at 95⁰C for 15 mins, denaturation at 94⁰C for 30 sec, annealing 
at 56⁰C for 30 sec and extension at 72⁰C for 1 min for 35 cycles, followed by final 
extension at 72⁰C for 10 min. Products were stored at -20⁰C until needed or 





Table 2.3 Primers used in RT-PCR 
 
 
2.2.4.3 Agarose Gel Electrophoresis  
 
Agarose gels were prepared by adding powdered agarose to distilled water, usually 
2% (w/v), and heating for 1min in the microwave. Once melted, 5μl ethidium bromide 
was added per 100mls, and a gel was poured and left at room temperature to solidify. 
Samples were prepared with loading buffer (1:5 ratio) and added to wells. Gels were 
run at 100V until an adequate separation had been achieved and the relevant band 
were excised using a scalpel and a flat UV lamp. 
 
2.2.4.4 Taqman qPCR 
 
200ng-1μg of RNA was reverse transcribed in an Eppendorf™ Mastercycler Gradient 
thermocycler using the High capacity reverse transcription Kit (Applied Biosystems) 
according to the manufacturer’s instructions (RT was primed by random hexamers 
supplied) in a nuclease-free 96-well low profile PCR plate (Thermo, Fischer 
Scientific). cDNA was diluted in 3 volumes of nuclease free H2O (optimal dilution 
determined previously by Dr James Reading) and stored at -20ºC or used directly in 
a qRT-PCR assay. Relative gene expression was performed using commercially 
available Taqman™ gene expression hydrolysis probe sets. The WFDC1 Taqman™ 
gene expression assay was custom designed by submission of a 3’ based amplicon 
(exons 4-6) to the Applied Biosystems Assays-by-Design™ service, using the 
Filebuilder 3.0™ software (Applied Biosystems) with the resulting assay spanning 
WFDC1 Fwd 5’ CGACCTTGACCATCTTTGGA 3’ 
WFDC1 Rev 5’ GCTTACTGAAAGTGCTTCTG 3’ 
GAPDH Fwd 5’ AGGTCGGAGTCAACGGATTTG 3’ 
GAPDH Rev 5’ GTGATGGCATGGACTGTGGT 3’ 
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exon boundaries (>1Kb intronic sequence) to avoid genomic DNA contamination and 
showed results matching previous qRT-PCR and RT-PCR assays described 
previously(Alvarez et al., 2008). Assay sequences FWD: 5’ TCGCCCATCTGCTTGC 
3’, probe 5’ FAM- GAGTCACCTTCTGGATATTCTTTGTAAAGT -NFQ 3’, REV: 5’ 
GTGGGCAGTGCGTCAAG 3’. GAPDH was employed as a reference gene. Previous 
members of the laboratory had optimised the assay using time course gene 
expression studies with an index of multiple reference genes to validate results (β-
actin, GAPDH, HPRT) and the experiments contained within this thesis used GAPDH 
as a reference gene as previous data had suggested this remains most stable under 
various tested treatments. Data analysis was performed using the SDS 2.3 Relative 
quantification software (Applied Biosystems) according to the manufacturer’s 
instructions and the ΔΔCt method of relative quantification (ABI prism 7700 SDS User 
Bulletin 2-Applied Biosystems). However, relative copy number was also calculated 
to assess levels of transcripts using the 2-ΔCt method. Cycling conditions were set 
according to Taqman™ gene expression assays protocol (Applied Biosystems 
catalogue ref: p/n4333458) in a 10ul final volume containing 5ul dilute cDNA, 4.5ul 
Taqman™ universal PCR mix 141 with AMPErase (Applied Biosystems) and 0.5ul 
primer/probe Taqman™ gene expression assay (Applied Biosystems). RT-PCR, no 
template, inter-run calibrating and positive/negative controls were run routinely in a 
384-well optical plate (Applied Biosystems) and optical adhesive film (Applied 
Biosystems). All reactions were set up in UV irradiated Laminar flow hoods 
(Labcaire™).  
 
2.2.5  Generation of Transduced PCa cell lines. 
 
In cloning WFDC1/ps20 we wished to achieve two goals, i) to generate a convenient 
vector for transient expression of ps20 protein species in mammalian cell lines; and 
ii) to generate retroviral particles encoding WFDC1 which can transduce mammalian 
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cell lines to generate novel variant cell lines ectopically secreting ps20. In order to 
serve both these ends we chose to clone the full length and truncated WFDC1 mRNA 
species expressed in HeLa cells, into the pMIGR1-eGFP (pMIGR1) retroviral 
plasmid. pMIGR1 serves as both a mammalian and retroviral expression vector and 
encodes a multiple cloning site (MCS) upstream of enhanced green fluorescent 
protein (eGFP) separated by an internal ribosome entry site IRES. Genes inserted 
into the multiple cloning site undergo 5’ cap-dependent translation independent of the 
eGFP gene which is transcribed independently initiated by the IRES element. 
Consequently the eGFP acts as a reporter of successful retroviral integration and 
gene expression. The schema for cloning of the WFDC1 cDNAs, generation of 
plasmids, viral particles and transduction of cells is presented in fig. 2.1. 
 
2.2.5.1 Amplification and Cloning of WFDC1 cDNA 
 
mRNA was extracted form HeLa cells and RT-PCR using WFDC1 specific primers 
(table 2.4) performed and the resulting product run on a 2% agarose gel. Two WFDC1 
cDNAs were amplified, one representing the full length 660bp sequence, and one a 
truncated variant lacking exon3, a total of 576bp. Both species were excised from the 
gel and extracted using the gel extraction kit according to the manufacturer’s 
instructions (Qiagen). These species were then amplified by PCR using a Phusion 
polymerase for improved fidelity and using primers adding Xho1 and EcoRI 
sequences to the 3’ and 5’ ends respectively and shown in table 2.4. The products of 
each reaction were again run out on a 2% agarose gel and the single band in each 
lane excised and extracted as before. These products were combined in individual 
aliquots with Xho1 and EcoRI and the relevant buffer in a digest reaction at 37⁰C for 
2h, as outlined in table 2.2 simultaneously, pMIGR1 was digested with the same 
restriction endonucleases to linearize the vector and generate the appropriate 










Table 2.5 Constituents of endonuclease digest reaction 
Either pMIGR1  1μg 
or ps20 cDNA 18μl 
Xho1 0.5μl 
EcoR1 0.5μl 




primer direction primer sequence 
Fwd (XhoI) 5’-ATATATACTCGAGGCATGCCTTTCCGGC-3’ 




Figure 2.2 Schematic or cloning WFDC1 and generating ps20 expressing cells 
 
The schematic above outlines the sequence of steps undertaken to amplify and clone 
WFDC1 from HeLa cells, generate infectious MLV virions, and transduce target cells with 




Following digestion, the cleaved WFDC1 cDNAs and pMIGR1 were run on a 2% 
agarose gels, excised, and extracted. Again the nanodrop was used to obtain the 
amount of digested plasmids and ps20 cDNA obtained from the extraction prior to 
ligation. In order to insert the ps20 cDNAs into the linear plasmid ligation reactions 
were then set up as outlined in table 2.6 and incubated at RT for 2h. 
 
Table 2.6 Constituents of ligation reaction 
digested pMIGR1 50ng 
ps20 cDNA 20ng 
T4 ligase 0.5μl 
10x T4 ligation buffer 1μl 
ddH2O to 10μl 
 
 
Subsequently, in each instance 2μl of each ligation reaction was then transformed 
into competent bacteria and colonies selected by overnight culture on ampicillin 
containing agar. Colonies were picked at random and grown in 5mls of LB broth. 
Minipreps were performed and samples were then digested with Xho1 and EcoR1 
and run on a gel to identify WFDC1 containing clones. Two were selected, grown in 
200mls of LB broth and a maxiprep prepared. A small amount was sent for 
sequencing using the primers indicated in table 2.3 to confirm the fidelity of the 
WFDC1 insert. 
 
2.2.5.2 Expression in 293T cells  
 
To confirm that we had generated vectors capable of expressing ps20 we transfected 
293T cells with pMIGR1 containing ps20 full length and truncated cDNAs, named 
ps20FL and ps20TR respectively, or an empty vector (EV) according to the standard 
transfection protocol described in section 2.2.2.  
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2.2.5.3 Generation of retroviral particles. 
 
Retroviral particles were produced using 293T cells transfected to express viral 
components. 293T cells were seeded at 4x105 cells in 6 well plates 16h prior to 
transfection. The following day each well was transfected with the constituents listed 
in table 2.7 including either the MIGR1-EV, MIGR1ps20FL or MIGR1ps20TR plasmid. 
DNA and PEI were added to the optimum medium briefly vortexed and incubated at 
room temperature for 20 mins. The mixture was then added drop-wise to individual 
wells containing fresh complete media. After 6h the complete media was changed. 
Following this, cells were incubated for 48h to express virus which was then collected, 
clarified by centrifugation, aliquoted and stored at -80⁰C. 
 
Table 2.7 Transfection reaction constituents for retroviral particle generation 







2.2.5.4 Transduction / Sorting of eGFP+ transduced cells. 
 
Target cells (WPMY-1, PC-3, and DU145) were plated to 50% confluency in 6 well 
plates. Virus was added 1:1 with complete media. After 48h, media was changed and 
virus was added again at 1:1 with complete media+10% FCS. After a further 48h cells 
were viewed under a fluorescence microscope to confirm the expression of eGFP. 
Cells were then harvested using TrypLE™ as described in section 2.2.1, washed in 




Figure 2.3 Sorting of eGFP+ve transduced cells 
Figure shows a representative cell sorting experiment following transduction with ps20 
encoding retroviral particles. A) Shows gating for viable cells using forward and side scatter 
parameters. B) Shows eGFP+ transduced populations that were sorted from parental WPMY-
1 cells. (Cell sorting was performed by Tom Hayday of the Programme in Infection & Immunity 
Flow Cytometry Facility.) 
WPMY-1 ps20FL 




for cells expressing high levels of eGFP using a FACS Aria™ (BD Biosciences). 2000 
cells were sorted from each condition into a 12 well plate. These cells were then 
grown out to confluency over 2-3 weeks. Once 80-90% confluent, cells were passage 
into 10cm culture dishes and expanded again. Cell stocks were made by 
cryopreservation as described.   
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2.2.6 Biochemical Assays 
 
2.2.6.1 Ps20 Enzyme Linked Immunosorbant Assay (ELISA) 
 
96-well flat bottom ELISA plates were used for ELISA assays. Three washes with 
200μl wash buffer were performed at each wash stage. Plates were coated with anti 
ps20 rabbit polyclonal antibody 5301(see Section 2.1.4) at 8μg/ml. Ab stock was 
dissolved in 11 ml PBS and 100μl of Ab solution was dispensed into each well and 
the plate covered with an adhesive sheet and incubated overnight at 4⁰C.  All 
subsequent incubation were conducted at room temperature. The following day 
contents were ejected into a waste receptacle and the plate blotted by banging on 
tissue paper to ensure complete removal of excess fluid. Blocking was then 
performed by placing 200μl blocking buffer to each well followed by incubation for 2h 
at RT. After washing 100μl of samples were incubated for 2h. After sample 
incubation, plates were washed. Detection antibody solution was prepared: clone 
1G7 pre-conjugated to horseradish peroxide (HRP) was diluted to a concentration of 
3.7μg/ml in AB binding buffer. 100μl was added to each well and incubated for 2 h. 
Plates were then washed and incubated with 150μl of substrate buffer (Sigma fast 
OPD, Sigma Aldrich) in the dark. Colour development (yellow to orange) was allowed 
to proceed and the reaction stopped at 30 minutes. Reactions were stopped by 
addition of 25μl 4M H2SO4 to each well. Following agitation for 5secs colourimetric 
reading was performed at 490nm using a colorimetric plate reader (Biorad, USA). 
Analysis was performed using Graphpad Prism® 4.  
 
In order to extrapolate the concentrations of ps20 within sample using the ps20 
ELISA, in every assay a standard of known concentration was prepared using ps20-
GST (Proteintech). Ps20-GST was incubated starting at 50ng/ml with serial ½ 
dilutions titrated across 8 wells. An average of ps20-GST standard curves from 6 
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ELISA assays are shown in fig. 2.3. From the standard curve within each ELISA the 
concentrations of ps20 in samples was calculated using the following equation. 
 
 
Figure 2.4 ps20-GST Standard curve 




2.2.6.2 ProcartaPlex™ Multiplex Immunoassay (performed by Sangmi Kim) 
 
ProcartaPlex™ Immunoassays use multi-analyte profiling beads to enable the 
detection and quantitation of multiple protein targets simultaneously in samples such 
as CM using fluorescent-dyed beads with dual-laser design and digital signal 
processing using luminex instruments. 
 
All buffers provided were prepared by dilution with recommended volume of ddH2O.  
Individual target standards were prepared by 4-fold serial dilution of the standard mix.  
Antibody magnetic beads were vortexed and 50μL added to each well. 96-well flat 





















bottom plate was inserted into the hand-held magnetic washer to prevent loss of 
magnetic beads washed with 150μL of wash buffer. At each step 30secs was left for 
beads to accumulate on the magnetic surface of the plate. Wash Buffer was removed 
by inverting the plate/magnetic washer over a sink and blotted on tissue. 50μl of 
standard or CM was added to each well and the plate was removed from magnetic 
washer and incubated for 2h with agitation followed by washing as described. 
Detection antibody mixture was prepared according to the manufacturer’s instruction 
and 25μl added into each well. The plate was then sealed, the magnetic washer 
removed and the plate incubated for 30 min at RT with agitation. Following washing 
50μL of streptavidin-PE solution was added into each well and the plate was again 
incubated for 30 mins at RT with agitation. 
 
For analysis 120μL of reading buffer was added into each well and the plate shaken 
for 5 min at RT and the plate analysed using a luminex instrument.  Data analysis 
was performed using ProcartaPlex™ analyst software and standard curve generated 




For electrophoretic separation of proteins the sodium docecyl-sulfate – 
polyacrylamide-gel electrophoresis (SDS-PAGE) technique was employed. 12% Bis-
Tris NuPage™ pre-made gels were used (Invitrogen Life Sciences). Gels were 
loaded into the XCell SureLock® Mini-Cell gel tank (Novex, Invitrogen Life 
Technologies) and the tank filled with MOPS SDS loading buffer (Novex, Life 
Technologies). Samples to be electrophoresed (e.g. recombinant protein, serum free 
conditioned medium or cell lysates) were diluted to an appropriate concentration in a 
suitable diluent (e.g PBS or lysis buffer) and then NuPage™ LDS loading buffer was 
added alongside NuPage™ reducing reagent (Both Life Technologies). These 
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ingredients were compiled in the following ratio: sample:LDS-buffer:reducing agent – 
15:5:2. Samples were then boiled for at least 5 mins at 85⁰C and then briefly 
centrifuged to remove evaporated liquid from the top of the tube. If 15 well gels were 
used, 12μl of sample were loaded with gel loading tips, if larger combed gels were 
used an increased amount of sample would be loaded. A 7-177kDa pre-stained 
protein ladder (New England, Biolabs) was loaded alongside samples. 
Electrophoresis was at 180V on ice for 1h. 
 
2.2.6.4 Silver Stain 
 
Silver staining for total protein was performed using the SilverXpress® Silver Staining 
Kit (Invitrogen Life Technologies) which contains a number of premade solutions. The 
primary reagents contained within these solutions is indicated where advised. 
Staining was conducted in a plastic lid or tray washed carefully to avoid keratin 
contamination, and with gentle agitation. At each step solutions were poured into and 
decanted from the tray after the appropriate incubation time and washes were with 
50mls ddH2O. Following electrophoresis, gels were placed in tray and fixed in 50mls 
10% Acetic acid, 40% ddH2O, 50% MEOH for 30-60 mins. Gels were then treated with 
sensitizing solution (containing gluteraldehyde) twice for 5 mins each following by 
washing twice. Gels were then stained with a 1:1 mixture of solution A (containing 
silver nitrate) and solution B (Containing ammonium hydroxide & sodium hydroxide) 
for 10 mins followed by washing twice. Gels were then incubated with developing 
solution (containing formaldehyde and citric acid). The reaction was stopped after 
appropriate time with stopper solution for 5 mins (containing citric acid) followed by 
washing twice. Gels were imaged using a flatbed scanner and presented using 




2.2.6.5 Western Blotting   
 
Electrophoresed samples were transferred to nitrocellulose membranes (Protran, 
Whatman, GE Healthcare) using a wet transfer process. To transfer proteins to gel, 
appropriate sized pieces of membrane and filter paper were cut and pre-soaked in 
transfer buffer (>5 mins). The gel was carefully extracted from its plastic case and 
sandwiched appropriately between the membrane with filter paper either side. The 
sandwich was then loaded into a transfer tank (Biorad) and transferred on ice for 45 
mins at 90Vs. Transfer buffer was stored at 4⁰C and used repeatedly until current 
exceeded 400mA when running at 90V (≈10 times). Following transfer, membranes 
were placed in 50ml falcon tubes and blocked for 30 mins at room temperature on a 
roller with gentle agitation. Following blocking, primary antibodies were diluted in 
blocking buffer at the dilution/concentration indicated in table 2.8. Hybridisation was 
with 5mls of antibody solution for 2h at RT or overnight at 4⁰C on a roller with gentle 
agitation. HRP conjugated secondary antibody was added at 1/2000 in blocking 
buffer and 5mls of antibody solution was hybridized for either for 2h at RT or overnight 
at 4⁰C. Following hybridisation tubes were emptied and wash buffer added. Washing 
was with 10mls and it depended on the antibody being used the number of wash 
steps was altered to give the clearest background to signal ratio following empirical 
testing (e.g anti-ps20-1G7 = 6 washes, anti-actin-C = 2 washes). Following the 
appropriate number of wash steps foil was added to tubes to block light, and 
colourimetric substrate was added (Thermo scientific): 1ml each of reagent A and B 
were used and incubated on a roller for ≈1 min. Membranes were then transferred to 
thin transparent PVC sheet and acquired using the Imagequant™ system (GE 
Healthcare). Images were analysed and presenting using ImageJ software (National 








Table 2.8 Antibody dilutions for western blot 
antibody dilution concentration 
5301 1/1000 5.2μg/ml 
651 1/500 3.2μg/ml 
650 1/500 3.2μg/ml 
1G7 1/1000 3.3μg/ml 
actin-c 1/5000 40ng/ml 
anti-V5 1/2000 25ng/ml 
 
 
2.2.6.6 Heparin binding assay 
 
Heparin binding experiments were performed using the Aktӓ-purifier (GE, 
Healthcare) fast protein liquid chromatography system. 1ml HiTrap™ Heparin coated 
columns were washed with >5 Column volumes (CV) of 50mM Tris-HCL buffer 
(pH7.5). 2mls of 293 generated ps20 CM were then loaded onto the column and 
further 5 CVs of buffer used to wash away unbound material. A NaCl gradient was 
then applied to the column over 10 CV taking the NaCl concentration of the buffer 
from 0M to 1M as 1ml fractions were collected. The flow-through, wash and elution 
fractions were then subjected to western blotting to detect ps20.  
 
2.2.6.7 Glycosaminoglycan ELISA 
 
Glycosaminoglycan stocks were prepared in ddH20 at 1mg/ml and subsequently 
diluted to 25μg/ml and coated overnight onto specially prepared ELISA plates in a 
volume of 100μl/well. Blocking was for 2h with 1%BSA in PBS. Ps20V5 was then 
titrated onto the plate in doubling dilutions and incubated for 2h prior to washing with 
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PBS. Subsequently anti-V5-HRP diluted in PBS (1/2000) was incubated for 2h, prior 
to washing with PBS and incubation with 100μl of TMB ELISA substrate. Reaction 
was stopped after 15 mins with 50μl H2SO4 4M and the plate read with a biorad 
colourimetric reader at 450nm. 
 
2.2.6.8 Transglutaminase cross-linking assay 
 
Tissue transglutaminase (TG) from guinea pig liver (Sigma Aldrich) was re-solubilised 
in ddH2O, to a concentration of 2U/ml and stored at -80⁰C. All experiments were 
conducted in 1.8ml Eppendorf tubes. Prior to experiments ps20 was dialysed into 
buffer containing 50mM Tris-HCl pH8 as transglutaminase-mediated transamidation 
is a calcium dependent reaction and calcium is precipitated out of solution in 
phosphate containing buffers. Samples of ps20 were prepared according to 
conditions described in individual experiments. Calcium was then added from a 1M 
stock of calcium chloride (Sigma Aldrich) to a final concentration of 10mM. DTT 
(sigma Aldrich) was added from a 1M stock to a final concentration of 5mM. To cross 
link ps20, TG was added at a final concentration of 0.1U/ml to samples and incubated 
between 5 mins and 3h at 37⁰C. Transamination was stopped by adding western blot 
loading buffer (NuPage™ LDS loading buffer + NuPage™ reducing reagent, as 
described). Sampled were frozen at -20⁰C or immediately analysed by 
electrophoresis and western blotting. 
 
2.2.6.9 Transglutaminase cross-linking ELISA 
 
Fibronectin at 1μl/ml or 1% BSA was coated onto nunc 96 well plates overnight at 
4⁰C. Blocking was with 1% BSA for 2h at RT. Samples containing 10mM CaCl2, 4mM 
DTT in pH7.5 50mM TRIS were added to wells. Ps20 was added at 25ng/ml or 5ng/ml 
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and TG was added at 0.2U/ml. Incubation was at 37⁰C for 2h. Plates were washed 
3x with 200μl wash buffer as per the regular ps20 ELISA. Detection antibody solution 
was prepared: clone 1G7 pre-conjugated to HRP was diluted to a concentration of 
3.7μg/ml in Ab binding buffer and 100μl was added to each well and incubated for 
2h. Plates were then washed 3x and incubated with 150μl of substrate buffer (Sigma 
fast OPD) in the dark. Colour development (yellow to orange) was allowed to proceed 
and the reaction stopped at 30 minutes. Reactions were stopped by addition of 25μl 
4M H2SO4 to each well. Following agitation for 5secs colourimetric reading was 
performed at 490nm using a colorimetric plate reader (Biorad, USA). 
 
2.2.6.10 Cleavage of ps20 by cathepsin L / B 
 
Cathepsin L or B (both R&D systems) were resolubilised in PBS at a final 
concentration of 40μg/ml and 10μg/ml respectively, and stored at -20⁰C. For 
individual experiments, proteases were diluted in 50mM MES buffer to working 
concentrations of 800pg/ml and incubated with a molar excess of 293T purified ps20 
in 50mM MES buffer + 4mM DTT for 1 hour at 37⁰C according to the specific 
experimental conditions described. Reactions were stopped by addition of western 
blot loading buffer and samples were analysed by western blotting as described. For 
modified ELISA assay, cathepsin L was prepared in 50mM MES+ 4mM DTT and 
added to ELISA plate following TG crosslinking step for 2h at 37⁰C prior to washing 
and detection as described (the plate was read at 490nm). 
 
2.2.6.11 Ps20 depletion from WPMY-1 CM using antibody conjugated beads. 
 
Antibodies (5B9, 1G7 or IgG1 control) were conjugated to HiTrap NHS-activated 
columns as described below. Beads were liberated from individual columns using a 
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scalpel and resuspended in 1ml of 20% ETOH and stored at 4⁰C until used. Before 
use, beads were centrifuged and ETOH aspirated, followed by washing 3 times with 
5mls sterile PBS. After washing, beads were resuspended in 1ml of sterile PBS. 
Depletion of ps20 from WPMY-1 CM was performed by addition of 100μl beads to 
1ml of CM with incubation at 4⁰C for 1 hour with agitation. Beads were pelleted by 
centrifugation and CM aspirated and used for cellular assays and the ps20 ELISA to 
confirm ps20 depletion.  
 
2.2.6 Purification of ps20  
 
2.2.6.1 Preparation of HiTrap™ NHS-activated columns. 
 
HiTrap™ NHS activated columns are sepharose bead based pre-packed columns 
which provide a matrix for the conjugation for molecules such as antibodies and 
peptides via primary amines. The sepharose beads are coated with N-
hydroxysuccinimide (NHS) ester attached by epichloro-hydrine via a 6-atom spacer 
arm. The esterification leads to the formation of activated esters, which react rapidly 
and efficiently with ligands containing amino groups resulting in a very stable amide 
linkage.  In the first instance the isopropanol storage solution is washed out with 1ml 
of ice cold 1mM HCL solution. Then 1mg of antibody (IG7, 5B9 or Mouse IgG1 
control) was injected in the presence of bicarbonate buffer, pH 9, and incubated at 
RT for 30 mins. The uncoupled ester groups are then inactivated with 5 column 
volumes of Buffer A (table 2.9), 5 columns of buffer B and a further 5 column volumes 
of buffer A. The column was left to stand for 30 minutes before the wash was repeated 
in the order buffer B, Buffer A, Buffer B. The columns were stored in 20% ethanol at 





Table 2.9 Buffers used for HiTrap column conjugation 
Buffer A 0.5 M ethanolamine, 0.5 M NaCl, pH 8.3 
Buffer B 0.1 M acetate, 0.5 M NaCl, pH 4 
 
 
2.2.6.2 Purification of ps20 from HeLa cells (performed by eurogentech) 
 
 HeLa cells were ‘weaned’ onto a chemically defined protein media formulation 
(SFM4CHO utility; Hyclone cat # SH30516.02) and cultured in roller bottles with 
harvesting at 72h. EDTA (10mM) was added to clarified harvested supernatant which 
was then concentrated by approximately 10 fold using a tangential cross flow filtration 
unit (Vivaflow 200, 5kDa MWCO PES). Concentrated, clarified harvests were purified 
by application to an IG7 affinity matrix (IG7 monoclonal antibody amino coupled to 
NHS activated Sepharose Fastflow). Binding of ps20 was performed in 25mM Tris 
HCl/150mM NaCl ph7.2 at a flow rate of 1ml/min. Following sample loading, the resin 
was washed with 10 column volumes of binding buffer to return to baseline.  Elution 
of ps20 was with 0.1M glycine pH3.  Although this elution method worked once the 
yield was deemed too low on a subsequent purification.  More recently 0.2M glycine 
pH2.0 has been used with a projected better yield.  The complete elution peak was 
collected and neutralised immediately with 1M Tris pH9.   
 
2.2.6.3 Purification of ps20 from transfected 293T and 293F cells. 
 
Batches of 293T and 293F cell CM containing ectopically expressed ps20 were 
purified using 1G7 activated 1ml or 5ml HiTrap™ columns to produce highly 
enriched/purified ps20 protein. A number of batches were produced throughout the 
study and are specifically alluded to in the chapter 3, but the method was the same 
throughout. The volume of serum free CM was collected from the ps20 expressing 
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cells, clarified by centrifugation >1000g for 10 mins, and filtered through a 0.2μM filter 
using either a syringe filter of filtration unit. The filtered CM was then fed onto a PBS 
washed column at <0.5ml/min at 4⁰C. Once loaded, the column was washed with at 
least 5 volumes of PBS and then eluted with 5 column volumes of 0.2M Glycine buffer 
pH2.3. Fractions of 1ml (1ml columns) or 5ml (5ml columns) were collected and 5% 
v/v 1M Tris buffer added to pH buffer the solution. Fractions were then dialysed 
against 50mM TRIS buffer overnight at 4⁰C using snakeskin tubing. Ps20 high 
fractions were pooled and stored at -80⁰C.  
 
2.2.6.5 Expression and purification of ps20V5 in drosophila cells (performed by 
eurogentech) 
 
A batch of ps20 produced from drosophila cells was used for numerous experiments 
in this thesis. The vector was produced by a previous lab member and the protein 
expressed and purified by (both as described below). Due to the use of the V5 tag in 
the proteins detection by western blot, this batch of ps20 heretofore referred to as 
ps20V5 
  
The Drosophila expression system (Invitrogen) was used to express a V5-His-tagged 
human ps20 protein in Schneider 2 (S2) cells (Invitrogen) in a copper-inducible 
manner. The pMT/Bip/V5-His/ps20 vector and pCoHYGRO (Invitrogen) at a ratio of 
19:1 were transfected into S2 cells with a CaPO4 transfection kit (Invitrogen) following 
the manufacturer's protocol. Stably transfected S2-ps20-V5-His cells were selected 
in complete drosophila expression system medium containing 300 μg/ml of 
hygromycin B for 3 weeks, and the culture medium was switched stepwise to ultimate 
insect serum-free medium containing 300 μg/ml of hygromycin B. The stable S2-
ps20-V5-His cells were then cultured in suspension. When cell density reached 2 × 
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106 cells/ml, 500μM CuSO4 was added to induce rps20-V5-His protein expression 
driven by the Drosophila metallothionein promoter, as confirmed by Western blotting 
with the anti-V5 Ab. For human rps20-V5-His protein purification, 500 ml of CM from 
CuSO4-induced S2-ps20-V5-His cells was collected, centrifuged to remove S2 cells, 
and concentrated 10 times by using the Amicon stirred ultrafiltration cell model 8400 
(Millipore, Bedford MA) with a 5-kDa cut-off membrane, followed by dialysis against 
Tris-HCl buffer (20mM Tris-HCl, 15mM NaCl, pH 7.6) at 4°C. The sample was then 
loaded slowly onto a Tris-HCl buffer-balanced Ni-nitrilotriacetic acid column. After 
loading, the column was washed extensively with Tris-HCl buffer with 20mM 
imidazole and 40mM imidazole. The rps20-V5-His protein was eluted with 20mM Tris-
HCl, 150mM NaCl, pH 7.6, with 250 mM imidazole. The protein was then dialyzed 
against 20 mM Tris-HCl, 150 mM NaCl, pH 7.6, and concentrated to around 1mg/ml 
by using Amicon Ultra-4 (Millipore). The protein concentration was measured using 









In the original purification of ps20, published by David Rowley’s lab in the mid-
nineties, they used litres of conditioned media (CM) generated from rat urogenital-
sinus mesenchymal cells and a complex series of cation-exchange, size exclusion, 
and high pressure liquid chromatography techniques to purify a small amount of ps20 
to homogeneity. In so doing they were able to isolate the novel protein species, 
identify the sequence, and confirm it as the active growth inhibitory molecule in the 
suppressive CM from the cells they had been studying. They subsequently cloned 
the mRNAs and used these cDNAs to express and conduct further in vitro and in vivo 
studies. 
 
In a collaboration between our lab and David Rowley’s a ps20-V5-His tagged protein 
was generated, purified using a nickel-chelate column, and used to inoculate mice in 
order to generate a monoclonal antibody to ps20. This antibody, termed 1G7 (table 
3.1), has been used in several studies to visualize ps20 by western blotting, and in 
order to assess expression of ps20 immunohistochemically in mouse and human 
samples. However, no further published data has emerged using either the untagged 
rat ps20, or the v5-his tagged ps20 subsequently generated in order to study ps20 
function. Indeed, experiments in our lab have suggested this tagged ps20 is not 
functionally active.  
 
Other studies, including in our own lab have used cellular overexpression of ps20 in 
order to study its function. Specifically, Madar et al, expressed WFDC1/ps20 in 
fibroblasts showing reduced growth rates in ps20 expressing cells (Madar et al., 
2009), while Lui et al over expressed WFDC1 in melanoma cells (Liu et al., 2009). 
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Neither lab assess successful overexpression of ps20 at the protein level. To my 
knowledge, our lab was the first to generate a cell line stably expressing 
WFDC1/ps20, in order to study the effect of ps20 on the adhesion of T cells and the 
subsequent effects on the cell-to-cell transmission of HIV virions, Alvarez et al 
constructed a Lentiviral-WFDC1 construct, subsequently transducing Jurkat cells 
(Alvarez et al., 2008).  
 
In this chapter I present a series of novel tools critical to interrogating ps20 
functionality: i) A panel of in house antibodies used within this thesis, ii) I demonstrate 
a novel technique for purifying ps20 to near homogeneity using immunoaffinity to the 
1G7 antibody, iii) I present data showing the cloning of two WFDC1 mRNAs known 
to be expressed in prostate cancer cells into retroviral vectors co-expressing eGFP 






3.2.1 Characterization of anti-ps20 antibodies. 
 
Several antibodies to ps20 have been raised. Figure 3.1A shows the AA sequence 
of ps20. Underlined are the binding sites of a series of antibodies our lab has raised 
against the molecule, Listed in table 3.1 Rabbit polyclonal antibodies were previously 
raised and purified against peptides based on sequences taken from N- and C-
terminal regions of the ps20. In addition we use the 1G7 mouse monoclonal raised 
against a recombinant ps20 molecule as described previously (Alvarez et al., 2008) 
and used for western blotting and immunohistochemistry. The hybridomas of this 
mouse antibody were kindly donated to our lab and since then IG7 has been 
conjugated to horseradish peroxidase for use as the detection antibody in a ps20 
ELISA.  In addition, we used a mouse monoclonal Ab5B9, raised to the C-terminus 
peptide by eurogentech. All antibodies used were optimized for use in an anti-ps20 
western blot, and shown to bind to ps20 at the predicted molecular weight.   
 
3.2.2 Use of immunoaffinity columns to purify ps20 from conditioned media. 
 
Previously, ps20 was purified by nickel chelate chromatography via a C-terminal HIS 
tag. However, previous reports have shown that this material was not functional. Our 
lab also undertook expression of HIS tagged ps20, and previous lab members cloned 
the WFDC1 full length (FL) mRNA into the pMT-V5-His vector for expression in the 
SH2 drosophila cell system. Expression and purification of the resulting material 
yielded variable results. The first small batch was highly pure and is used in Chapter 
4 of this thesis in numerous biochemical characterization experiments. However, 
subsequent attempts to purify the ps20V5His material yielded highly impure material, 















Figure 3.1 Epitopes and specificity of anti-ps20 antibodies 
Figure 3.1. Epitopes and specificity of anti-ps20 antibodies A) Emboldened residues 
highlight the secretion signal peptide sequence and the arrowhead indicates the predicted 
thrombin cleavage site. B) Western blotting of ps20-V5-His with anti-ps20 antibodies, 
under reduced and non-reduced (aV5 and 5031), or reduced conditions (651, 5B9, 1G7, 
650). 
 
        10          20          30          40  
MPLTGVGPGS  CRRQIIRALC  LLLLLLHAGS  AKNIWKRALP  
        50          60          70          80  
ARLAEKSRAE  EAGAPGGPRQ  PRADRCPPPP  RTLPPGACQA 
        90         100         110         120 
ARCQADSECP  RHRRCCYNGC  AYACLEAVPP  PPVLDWLVQP 
       130         140         150         160  
KPRWLGGNGW  LLDGPEEVLQ  AEACSTTEDG  AEPLLCPSGY 
       170         180         190         200                                      
ECHILSPGDV  AEGIPNRGQC  VKQRRQADGR  ILRHKLYKEY 
       210         220 




Table 3.1 Epitopes of ps20 binding antibodies 
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large range of immunoreactive ps20 species, likely representing oligomers of ps20 
or stable complexes with other proteins (appendix fig. 8.1 A and B). Because of these 
difficulties we developed a novel purification system based on immune-affinity 
purification with anti-ps20 antibodies. Previous work within our lab had shown that 
293T cells could be effectively transfected with a pBK-WFDC1 vector and yielded 
good expression of ps20 as a result. As such we decided to use the freestyle 293F™ 
expression system, comprising a suspension adapted 293T derived cell line, 
combined with transient transfection. The schematic shown in fig. 3.2 demonstrates 
the approach to purification. 293F cells are seeded in conical flasks in specialised 
serum free media and cells are transfected. 72h later CM is collected, clarified by 
centrifugation and filtration (0.2µM) and added to a NHS-sepharose column 
previously conjugated to anti-ps20.  
 
Figure 3.2 Schema for the immunoaffinity purification of ps20 
Figure 3.2 Schema for the immunoaffinity purification of ps20. 
293 cells are transfected with the pBK-WFDC1 plasmid for 72h. Conditioned media is 
collected and following clarification, added to an anti-ps20 column. Following elution, 
material is pH neutralised using 1M Tris-HCl buffer and dialysed overnight into PBS.  
1M Tris-HCl buffer 
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In order to optimize the expression of ps20 in the system outlined, we performed a 
time course transfection of 293F cells using Lipofectamine or PEI on 293F cells 
cultured in a 30ml vessels (fig 3.3). Surprisingly PEI yielded higher ps20 expression 
than the more expensive lipofectamine reagent. As such, we decided to use a 72h 
transfection with PEI to express ps20 in 293F cells for purification. 
293F ps20 expression




















Figure 3.3 Optimisation of 293F™ cell transfection 
Figure 3.3 Optimisation of 293F™ cell transfection 
293F cells were seeded in 24 well plates at 6x104 cell/well. Cells were treated with the 
indicated formulation of reagent and incubated on a rotation platform for 72h. CM were 
assayed in the 651-1G7-HRP ELISA as described in materials and methods (the plate was 
read at 490nm).  
 
3.2.3 Purification of ps20 from conditioned media using anti-ps20 
immunoaffinity chromatography. 
 
To test the hypothesis that anti-ps20 immunoglobins conjugated to NHS activated-
sepharose columns could generate pure ps20 we prepared two columns. Each 
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column was conjugated to either 1mg of 1G7 or 5B9 antibody as described in 
materials and methods. Subsequently, two batches of 90ml of CM was generated as 
described above using the 293F cells. One batch of CM was absorbed to each 
column followed by washing, and ps20 was eluted as described in materials and 
methods. Significant fractions, including the loading material, the flow-through, the 
wash fraction, and the final eluted material were subjected to SDS-PAGE followed by 
a silver stain or an anti-ps20 western blot (fig. 3.4A and B). Both experiments results 
yielded significantly enriched ps20 as demonstrated in table 3.2. However, there 
appeared to be more non-ps20 species resolved in the eluted fraction in material 
purified using a 5B9 column (fig 3.4B). Given that the yields were so similar. It was 
decided that the 1G7 column represented a better tool for purification given the 
comparable yield and the reduced number of contaminating species present. 
 
Table 3.2 Yield of ps20 purified from immunoaffinity columns 
Column: 5B9 1G7 
Conditioned media [ng/ml] 32.456 [1.35nM] 35.198 [1.46nM] 
Eluate [ng/ml] 509.245 [21.22nM] 534.481 [22.27nM] 
Yield (%) 87.168 84.361 
 
Previous reports have indicated that purified ps20 is functionally active down to a 
concentration of 7.3nM (Larsen et al., 1998). Consequently, in order to produce a 
batch of ps20 concentrated enough for functional assays ps20 at least 10x as 
concentrated (70nM) would be required. In order to generate enough ps20 for 
functional testing we therefore transfected 20 x 30ml flasks of 293F cells with pBK-
WFDC1 and collection the CM. This CM (≈600mls) was absorbed onto a 5ml NHS 
activated sepharose column conjugated to 1G7. The eluate was collected as before 




Figure 3.4 Purification of ps20 from CM using1G7 and 5B9 columns 
 
Figure 3.4 Purification of ps20 from CM using1G7 and 5B9 columns. 
90mls of clarified CM was loaded onto A) a 1ml 1G7 column or B) a 1ml 5B9 column at 
1ml/min flowrate. Columns were washed with 5 column volumes (CV) of PBS and eluted 
with 5CVs of 0.2M Glycine buffer (pH2.3). Fractions were electrophoresed and silver 
stained or western blotted as indicated. 
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concentrated the eluted material 10x using a 3kDa cut-off centrifugal filter (fig. 3.5). 




Figure 3.5 Purification of ps20 from 600mls of 293F CM 
Figure 3.5 Purification of ps20 from 600mls of 293F CM 
A) 600mls of ps20 was absorbed to a 1G7 column at 1ml/min, washed with 5CVs of PBS 
and eluted with 5CV of elution buffer. Following dialysis, the resulting material was 
concentrated 10x and subjected to SDS-PAGE analysis and silver stained. B) Amino acid 
sequence of ps20 showing the coverage obtained by MS analysis of ps20 peptides. 
 
Ps20293F contained significant purified ps20 corresponding to the predicted MW under 
reduced conditions. However, a significant single contaminating factor was also 







spectrographic analysis. This analysis confirmed the presence of ps20 with good 
coverage of the FL molecule within 15aa of the C-terminus and 5aa of the proposed 
thrombin cleavage site after the N-terminal signal peptide (fig. 3.5B). Sequencing of 
the contaminating higher molecular weight band showed this to be galectin 3 binding 
protein (appendix fig. 8.2).   
 
We next calculated the concentration of the resulting ps20 using two methods. Firstly 
we estimated the concentration using our in house ELISA based on the ps20GST 
standard presented in materials and methods.  The results are presented in Table 
3.3. The binding kinetics of ps20293F are clearly different from ps20GST, making it 
difficult to use the ps20GST in order to establish an accurate concentration. 
 
 
Table 3.3 Results of ELISA quantification of ps20293F 
 
 
Because the material appeared to contain comparable amounts of galectin 3 Binding 
protein and ps20 it was decided that generic protein quantification assays, such as 
bradford staining, would be inappropriate. As such we used a highly pure protein of 
known concentration as ps20 to compare the profile of ps20 on a stained SDS-PAGE 
gel. The chosen protein, transforming growth factor β2 (TGFβ2) is also a secreted 
soluble protein of a similar MW to ps20. Figure 3.6 shows an SDS-PAGE gel stained 
with a fluorescent lumitein stain. Using a typhoon fluorescent scanner (GE healthcare) 
we were able to arbitrary densitometry values of the titrated TGFβ2 sample and plot a 
standard curve. We then titrated ps20293F onto a gel and performed a lumitein stain. The  
ELISA OD dilution Concentration [ng/ml] 
2.9816 10 311.4 
2.1736 100 1445 
0.7876 1000 4070 




Figure 3.6 Calculation of the concentration of ps20293F using TGFB2 as a standard 
Figure 3.6 Calculation of the concentration of ps20293F using TGFB2 as a standard. 
A and B) Indicated concentrations of TGFβ2 (A) and ps20293F (B) were run on SDS-PAGE 
and lumitein stained. C) The densitometric value of neat ps20293F and the corresponding 
concentration predicted from non-linear regression analysis. 
 
resulting densitometric analysis allowed us to predict the concentration of ps20293F 
from the TGFβ2 standard by non-linear regression analysis using prism (fig 3.6B and 
C). The predicted concentration was shown to be 2.03µg/ml. This was a good match 
with the estimated concentration taken from the average of the ELISA values shown 
in table 3.3. As such, we deemed the concentration of ps20293F to be 2µg/ml and it is 




3.2.3 Cloning of WFDC1 from HeLa cells 
 
In order to undertake a functional characterisation of ps20 I decided to make cell lines 
stably expressing ps20. To generate these lines we utilised the MIGR1 plasmid (fig. 
3.7A) originally generated from murine stem cell virus (Pear et al., 1998). This vector 
has the advantage of being able to form infectious retroviral particles when co-
transfected with the VSVg packaging and Gag/Pol capsid plasmids, or can be directly 
transfected into mammalian cell lines for transient expression. It also has the eGFP 
reporter to allow sorting of successfully transduced clones. 
 
We used HeLa cells as the source of WFDC1 mRNA as they has previously reported 
high expression of both the full length and truncated WFDC1 mRNA species. 
Sequencing revealed these mRNA species to encode the FL ps20 aa sequence and 
a 192 aa truncated species lacking exon3, which was previously reported to be 
expressed at low levels by PC-3 and DU145 cells (Watson et al., 2004b). WFDC1 
mRNAs were reverse transcribed and amplified by one-step RT-PCR as described in 
methods (section 2.2.4.2) and presented in fig. 3.7B.  
 
In order to produce sticky ends for ligation into the EcoR1 and Xho1 sites in MIGR1 
we optimized a PCR using a titration of the primers indicated in materials and 
methods (section 2.2.5.1), shown in fig. 3.7C. Once an optimal concentration for 
primers had been achieved, we amplified both FL and TR WFDC1 mRNA species 
(fig. 3.7D). These amplified cDNA species were extracted from the gel and ligated 
into the digested MIGR1 plasmid. Following transformation of JM109 colonies several 
were picked at random. Following minipreps to identify successfully transformed 




Figure 3.7 Generation of cDNAs for expression of WFDC1 in MIGR1 plasmid 
 
Figure 3.7 Generation of cDNAs for expression of WFDC1 in MIGR1 plasmid. A) 
Plasmid map of MIGR1 plasmid. B) RT-PCR showing WFDC1 cDNA species amplified 
from HeLa mRNA run on an agarose gel. C) PCR using EcoR1 and Xho1 WFDC1 primers. 




Figure 3.8A shows the digestion of resulting maxipreps showing the 576bp and 660bp 
TR and FL WFDC1 cDNA species respectively. Both plasmids were sent for 
sequencing as described in materials and methods to confirm fidelity of the WFDC1 
inserts. 1µg of each plasmid was transfected into 293T cells in 6 well plates. 48h later 
images were taken using a fluorescence camera to confirm expression of the MIGR1 
eGFP reporter protein (fig. 3.8B). CM was then collected from individual wells and 
subjected to ps20 ELISA to confirm expression of ps20FL and ps20TR protein species 





Figure 3.8 Characterisation and expression of MIGR1-WFDC1 plasmids 
 
Figure 3.8 Characterisation and expression of MIGR1-WFDC1 plasmids. A) Maxi-
preparations of MIGR1-WFDC1FL and MIGR1-WFDC1TR were digested with EcoR1 and 
Xho1 and run on an agarose gel. B-C) 1µg of MIGR1-WFDC1 plasmids were transiently 
transfected into 239T cells and assessed for eGFP expression (B) and the CM analysed 






To date, the only function of soluble ps20 protein to be identified is as an inhibitor of 
cellular growth, namely in PC-3 and COS-7 cells. Other proposed functions, such as 
the regulation of ICAM-1 (Alvarez et al., 2008), regulation of cellular senescence 
(Madar et al., 2009), induction of angiogenesis (McAlhany et al., 2003) have used 
cellular models overexpressing ps20 to investigate function. As such, in order to 
effectively study the role of ps20 in vitro, an effective means of obtaining purified 
ps20, and of producing WFDC1/ps20 overexpressing cell lines is needed. 
 
Herein I have demonstrated that through transfection of 293F cells, ps20 secretion 
into serum free CM can be induced.  Subsequent immunoaffinity chromatography on 
Ab1G7 and Ab5B9 conjugated media resulted in comparable yields of purified ps20 
around 80%. However, 1G7 purification resulted in a more homogenous material, 
with a sole contaminant identifiable by mass spec (appendix fig. 8.2). This 
contaminant G3BP was found to present at similar levels to ps20, but addition of 
recombinant G3BP to PC-3/WPMY-1 proliferation assays resulted in no 
demonstrable inhibition of cellular growth (appendix fig. 8.3). Given this proliferation 
assay will be our primary readout of ps20 function in the next chapter we considered 
the 1G7 technique and the ps20293F purified thereby to be suitable for downstream 
analysis. The concentration of this protein, determined by a combination of ps20 
ELISA and a SDS-PAGE staining with comparison to a TGFβ2 standard, revealed 
the concentration to be 2μg/ml. Although purification of ps20 to a higher concentration 
would be more optimal in terms of providing sufficient material for extensive 
downstream analysis, larger scale production was beyond the scope of this study. 
Despite this 2μg/ml (83nM) is concentrated enough to treat cells at concentrations 
comparable to that seen in earlier studies of purified ps20 function, i.e. 7.3nM (Larsen 
et al., 1998). 
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Our second approach to studying the function of ps20 was to clone WFDC1 and 
express ps20 in prostate stromal and PCa cells. There are two WFDC1 isotypes 
expressed in the prostate. These comprise a FL length transcript encoding a 660aa 
ps20 molecule. The second is an WFDC1 mRNA species lacking exon3. Notably, 
exon 3 is the most highly conserved region of ps20 with 100% homology between 
humans and insects. Both are expressed in HeLa cells, as confirmed by RT-PCR and 
sequencing using WFDC1 specific primers. It is notable that HeLa cells express high 
levels of ps20, given its role as a growth inhibitor and potential tumour suppressor 
protein. HeLa cells are highly proliferative which is in contrast to data presented by 
Madar et al showing WFDC1 is least expressed by the most proliferative cells within 
a population, suggesting WFDC1 expression is incompatible with high rates of 
cellular proliferation (Madar et al., 2009). However, no mechanistic understanding of 
how ps20 mediates its function is yet known, and given the aberrant genetic and 
functional characteristics of the HeLa cell line (Landry et al., 2013) it is likely an 
inappropriate model for study of ps20 function. HeLa WFDC1 mRNA was 
successfully cloned, and inserted into the MIGR1 expression vector. Transfected 
cells showed high levels of eGFP and ps20 expression. This is the first evidence that 
the uncharacterised exon 3 splice variant mRNA can be translated and secreted. The 
MIGR1-WFDC1 expression vectors will be useful tools in studying the function of both 









 Despite having been first purified 17 years ago, little is known about its biochemical 
properties of ps20 in the context of the wider WFDC family.  In this chapter I attempt 
to address this issue by examining three important biochemical properties of WAPs: 
glycosaminoglycan binding; transglutaminase-induced cross-linking and cathepsin L 
cleavage.   
 
WFDC family members, including SLPI and elafin, lack known cell surface receptors, 
and no means of signalling has been elucidated for any member. While binding to a 
number of cell surface proteins has been observed for SLPI (Py et al., 2009) none of 
these has been linked to cell-intrinsic functionality. Both SLPI and elafin have well 
documented non-cell-intrinsic extracellular functions, such as protease inhibition and 
anti-microbial effects (Moreau et al., 2008) which do not rely on protein-cell 
interactions. However, there is now an abundance of literature demonstrating cellular 
functions, such as the conditioning of monocytes to inhibit T cell proliferation 
(Guerrieri et al., 2011) and the regulation by SLPI of MMP expression in ovarian 
cancer cells (Hoskins et al., 2011). Similarly, knockdown of elafin expression in 
ovarian cancer cells was shown to reduce the susceptibility to apoptosis induction by 
chemotherapeutic agents via the caspase-3 pathway, suggesting elafin is regulating 
this pathway in a cell-intrinsic manner (Wei et al., 2012).  
 
Like SLPI and elafin, ps20 has a number of demonstrated cell-intrinsic functions 
(Alvarez et al., 2008, Madar et al., 2009, Wilson et al., 2014, Rowley et al., 1995), but 
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no interacting proteins have been identified and how ps20 interacts with cells to inhibit 
growth and induce ICAM-1 expression is unknown. Interestingly, both SLPI and elafin 
are known heparin-binding proteins (HBP) (Fath et al., 1998, Guyot et al., 2005b) and 
an inspection of the ps20 peptide sequence shows the presence of two ‘Cardin and 
Weintraub’ glycosaminoglycan (GAG) binding domains (Imberty et al., 2007). These 
linear, sulphated disaccharide chains are ubiquitous at the surface of cells and in the 
ECM where they sequester soluble proteins, facilitate interactions between HBP 
ligands and cognate signalling receptors (Nakamura et al., 2011), binding all known 
chemokines, cytokines, growth factors and many proteases and their inhibitors 
(Handel et al., 2005). There is also now increasing evidence that endocytic uptake of 
proteins may involve proteoglycans (Kobialka et al., 2009, Favretto et al., 2014, 
Gump et al., 2010). SLPI has been shown to elicit immune regulatory functions by 
entering monocytes, translocating to the nucleus and binding DNA. However, the 
mechanism by which this occurs is unknown (Taggart et al., 2005). More recently the 
same phenomenon was observed in neurons, where exogenous fluorescein labelled 
SLPI entered cells and rapidly became localised to the nucleus (Hannila et al., 2013). 
In lieu of known surface receptors, it remains to be seen if WFDC protein-GAG 
interactions are involved in the cell-intrinsic functions, especially those which may 
involve protein internalisation. 
 
In addition to being HBPs, SLPI and elafin have both been shown to interact with 
transglutaminase 2 (TG), a calcium dependent enzyme responsible for protein-
crosslinking of structural polymers and oligomeric protein complexes (Lorand and 
Conrad, 1984). Indeed, a number of secreted signalling factors are functionally 
modulated through the TG dependent formation of higher order multimers (Nishimichi 
et al., 2011, Dierker et al., 2009, Kaartinen et al., 1999). Both SLPI and elafin undergo 
TG mediated crosslinking to the ECM components fibronectin and elastin (Guyot et 
al., 2005b, Baranger et al., 2011) which is thought to tether them within the ECM from 
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where they can perform their protease inhibition and immune-modulatory functions. 
Another characteristic common to WFDC proteins is susceptibility to cleavage by 
cathepsins. Elafin’s function is dependent on the cleavage of pre-elafin (trappin-2) to 
the mature elafin form by one of several proteases including Cathepsins-L and -K 
(Sallenave et al., 1994). Similarly, SLPI has also been shown to be cleaved by 
cathepsins-B, L and S (Taggart et al., 2001). In contrast to elafin, the cleavage of 
SLPI by cathepsins was shown to abrogate the protease inhibitory function of the 
molecule. Cleaved SLPI was found in samples taken from lung epithelia, suggesting 
this cleavage is a physiologically relevant process (Taggart et al., 2001) and may be 
a mechanism for regulating extracellular SLPI activity. This posits TG crosslinking 
and cathepsin cleavage as potential mechanisms for regulating WFDC protein 
function, though the in vivo implications of these processes has not yet been studied. 
 
The interest of our laboratory in studying ps20 was rooted in its potential as a growth 
inhibitor of PCa cells. However, in order to study ps20 effectively, or to utilize ps20 
therapeutically, a far greater understanding of its structure-functional characteristics 
are required. Herein I present data which demonstrates that ps20 undergoes a high 
affinity interaction with GAGs and can interact with cell surfaces in a GAG dependent 
manner. We demonstrate that ps20 growth inhibitory function is regulated by protein 
cleavage and post-translational processing, and that ps20 interacts with both TG and 
cathepsins. We propose this crosslinking, and subsequent cleavage as a mechanism 






4.2.1 Ps20 interacts with Glycosaminoglycans (GAGs) at the cell surface. 
 
Secreted signalling molecules including WFDC family proteins SLPI and elafin have 
a demonstrated affinity for heparin, and GAGs (Imberty et al., 2007, Hoogewerf et al., 
1997, Fath et al., 1998, Guyot et al., 2005b). In order to investigate whether the 
Cardin-Weintraub heparin binding motifs observed in the ps20 amino acid sequence 
conferred the ability to interact with GAGs, we performed heparin-sepharose affinity 
chromatography on CM from 293T cells transfected to express ps20 (fig. 4.1). The 
binding-to and elution of ps20 from a heparin column at between 0.2 and 0.4M NaCl 
indicated that ps20 is able to bind to heparin. Notably, the concentrated 0.5ml eluted 
fractions revealed numerous ps20 protein species of different molecular weights 
(MW).  
 
While physiologically heparin is a heavily sulphated soluble glycosaminoglycan, 
heparan-sulphate and chondroitin sulphates are cell and ECM associated through 
their attachment to core proteoglycans (Hamel et al., 2009). As such, we used a 
modified GAG solid-phase ELISA to assess the in vitro binding affinity of recombinant 
human ps20V5 for these GAGs. Binding curves (fig. 4.2A-C) demonstrate the affinity 
of ps20V5 for physiologically relevant glycosaminoglycans, heparan-sulphate, 
chondroitin sulphate-A, and chondroitin-sulphate-C.  Interestingly, ps20 had notably 
different affinities for different GAG species, with the highest being for heparan-
sulphate, and the lowest being the most widely distributed GAG, chondroitin sulphate. 
Furthermore, all interactions were in the nanomolar range.  We then investigated 
whether ps20 could interact with GAGs present at the cell surface. Fig. 4.2D shows 
293T cells treated with ps20V5 in the presence of absence of soluble heparin. We 




Figure 4.1 Multiple ps20 species bind heparin 
Figure 4.1 Multiple ps20 species bind heparin. 5mls of CM from 293T cells expressing 
pBK-ps20 loaded onto a 1ml heparin column, washed, and bound protein was eluted with 
0-0.5M linear NaCl gradient. Fractions were subjected to western blot with ab1G7.  
 
Figure 4.2 Ps20 binds to solid-phase and cell surface glycosaminoglycans 
Figure 4.2 Ps20 binds to solid-phase and cell surface glycosaminoglycans. (A-C) 
rps20V5 bound to GAG coated ELISA plate and was detected using anti-V5-HRP. (D-E) 
rps20V5 [10μg/ml] was absorbed to 293T cells in presence or absence of heparin (D) or 
following treatment with sodium chlorate (E) before lysates were subjected to WB with anti-






concentration dependent manner by addition of soluble heparin, indicating that ps20 
is undergoing an interaction with cell surface GAGs. To confirm this interaction, we 
treated cells with sodium chlorate prior to treatment with ps20. Sodium chlorate has 
been shown to interrupt the coupling of GAG to the protein core of proteoglycans. 
Fig. 4.2E shows a clear association between ps20V5 and untreated cells. However, 
following treatment with either 20mM or 40mM sodium chlorate this interaction is 
reduced suggesting this interaction is GAG dependent. 
 
4.2.2 Ps20 undergoes post-translation modification into multiple molecular 
forms. 
 
Our heparin binding experiments revealed that ps20 is secreted into CM in numerous 
molecular weight species. Using the ps20293F generated by immunoaffinity purification 
presented in chapter 3 we interrogated the nature of ps20 species present using ps20 
binding antibodies with known binding epitopes. Western blotting with C-and N-
terminal antibodies to ps20 revealed one predominant molecular species of ps20 at 
≈26kDa, with several minor subspecies resolving at lower MW (fig. 4.3A). The 
concentration calculated in Chapter 3 is shown again in table 4.1. Interestingly, we 
observed two immunoreactive minor species at about 22kDa and 16kDa respectively. 
Functional analysis showed that ps20293F induced a >40% inhibition on WPMY-1 cells 
while PC-3 cells were inhibited ≈30%. This is in line with growth inhibitory activity 
seen previously by David Rowley’s lab, in which ps20 inhibited the proliferation of 
PC-3 cells by up to 60% down to a concentration of 7.3nM (Larsen et al., 1998).  
 
In order to compare ps20 secreted from cells transfected with recombinant WFDC1 




Figure 4.3 Functional purified ps20 contains multiple immunoreactive species  
Figure 4.3. Functional purified ps20 contains multiple immunoreactive species. (A) 
ps20293F (diluted 1:100) was subjected to WB with AB3051 and Ab650. (B) PC-3, or 
WPMY-1 cells were treated with 8.3nM ps20293F and growth assessed by  MTS at 72h (C) 
ps20HeLa and 293T CM were subjected to western blot with the indicated antibodies.  
Arrowheads indicate the ps20 FL species, arrows the ps20 TR species, and LMW species 
are indicated with asterisks. (D) PC-3, or WPMY-1 cells were treated with 68pM ps20HeLa 
and growth assessed by MTS at 72h (the plate was read at 490nm).*P<0.05 **P<0.001 by 




media. Figure 4.3C shows purified native secreted ps20 from a suspension culture of  
HeLa cells is shown alongside CM from 293T cells transfected to express ps20, used 
as a positive control (it should be noted that as this CM contained 10% FCS there is 
a large amount of non-specific immuno-reactivity to serum components at 60-70kDa). 
Interestingly, multiple ps20 subspecies were again present and were prominent in 
ps20HeLa. The full-length (FL) ps20 molecule (fig. 4.3C, arrowhead) is present, 
however two lower MW bands (LMW) are prominent. The first at 25kDa recognised 
by both C- and N-terminal antibodies (fig. 4.3C, arrow) has both N-terminal and C-
terminal regions intact. The second at ≈16kDa, is only detected by the C-terminal 
antibody (fig. 4.3C asterisk), suggesting a product of proteolytic cleavage close to the 
N-terminus of the molecule.  Notably both these ps20 subspecies are comparable to 
those LMW species visible in the ps20293F material (fig 4.2A). To establish the 
concentration of the purified ps20, we ps20HeLa using our ps20 ELISA and a ps20-
GST standard of known concentration (table 4.1). We then tested ps20HeLa for 
functional activity. Due to the small amount of material available, a full titration wasn’t 
not possible, however, when added at the highest concentration available ps20HeLa 
induced potent growth inhibition on PC-3 cells and WPMY-1 cells (Fig. 4.3D) but 
which was effective at a concentration 2 logs below those observed with ps20293F (fig. 
4.2C), or reported previously (Larsen et al., 1998). 
 





(based on MW of 
24kDa) 
ps20HeLa 15ng/ml 0.68nM 
ps20293F 2μg/ml 83nM 
ps20FL 190ng/ml 7.9nM 






4.2.3 Ps20 is cleaved by Cathepsin L 
 
Because SLPI and elafin are substrates for proteolytic cleavage by cathepsins we 
investigated the effect of cathepsins B and L on ps20. ps20FL and ps20TR represent 
intact ps20 molecules prior to any post-translational cleavage. As such we cloned, 
expressed (as described in chapter 3) and subsequently purified both FL and TR 
variants, herein called ps20FL and ps20TR (fig 4.4A). Again the concentrations of these 
two ps20 batches were discerned by ELISA (table 4.1) and both were tested in 
WPMY-1 cell growth inhibition assays. Neither were found to have any functional 
activity (not shown). 
 
In a series of assays to test the effect of cathepsins on ps20 we observed that both 
ps20FL and ps20TR were cleaved in a concentration dependent manner when 
incubated with recombinant cathepsin L (fig. 4.4B). A cleavage of 4-6kDa is clearly 
evident from the shift in electrophoretic mobility in the upper panels, probed with the 
N-terminal antibody. This cleavage results in a new distinct protein band indicating a 
discreet cleavage event is taking place. By contrast, the lower panels, probed with 
the C-terminal antibody, reveal the disappearance of ps20 from the blot with 
increasing concentrations of cathepsin L. This indicates that cathepsin L is able to 
efficiently cleave ps20 at a specific point near the C-terminus.  
 
To confirm this, and to test whether native ps20 was subject to cleavage in the same 
way as recombinant ps20FL and ps20TR, material previously purified from HeLa cells 
was subjected cathepsin L under identical conditions (Figure 4.4C). In this sample 
both the FL and TR ps20 species can be seen to be cleaved, as evidenced by the 




Figure 4.4 ps20FL and ps20TR are substrates for C-terminal cleavage by Cathepsin L but not 
Cathepsin B 
Figure 4.4 ps20FL and ps20TR are substrates for C-terminal cleavage by Cathepsin L 
but not Cathepsin B. (A) ps20FL and ps20TR were subjected to western blot with Ab201-
254. (B) 20ng of ps20FL or ps20TR were incubated with an increasing molar ratio of 
cathepsin-L for 1h at 37⁰C. (C) Purified hela-ps20 was subjected to cleavage by an 
increasing molar ratio of cathepsin-L for 1h at 37⁰C. (D)  Ps20FL was incubated with an 
increasing molar ratio of cathepsin-B for 1h at 37⁰C. (B-D) All Samples were 
electrophoresed on 12% gels and resolved by western blotting with C-terminal anti-ps20 
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the N-terminal antibody, and the disappearance of both bands from the bottom panel 
probed with the C-terminal antibody. Together these results suggest that ps20 is a 
substrate for cathepsin L. In contrast, incubation with cathepsin B resulted in no 
apparent cleavage in ps20FL indicating that ps20 is not a substrate of Cathepsin B 
(fig.4.4D).  
 
In order to test the functional effects of C-terminal cleavage of ps20 by cathepsin L, 
we repeated the cathepsin cleavage assay on the highly concentrated batch of 
ps20293F. This batch induced a significant degree of growth suppression especially 
on WPMY-1 cells (fig. 4.3B), and so was suitable to test if cathepsin L cleavage either 
enhanced or abrogated ps20 function. Ps20293F was incubated with cathepsin L as 
described, and subsequently stained for total protein using lumitein (fig. 4.5A). This 
reveals a clear shift in electrophoretic mobility in the predominant FL ps20 band as 
well as in a number of LMW bands, suggesting cathepsin L was able to cleave any 
ps20 species with an intact C-terminus. Interestingly, despite undergoing substantial 
cleavage no change in growth inhibitory function was observed (fig. 4.5B). Taken 
together, these experiments indicate that cathepsin L is unlikely to be involved in i) 
generating functionally active ps20 protein species, or ii) for inactivating the growth 
inhibitory function of ps20 species. 
 
4.2.4 Ps20 is multimerised by transglutaminase  
 
SLPI and elafin are cross-linked to the ECM, likely as a means of regulating their 
function in situ. We investigated the interaction between ps20 and solid phase of TG 
in a modified ELISA. Ps20V5 bound with high affinity to TG with non-linear regression 
indicating a Kd of 6.4nM (Fig. 4.6A). We then assessed the ability of TG to catalyse 
the formation of ps20 HMW multimers. Ps20V5 incubated with TG in the presence of 





Figure 4.5 Cleavage by cathepsin L fails to abrogate the growth suppressive function of ps20293F 
F 
Figure 4.5 Cleavage by cathepsin L fails to abrogate the growth suppressive 
function of ps20293F. (A) Neat ps20293F was incubated with 200ng/ml Cathepsin L or buffer 
for 2h at 37⁰C and subjected to SDS analysis and lumitein stain. (B) 10μl of each ps20 
reaction or indicated controls were added to WPMY-1 cells and proliferation was assayed 
after 72h by addition of MTS (the plate was read at 490nm). The remaining samples were 
subjected to western blot with the indicated antibody. *p<0.05 relative to the condition 
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Figure 4.6 ps20 undergoes transglutaminase mediated multimerisation into higher order 
multimers 
Figure 4.6 ps20 undergoes transglutaminase mediated multimerisation into higher 
order multimers. (A) ps20V5 was titrated in doubling dilutions onto a solid phase of TG. 
Binding was then detected using anti-V5 conjugated to HRP. Baseline was determined by 
binding of ps20 to BSA coated wells at each concentration, and subtracted before non-
linear regression analysis to determine binding kinetics. Curve shows means/SD of three 
experiments in duplicate. (B) To induce crosslinking, ps20V5 was incubated with 0.2U/ml 
TG for the indicated time. Controls containing either cystamine, EDTA or without 
transglutaminase were incubated for 180 mins. Samples were taken into loading buffer 
containing reducing agents and boiled for 5 mins before SDS-PAGE analysis Western 
blotting was with anti-V5. (C) ps20293F at 200ng/ml was incubated with 0.2u/ml TG or buffer 
control for 1h. Samples were taken into loading buffer containing reducing agents and 
boiled for 5 mins before SDS-PAGE analysis and western blotting with the indicated 
antibodies. (D) Peptide sequence of the C-terminus of ps20 with the glutamine residues 
highlighted.  
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approximately 160kDa, and iii) multimers which were too large to migrate into the gel 
(Fig. 4.6B). Addition of the competitive TG inhibitor cystamine, or the chelating agent 
EDTA prevented multimerisation, confirming that this was a TG specific event. 
Together these data indicate imply that TG is able to cross-link ps20 to irreversibly 
form stable high order multimers. Given the presence of the C-terminal tags on the 
ps20V5 protein we sought to confirm the TG dependent multimerisation using 
untagged ps20293F. Fig 4.6C right panel shows multimerisation of ps20293F to a 
predominant ≈150kDa species, and a less distinct species which failed to migrate into 
the gel, suggesting the presence of higher order multimers. Interestingly, the left 
panel shows a blot of the same experiment using a ps20 C-terminal antibody which 
binds the monomeric protein but fails to detect the multimerised forms. The last 15 
amino acids of the ps20 peptide (Fig. 4.6D), against which the C-terminal antibody 
was raised, features three glutamine residues. These are potential substrates for 
transamination by transglutaminase which we hypothesis is why the C-terminal 
epitope is obscured by the cross-linking (fig. 4C left panel). 
 
4.2.5 Ps20 becomes cross-linked to fibronectin and is liberated by cathepsin L 
cleavage. 
 
We then investigated the interaction between ps20 and fibronectin, a component of 
the ECM known to cross link to SLPI and elafin. TG efficiently catalysed cross-linking 
to fibronectin in a modified ELISA assay (Fig. 4.7A), with only a small level of binding 
to fibronectin observed in the absence of TG. In contrast, no interaction was seen 
between ps20 and BSA either in the presence or absence of TG, suggesting the 
crosslinking between fibronectin and ps20 catalysed by TG was a specific interaction. 




Figure 4.7 ps20 undergoes transglutaminase dependent crosslinking fibronectin and is 
liberated by cathepsin L cleavage 
Figure 4.7 ps20 undergoes transglutaminase dependent crosslinking fibronectin 
and is liberated by cathepsin L cleavage. (A) Ps20 at the indicated concentrations was 
incubated with solid-phase of fibronectin or BSA and TG at 0.02U/ml for 2h, followed by 
washing and detection using 1G7-HRP. (B) Purified hela-ps20 was subjected to cleavage 
by an increasing molar ratio of cathepsin L for 1h at 37⁰C then added to buffer containing 
10mM CaCl2 +/- 0.02U/ml TG and incubated for a further hour before being subjected to 
western blot. (C) 25ng/ml ps20FL was incubated with a solid phase of fibronectin or BSA 
+/- 0.02U/ml TG for 2h. Following washing, MES buffer +/- 400ng/ml cathepsin L was 
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by TG was abrogated by cathepsin L, we performed a digestion of ps20 at the C-
terminus by cathepsin L, followed by an incubation with TG to mediate the formation 
of HMW multimers (Fig. 4.7B). Multimerisation is far less apparent in ps20 which has 
been cleaved by cathepsin L, suggesting TG mediated cross-linking involves the poly 
glutamine motif present at the ps20 C-terminus. We then cross-linked ps20 to 
fibronectin followed by a digestion using cathepsin L in order to investigate whether 
cathepsin L cleavage of the C-terminus could liberate the N-terminal portion of the 
molecule. As before, we observed high levels of ps20 cross-linked to fibronectin in 
the presence of TG, but far lower with either solid phase BSA or where TG was absent 
(Fig. 4.7C). Following incubation of crosslinked ps20 with cathepsin L, level of 
detected ps20 is reduced almost to baseline. This indicates that once cross-linked to 






Despite being first isolated 20 years ago and being associated with various 
physiological processes (Larsen et al., 1998, McAlhany et al., 2003, Ressler et al., 
2014, Alvarez et al., 2011, Alvarez et al., 2008, Rogers et al., 2012), ps20 remains 
largely uncharacterised at the protein level. Here we have used SDS-PAGE/western 
blot and ELISA based assays to characterise ps20 as a Cathepsin L and TG 
substrate which is present in multiple endogenous molecular species capable of 
interacting with ECM and cell surface proteoglycans.  
 
We first confirmed that ps20 was a GAG binding factor like family members SLPI and 
elafin (Guyot et al., 2005b, Fath et al., 1998). GAG containing proteoglycans are 
important structural and functional components of the ECM (Imberty et al., 2007) as 
well as being potentially important in mediating cell surface signalling and 
import/export interactions (Poon and Gariepy, 2007). Our experiments demonstrated 
a clear interaction between ps20 from 293T CM and heparin, and ps20V5 showed a 
high affinity interaction with HS, CS-A, and CS-C. Furthermore ps20we shown to bind 
to the cell surface in a GAG dependent manner. This data supports the predicted 
interaction between ps20 based on the presence of two Cardin-Weintraub heparin 
binding motifs (Cardin and Weintraub, 1989). To date this is the first ps20 study to 
have identified possible binding partners or a means of ps20-cellular interaction. GAG 
binding may have important functional implications for WFDC family proteins; SLPI 
has previously been shown to become internalized in monocytes and neurons and 
enter the nucleus (Taggart et al., 2005, Hannila et al., 2013), suggesting the function 
of SLPI at least, and possibly other WFDC family members may be mediated by the 
ability to cross the membrane and interact intracellularly. It has been suggested that 
the cationic nature of SLPI may mediate the observed membrane transduction. 
Likewise, ps20 is relatively cationic protein, with a predicted isoelectric point of 8.3. 
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The mechanism by which proteins, cationic or otherwise, cross the cell membrane is 
still a matter of some debate [26]. There is much evidence from studies with cationic 
proteins/peptide such as HIV-TAT that cell-surface proteoglycans can mediate 
macropinocytotic protein/peptide uptake, possibly through interactions with actin and 
Rac protein (Letoha et al., Lambaerts et al., 2009, Gump et al., 2010). While it was 
beyond the scope of this study, the interaction shown herein between ps20 and GAG 
should be the subject of further investigation, whether as a mechanism by which ps20 
enters the cell in a manner analogous to SLPI, or as a component of a different 
signalling mechanism, such as FGF family proteins, which rely on GAG interactions 
to regulate the binding of their cognate receptors (Coltrini et al., 1993, Kwan et al., 
2001, Yang et al., 2008).   
 
Following purification from HeLa and 293F cells CM, multiple immuno-reactive 
protein species were identified by a panel of anti-ps20 antibodies. These represented 
monomeric full length, monomeric exon 3 truncated, and various putative cleaved 
variants lacking either the N- or C-termini. The presence of ps20 species lacking 
terminal regions of the peptide sequence is strongly suggestive of proteolytic 
cleavage, especially given that only two discreet WFDC1 mRNA isoforms can be 
detected in HeLa cells, the full length transcript, and the truncated variant lacking 
exon 3. Supporting this, the presence of two C- and N-terminal intact protein species 
indicates the translation and secretion of both known WFDC1 mRNA species is taking 
place. The presence of ps20 species lacking either N- or C- termini however, 
suggests that HeLa cells are also expressing proteins that are able to cleave ps20. 
Interestingly, ps20HeLa had growth suppressive activity comparable to ps20293F at a 2 
fold lower concentration. This led us to speculate that it may be one of the cleaved 
ps20 species that was functionally active. In should be noted that due to the 
configuration of the antibodies used in the ps20 ELISA, at the C-terminus and WFDC 
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domain, some LMW ps20 species may not be detectable, meaning the concentration 
of ps20HeLa generated by ELISA may not be accurate 
 
SLPI and elafin are both substrates of cathepsins (Guyot et al., 2005a, Taggart et al., 
2001), cleavage by which respectively inactivates, and activates the protease 
inhibitory function of these molecules. Herein we show Cathepsin L cleaves both 
ps20FL and ps20TR at the C-terminus, resulting in a change in MW of ≈4-6kDa, which 
we predict to result from a cleavage of around 30aa (fig. 4.4B). In contrast, cathepsin 
B failed to cleave ps20 suggesting that cathepsin L cleavage is a specific reaction 
and not an artefact of our experimental system. However, cathepsin L cleavage 
resulted in neither enhancement, nor inhibition of the ability of ps20293F to inhibit 
WPMY-1 cell proliferation (fig. 4.5B). From this we concluded cathepsin L cleavage 
is unlikely to be a direct functional regulator of ps20 growth inhibitory activity. In 
support of this, none of the LMW ps20 products we observed in the functionally active 
ps20HeLa preparation (Fig. 4.3) appeared to be analogous to the C-terminal cleavage 
product resulting from incubation of ps20 with cathepsin L. However, we speculated 
that cathepsin L may have other functional implications (discussed below).  
 
High affinity binding of ps20 to a TG solid-phase, and the TG dependent formation of 
HMW ps20 multimers demonstrated an interaction between ps20 and TG (fig. 
4.5A&B).  These multimers were highly stable even following boiling at 90⁰C for 20 
mins in the presence of 50mM DTT, suggesting the bona fide formation of covalent 
isopeptide bonds. Of interest was the formation of multimers of a specific size. Both 
ps20V5 and ps20293F formed multimers which resolved either at ≈150kDa, or which 
became lodged in the top of the gel. This indicates that TG dependent ps20 
multimerisation is not an ad hoc accumulation of ps20 monomers, but the formation 
of specific multimeric structures. HMW multimers formed by untagged ps20 were only 
detected with anti-ps20 directed against the N-terminus of the protein, leading us to 
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hypothesis that the cross-linking utilised one or several of the glutamine residues at 
the far C-terminal end of the ps20 protein.  
 
Our initial investigation into the crosslinking of ps20 to ECM proteins, utilized a 
commercially available, set of ECM proteins pre-coated on ELISA strip wells. This 
assay suggested that ps20 was able to interact with fibronectin, but there was little 
evidence of interactions with other ECM proteins (appendix fig. 8.4). As such we 
optimised this assay using ELISA plates coated with soluble fibronectin. These 
experiments confirmed that ps20 efficiently crosslinks to this ECM protein. We 
observed that ps20 becomes efficiently cross linked in a TG dependent manner to 
fibronectin (fig. 4.7A) in line with studies demonstrating that SLPI and elafin become 
cross linked with fibronectin and retain their protease inhibitory function (Guyot et al., 
2005b, Baranger et al., 2011). Ps20 has no known protease inhibitory function, and 
we were not able to demonstrate a retention of growth inhibitory function by ps20 
using this assay system, however, in line with the evidence that ps20 undergoes 
cross linking through cross-linking of C-terminal glutamine residues, we 
demonstrated that fibronectin crosslinked-ps20 can be liberated from the solid-phase 





Figure 4.8 Proposed model of the extracellular interactions of ps20 
Figure 4.8 Proposed model of the extracellular interactions of ps20. This schematic 
proposes a model to explain the observed interactions of ps20 in the extracellular 
environment. Ps20 is secreted from the stroma and cleaved into multiple molecular forms 
(1). Secreted ps20 interacts with GAGs (2). Ps20 is then cross-linked to extracellular matrix 
components by TG (3). Soluble ps20 is then made available by cleavage of the cross-
linked C-terminus by cathepsins (4). Ps20 is then available to undergo further downstream 
processing (cleavage/multimerisation) and suppress proliferation of stromal and epithelial 
cells (5).                  
151 
 
Taking these observations together, we propose that TG crosslinking may be part of 
an apparatus, common to SLPI, elafin and ps20, whereby bio-availability of these 
proteins is reduced through formation of HMW multimers, or which involves cross-  
linking of soluble protein to the ECM (fig. 4.8). Our subsequent observation that 
cathepsin L abrogates formation of HMW ps20 multimers and liberates ps20 from 
fibronectin cross-linking suggests that in the case of ps20, cathepsin L maybe another 
component of ps20 regulation. Digestion of ps20 by cathepsin L following cross-
linking to fibronectin provides an intuitive mechanism by which ps20 is liberated from 
its tethers to the ECM and is able to enact its cellular functions (fig. 4.9). This 
hypothesis is supported by our data showing that ps20 retains functional activity 
following C-terminal cleavage (fig. 4.6B). 
 
We propose that ps20 is secreted in both FL and TR forms and may be cleaved to a 
number of smaller protein forms (Fig. 4.8). Different ps20 species can then bind to 
GAGs, both on the cell surface and within the ECM. Within the ECM, TG is able to 
cross-link the C-terminus of ps20 to ECM components such as fibronectin, and 
cathepsin L is able to regulate the bioavailability of ps20 by cleaving the C-terminal 
fragment from the main protein leaving a function N-terminal ps20 to mediate growth 
inhibition (fig. 4.7). As we have seen from other studies (Ressler et al., 2014, Alvarez 
et al., 2011, Alvarez et al., 2008, Rogers et al., 2012), the function of ps20 is likely 
not limited to cellular growth inhibition, and like other WFDC family proteins there is 
evidence it mediates pleiotropic functions with a range of growth regulatory and 
immune effects. The diversity of ps20 species observed in this study suggests that 
different processing events may produce ps20 species with different functional roles, 
and these events form part of a larger regulatory apparatus which involved 
sequestering of ps20 at the ECM through TG cross-linking, and liberation through C-
terminal cleavage by Cathepsin L. Future work should seek to characterise the 
individual forms of ps20 present in the extracellular milieu and elucidate i) the 
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proteases which generate them, and ii) their individual functions. Any future 
mechanistic studies of ps20 may benefit from incorporating the role of ps20-GAG 
binding in any proposed model of ps20-cell interactions. The role of ps20 as an 
inhibitor of growth and as an immune regulatory protein may be of significant 
therapeutic application, but its utility may be limited by its complex biochemistry and 


















In Prostate cancer (PCa), reciprocal signalling between neoplastic epithelium and the 
surrounding tissues leads to the emergence of a ‘reactive stroma’ which co-evolves 
to support the growth, invasion, immune-suppression and eventual metastasis of the 
tumour (Barron and Rowley, 2012). In the healthy adult prostate, stromal tissues 
acting under the influence of androgens secrete the extracellular matrix, which 
preserves the architecture of the organ; and produce soluble signals to control the 
growth and differentiation of the epithelial compartment (Cunha et al., 1996, Ressler 
and Rowley, 2011). Dysregulated stroma occurs during carcinogenesis and supports 
growth of the tumour by increasing the proliferation of neoplastic cells (Niu and Xia, 
2009) and by expressing soluble and membrane bound mediators of immune 
suppression (Feig et al., 2013). Indeed, it has been shown that experimental 
elimination of certain stromal compartments is sufficient to induce complete 
regression of tumours in mice, highlighting the significance of a dysfunctional stroma 
in tumour growth and survival (Kraman et al., 2010). 
 
In the mid-nineties David Rowley’s lab observed that cells from rat urothelial 
mesenchyme expressed CM that was potently growth suppressive of cell lines 
isolated from human prostate cancer, namely PC-3 cells (Rowley et al., 1995). Based 
on this functional activity a novel protein factor was purified from the CM and given 
the name prostate stromal 20 (ps20) due to its apparent molecular weight of 20kDa 
(Rowley et al., 1995). The human analogue was soon after identified, cloned and 
expressed and shown to contain a WFDC domain and given the gene name WFDC1. 
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The WFDC1 gene locus was subsequently mapped to chromosomal locus 16q24.3, 
a region whose loss of heterozygosity is specifically associated with progressive 
prostate cancer (Harkonen et al., 2005, Larsen et al., 2000) where it has been 
suggested to act as a tumour suppressor gene (Watson et al., 2004a). In experiments 
investigating the expression of WFDC1/ps20 in human prostate cancer, Rowley et al 
subsequently identified the loss of ps20 from the prostate stromal compartment as a 
key difference between healthy specimens and the reactive stroma associated with 
cancerous  samples (McAlhany et al., 2004, Ressler and Rowley, 2011). However, a 
subsequent in vivo study showed ps20 expressing xenografts achieved greater size 
and vascularity than control tumours in mice (McAlhany et al., 2003) suggesting the 
function of ps20 may be highly tissue specific with context and cell type specific 
functions which required further investigation.  
 
To date, numerous other studies have identified a loss or reduction in WFDC1 
expression in PCa (Watson et al., 2004b) and other cancer types including melanoma 
(Liu et al., 2008a), lung, brain, bladder and fibrosarcomas (Madar et al., 2009) and 
reduced WFDC1 expression in cancer associated fibroblasts relative to normal 
fibroblasts (Madar et al., 2009). Taken together, these observations highlight that 
understanding the molecular mechanisms by which ps20 regulates cell growth, which 
has not been examined in detail, is critical to unravelling its function.  
 
In the previous chapter we saw that a complex biochemistry adds numerous levels 
of complexity to efforts towards elucidating the function of ps20 using exogenously 
added protein. Consequently, in this chapter we attempt to further investigate the 
growth suppressive function of ps20 in the prostate through overexpression of two 
ps20 isoforms in a range of PCa cells lines. Namely, the full length mRNA and the 
exon 3 truncated splice variant. We aimed to elucidate the mechanisms by which 
ps20 mediates growth suppressive effects on PCa cells and further elucidate the cell 
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specific nature of these effects. Herein I present evidence to show that ps20 
expression has no effect on the proliferation of PCa cells. However, expression in 
WPMY-1 prostate stromal cells exhibits paracrine growth suppression of PCa cells 






5.2.1 Ps20 is secreted in two isoforms 
 
Previous studies have shown WFDC1/ps20 to be down-regulated in numerous 
cancers (Madar et al., 2009) including prostate cancer (Watson et al., 2004b), 
suggesting a putative role as a tumour suppressive factor. We used qPCR to assess 
WFDC1 expression in a number of prostate cancer derived cell lines (PCa) (PC-3, 
DU145, LNCaP and PNT-2), one prostate stromal cell line (WPMY-1) and HeLa cells, 
where we have previously observed high levels of ps20 expression (fig. 5.1). We 
found WFDC1 expression was extremely low in all prostate derived cells. In contrast, 
expression of SLPI, a WFDC family protein, was 2 -3 logs higher in all cells tested 
except WPMY-1. HeLa cells had approximately 4 log higher WFDC1 expression than 
all PCa cells tested. While RT-PCR has revealed WFDC1 transcripts in PC-3 and 
DU145 cells previously (Watson et al., 2004b), we demonstrate that this expression 
is very low compared to HeLa, a ps20 secreting cell line. RT-PCR has already 
revealed expression of two discreet mRNA species in HeLa cells (Chapter 3, fig. 3.7), 
a full length (660bp) transcript and a truncated (576bp) transcript in which exon3 was 
absent. Both species are translated and expressed and were cloned for expression 






Figure 5.1 Expression WFDC1/ps20 in PCa and HeLa cells 
Figure 5.1. Expression WFDC1/ps20 in PCa and HeLa cells. Taqman qPCR was 
performed on cell lines indicated. RT-PCR generated cDNA was probed for SLPI and 





Figure 5.2 Ectopic expression of ps20 in DU145, PC-3 and WPMY-1 cells 
Figure 5.2 Ectopic expression of ps20 in DU145, PC-3 and WPMY-1 cells. (A) CM from 
transduced PC-3, DU145 and WPMY-1 cells was collected and titrated on a ps20 ELISA 
and concentration extrapolated by non-linear regression in prism 4. (B) Serum free CM 
was collected from transduced WPMY-1 cells expressing EV, ps20FL or ps20TR, 
electrophoresed and blotted with N-terminal anti-ps20, 650.   
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Using these retroviral constructs we transduced PCa and stromal cells (PC-3, DU145 
and WPMY-1) with WFDC1 constructs and sorted for eGFP expression cells as 
described in materials and methods. All ps20 transduced cell lines showed high 
expression of ps20 in CM as assayed by ps20 ELISA (fig. 5.2A). Both ps20 protein 
species resolved at the predicted MW when serum free CM was subjected to western 
blot (fig. 5.2B).  
 
5.2.2 Ectopic expression of ps20 inhibits growth and induces apoptosis in a cell-
specific manner. 
 
Ps20 was originally purified from rat urothelial cells as a potent inhibitor of PC-3 cell 
proliferation (Rowley et al., 1995). Using an MTS based growth assay, we assessed 
the proliferation of transduced DU145, PC-3 and WPMY-1 cells expressing EV, 
ps20FL and ps20TR. Despite secreting high levels of ps20 no growth inhibition was 
seen in PC-3 or DU145 cell lines (fig. 5.3A - B). However, in line with a previous report 
showing growth inhibition in fibroblasts expressing ps20, WPMY-1 stromal cells 
secreting both ps20FL and ps20TR had reduced proliferation relative to the control EV 
line (fig. 5.3C). This growth inhibition was confirmed by cell counting of 7 passages 
of the transduced WPMY-1 cells (fig. 5.3D). We then looked at apoptosis, cell death 
and the cell cycle to further elucidate the nature of the reduced proliferation 
associated with ps20 expression. WPMY-1 cells expressing ps20FL had increased 
levels of apoptosis relative to the EV control, while the ps20TR expressing cells had 
an intermediate phenotype with levels of apoptosis increased 2-3 fold (fig. 5.3E). The 
increased levels of apoptosis observed in cells expressing ps20FL and ps20TR were 
even more pronounced when cultured in serum free media (fig. 5.3F), probably due 




Figure 5.3 Expression of ps20 in prostate stromal cells induces apoptosis and G1 cell cycle 
arrest 
Figure 5.3.  Expression of ps20 in prostate stromal cells induces apoptosis and G1 
cell cycle arrest. (A-B) PC-3 (A), DU145 (B), or WPMY-1 (C) cells transduced to express 
ps20FL or ps20TR were seeded in 100μl complete media in 96 well plates. At each 
respective time point 15μl of MTS reagent was added to respective wells and incubated 
for 2h and colourimetric readout taken at 490nm. (D) 106 transduced WPMY-1 cells were 
seeded in 75cm2 flasks and grown for 72h in complete media before counting. Represents 
7 passages of cells). (E-F) To investigate apoptosis, 3x104 EV or ps20 transduced WPMY-
1 cells were seeded in 24 well plates. At 48h cells were taken and stained with annexin V 
and PI, to identify (E) apoptotic and (D) dead cells. (G-H) Alternatively the cell cycle of 
WPMY-1 ps20 transduced cells was analysed by treating cells with RNase A, and staining 
with PI. Cell cycle staging was elucidated by Watson analysis on FlowJo™. Representative 
plots are shown in (G) and means of 3 experiments were presented in columns graphs 
(H). * p<0.05 and ** p<0.01 Student’s T test. 
A B C 




































































































































































































As indicated in fig. 5.3F the levels of PI positive, or dead cells in each culture condition 
mirrored the increased levels of apoptosis observed in cells expressing ps20FL or 
ps20TR. Cell cycle analysis of transduced WPMY-1 cell lines indicated that in cells 
expressing ps20FL a smaller proportion of cells were in G2 and S phase of the cell 
cycle (fig. 5.3G) suggesting cell-intrinsic expression of ps20 may also function to 
some extent to restrain cells in G1 phase. In contrast, ps20TR cells had a cell cycle 
profile comparable to the EV line, suggesting that only ps20FL expression conferred 
a bona fide reduced proliferative rate.  
 
Together these data indicate that the reduced growth rate manifest in ps20 
expressing WPMY-1 cells is likely due to an increased propensity to undergo 
apoptosis and, at least in ps20FL cells, an extended cell cycle.  In addition, expression 
of ps20FL was more biologically active than expression of ps20TR.     
 
5.2.3 CM from WPMY-1 cells expressing ps20 has broad growth inhibitory 
effects.  
 
Previous studies showed ps20 to be highly expressed in the healthy prostate stroma 
(McAlhany et al., 2004, McAlhany et al., 2003). Given the reported propensity for 
ps20 expression to be reduced or switched off within the context of tumours, we 
hypothesised that stromal ps20 may be a paracrine regulator of growth and a barrier 
to the development of prostate neoplasms. To assay the effect of ps20 expression in 
WPMY-1 cells in paracrine, CM was collected from WPMY-1 cells expressing EV, 
ps20FL or ps20TR and titrated onto PCa cells in culture. WPMY-1 CM from ps20 
expressing cells was potently growth inhibitory on metastatic (PC-3/DU145), 
androgen sensitive (LNCaP) and primary (PNT-2) PCa cell lines (fig. 5.4 A - D). Media 




Figure 5.4 CM from WPMY-1 cells expressing ps20 potently inhibits growth of PCa cells 
Figure 5.4. CM from WPMY-1 cells expressing ps20 potently inhibits growth of PCa 
cells.  (A-F) CM taken from transduced WPMY-1 following 72h in culture was titrated onto 
PC-3 (A), DU145 (B), LNCaP (C), PNT-2 (D), WPMY-1 (E), and HeLa (F) cells, and 
cultures where grown for 96h. Growth was assayed following addition of MTS reagent (the 
plate was read at 490nm). Following background subtraction ODs were plotted as a 
percentage of cells from each cell line grown in complete media only. Each plot represents 
at least two separate experiments with different batches of CM. *p<0.05 relative to EV 
































































































































































































































































































Figure 5.5 Conditioned media from ps20 expressing 293T cells does not suppress PCa cell 
growth 
 
Figure 5.5 Conditioned media from ps20 expressing 293T cells does not suppress 
PCa cell growth. (A) 293T cells were transiently transfected with constructs encoding 
ps20FL or ps20TR or an EV control. The resulting CM was collected, clarified and assayed 
by ELISA. (B-D) CM was then titrated onto PCa cells. Growth of PC-3 (B), DU145 (C), and 
LNCaP (D) following 96h in culture was ascertained by addition of MTS reagent (the plate 










































































































































(fig. 5.4E). In all cases this effect titrated when a lower concentration of CM was 
offered relative to CM from EV transduced WPMY-1 cells. However, ps20 transduced 
WPMY-1 CM did not suppress HeLa cell proliferation and conversely a slight growth 
enhancement was noted. Interestingly, despite having a ps20 concentration two logs 
higher than transduced WPMY-1 lines (fig. 5.5A), we failed to observe any specific 
growth suppression of PCa cell lines treated with CM from 293T cells expressing 
ps20 species (fig 5.5B-C), suggesting that i) ps20 is not directly inducing the growth 
suppression, and ii) that the growth inhibitory effect of ps20 expression is producer 
cell-type specific.   
 
5.2.4 CM from WPMY-1 cells expressing ps20 induces growth suppression 
through the induction of apoptosis. 
 
Having seen that CM collected from WPMY-1 cells transduced to express both ps20FL 
and ps20TR suppresses proliferation of PCa cells, we sought to elucidate whether this 
was related to cellular death or inhibition of cell division. Using a standard 
measurement of apoptosis we assayed cells for expression of annexin V at the cell 
surface following treatment with WPMY-1 cell CM.  Figure 5.6A-B demonstrates an 
increase in apoptosis in DU145 and PC-3 cells respectively following treatment with 
CM from ps20 transduced WPMY-1 cells. This data suggests that the growth 
inhibitory phenotype observed is due to a paracrine induced increase in apoptosis. 
We next looked at the effects on the cell cycle of cells treated with WPMY-1 CM. 
Again we assayed DU145 and PC-3 cells and used PI staining to assess the 
percentage of cells at different stages on of the cell cycle. WPMY-1 CM treatment 
had   little or no effect on the cell cycle in either cell line. Taken together, data from 
fig. 5.6 and fig. 5.7 suggests that ps20 expressing WPMY-1 cells is able to induce 
apoptosis through a paracrine mechanism without impacting the progression of cells 




Figure 5.6 Conditioned media from WPMY-1 cells expressing ps20 induces apoptosis in PCa 
cells 
 
Figure 5.6 Conditioned media from WPMY-1 cells expressing ps20 induces 
apoptosis in PCa cells. DU145 (A) or PC3 (B) cells were seeded at 3x103 cells in 24 well 
plates and cultured in WPMY-1 CM for 48h before harvesting. Cells were stained with PI 
and annexin V. Representative plots are shown and graphs are means and SEMs of 3 









































































































































































































































Figure 5.7 CM from WPMY-1 expressing ps20 does not impact entry to the cell cycle 
 
 
Figure 5.7 CM from WPMY-1 expressing ps20 does not impact entry to the cell cycle. 
(A-B) DU145 or PC3 cells were seeded at 3x103 cells in 24 well plates and cultured in 
WPMY-1 CM for 48h before harvesting. Cells were analysed by PI staining and FACS. (A) 
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5.2.5 Ps20 does not mediate growth suppression directly. 
 
Given that CM from 293T cells expressing ps20 was unable to specifically suppress 
the proliferation of PCa cell lines, we hypothesised that the suppressive effects of 
WPMY CM are mediated indirectly. To verify this possibility, we used beads coated 
with anti-ps20 antibody to deplete ps20 from the WPMY-1 CM. CM from ps20FL and 
ps20TR expressing WPMY-1 cells was successfully depleted to near background level 
(fig. 5.8A) whereas this did not have any demonstrable effect on the ability of ps20 
transduced WPMY-1 CM to inhibit proliferation (Figure 5.8B). These data indicate 
that the growth suppressive paracrine phenotype effects of ps20 is likely mediated 
by a secondary factor that is regulated by ps20. 
 
To determine the nature of the suppressive factor, and to exclude the possibility that 
the WPMY-1 cells were not mediating paracrine growth suppression by depleting the 
CM of vital nutrients, we treated PC-3 and DU145 cells to transduced WPMY-1 CM 
which had been boiled for 20 minutes. Data in fig. 5.8C-D shows that boiling 
completely abrogates the growth suppressive phenotype conferred by ps20 
expressing cells, suggesting that the suppressive effect is mediated by a soluble 
factor which can be denatured by heat, such as a protein or lipid (fig. 5.8C and D).  
 
5.2.6 Ps20 expression regulates expression of numerous growth inhibitory 
factors including COX-2. 
 
Given the potent paracrine growth suppressive activity exhibited by transduced 
WPMY-1 cells we sought to identify the differences in gene expression in WPMY-1 
cells expressing ps20 species relative to EV controls. To this end we performed a 




Figure 5.8 Suppression of PCa cell growth by WPMY-1 CM is not mediated directly by ps20 
 
Figure 5.8 Suppression of PCa cell growth by WPMY-1 CM is not mediated directly by 
ps20. (A & B) CM from transduced WPMY-1 cells was incubated overnight with beads 
conjugated to anti-ps20 ab1G7 or an isotype. Following centrifugation to pellet beads, CM 
was assayed by ps20 ELISA (A) or was titrated onto WPMY-1 cells and cultured for 96h  (B) 
followed by MTS assay (readout was at 490nm). (C-D) WPMY-1 CM was subjected to 20 
mins boiling at 95⁰C before addition to either DU145 (C) or PC-3 (D) cells for 96h. (B-D) 


































































































































































































































































WPMY1-ps20FL and WPMY-1-ps20TR cells. The results showed significant overlap in 
both upregulated and down regulated transcripts between ps20FL and ps20TR cells 
(fig. 5.9A-C) and subsequent pathway analysis revealed that ps20 altered the 
expression of a number of cytokine/chemokine pathways, metabolic pathways, and 
cell adhesion pathways (fig. 5.9D).  
 
To further investigate changes in the secretory profile of ps20 transduced WPMY-1 
cells, we mined the data specifically for differentially expressed growth inhibitory 
factors (table 5.1). Those upregulated in both ps20FL and ps20TR expressing WPMY-
1 cells are indicated with an asterisk. Factors of interest with known anti-proliferative 
effects that were upregulated were SerpinF1 (Pigment epithelium-derived factor) 
(Becerra and Notario, 2013) and IL-32 (Joosten et al., 2013). IL-8, on the other hand 
can stimulate the growth of prostate cancer epithelium (Waugh and Wilson, 2008). 
Lastly, we observed a 5.29, and 3.86 fold increase in the expression of PTGS2 in 
WPMY-1-ps20FL and WPMY-1-ps20TR respectively. PTGS2 encodes 
cyclooxygenase-2 (COX-2), an enzyme responsible to metabolising arachidonic acid 
into PGH2, which has diverse roles in the control of cellular growth, including inhibiting 
proliferation and the induction of apoptosis (Chaffer et al., 2006). COX-2 is not 
secreted, but rather associated with the nuclear envelop and endoplasmic reticulum. 
However, COX-2 is the rate limiting enzyme in a pathway which results in the 
formation of numerous growth inhibitory secreted prostanoids (Otto and Smith, 1994, 
Morita et al., 1995).  
 
The expression of the four above noted genes was verified by qRT-PCR. Using cDNA 
generated from 3 passages of transduced WPMY-1 cell lines we confirmed up-
regulation of COX-2, SerpinF1, IL-8 and IL-32 mRNAs in WPMY-1 cells expressing 




Figure 5.9 Transcriptome analysis of ps20 expression in WPMY-1 cells 
Figure 5.9 Transcriptome analysis of ps20 expression WPMY-1 cells. (A-D) WPMY-1 
cells transduced to express EV, ps20FL or ps20TR were subjected to a full transcriptome 
analysis as described. In materials and methods (A) Heat-map depicting differential gene 
regulation (log2) in WPMY-1 cells transduced to express EV, ps20FL or ps20TR according 
to the colour scheme shown and based on the mean of the EV replicates. (B-C) Venn 
diagrams depict the overlapping expression profiles of ps20FL and ps20TR WPMY-1 cells 
showing upregulated genes (B), and down-regulated genes (C). (D) Pathway analysis 
showing the number of genes up/down-regulated from specific cellular pathways in 








Figure 5.10  qPCR quantification of target mRNA species in ps20 transduced WPMY-1 cells 
 
Figure 5.10 qPCR quantification of target mRNA species in ps20 expressing WPMY-1 
cells. To assess expression of putative ps20-regulated targets cDNA was generated by RT-
PCR from WPMY-1 cells expressing EV, ps20FL or ps20TR and subjected to SYBR green 


































































































































extent in the ps20TR expressing cells than on those expressing ps20FL (fig. 5.10). This 
observation mirrors the intermediate growth suppressive phenotype observed in 
ps20TR expressing WPMY-1 cells relative to those cells expressing ps20FL, 
suggesting that the truncated ps20 molecule may be functionally equivalent to the full 
length molecule, but with different kinetics. 
 
5.2.7 Neutralisation of IL-6, IL-32 and TGFβ fails to abrogate growth suppression. 
 
We confirmed by qPCR that both SerpinF1, IL-32 were upregulated in ps20 
expressing cells. In order to test if either of these factors were responsible for the 
suppression of PCa cell growth elicited by WPMY-1 CM we performed a series of 
neutralisation assays. In addition, we assayed for TGFβ dependent suppression, 
given the established importance of this factor as a regulator of growth and apoptosis 
in the prostate. Antibodies that had been previously reported to neutralize the 
functional effects of their respective targets were chosen and incubated with cells at 
a concentration at least 2 fold above the reported IC50 (fig. 5.11A - C). In each case 
the antibodies failed to have any effect on the growth suppression induced by 
incubation of PC-3 cells with ps20 expressing WPMY-1 CM. 
 
5.2.8 WPMY-1 cells cultured in the presence of COX-2 inhibitor do not produce 
growth suppressive conditioned media.  
 
COX-2 is an enzyme which catalyses the conversion of arachidonic acid to 
prostaglandin H2 (PG-H2). COX-2 is the rate limiting enzyme in a pathway which leads 




Figure 5.11 Blocking of secreted factors has no effect on WPMY-1CM mediated growth 
suppression 
Figure 5.11. Neutralisation of secreted factors has no effect on WPMY-1 conditioned 
media mediated growth suppression. (A-C) PC-3 cells were cultured for 96h in 90% 
transduced WPMY-1 CM in the presence of neutralizing antibody to SerpinF1 (PEDF) 
[10g/ml](A), IL-32 [5g/ml](B), and TGFβ [20g/ml](C), or an isotype matched control 

























































































Figure 5.12 Inhibition of COX-2 abrogates ps20 dependent growth suppression of PCa cells 
Figure 5.12 Inhibition of COX-2 abrogates ps20 dependent growth suppression of 
PCa cells. Transduced WPMY-1 cells were seeded in 12 wells plates and cultured for 72h 
in the presence of 50μM Rofecoxib or the same volume of DMSO. CM was then added to 
DU145 cells (A, 70% CM) or PC-3 cells (B, 9% CM) respectively. Cells were cultured for 
96h and readouts taken by addition of MTS reagent (the plate was read at 490nm). 
Data of plotted as a percentage of cells grown in only in complete media only. Data is the 
Mean and SEM of 3 independent experiments with different batches of CM. PC-3, DU145 
or WPMY-1 cells were treated with complete media, DMSO, or 50μM Rofecoxib for 96h 
prior to addition of MTS reagent to assay growth (the plate was read at 490nm) (C). 










































































and 15d-PGJ2. 15d-PGJ2 is present in the prostate and seminal fluid (Jowsey et al., 
2003, Tokugawa et al., 1998) and prostate stromal derived 15d-PGJ2 has been 
shown to inhibit the growth and induce apoptosis of prostate cancer cells (Kim et al., 
2005, Nakamura et al., 2013). We used a COX-2 inhibitor, rofecoxib, to produce 
WPMY-1 CM in which the COX-2 pathway was inhibited. Fig. 5.12 shows PC-3 and 
DU145 cells cultured in ps20 transduced WPMY-1 CM produced in the presence of 
rofecoxib, or DMSO. We show that ps20 transduced WPMY-1 CM is no longer highly 
suppressive when cultured in the presence of the COX-2 inhibitor. When added to 
DU145 cells suppression is relieved to the level observed with WPMY-1-EV control 
CM, while on PC-3 cells the abrogation of suppression was less complete, but still 
pronounced. This strongly suggests that activation of the prostaglandin pathway by 
COX-2 is responsible for ps20 driven growth suppression exhibited by ps20 
expressing WPMY-1 CM. To control for non-specific effects on cell growth we 
cultured PC-3, WPMY-1 and DU145 cells in complete media alone, with or without 
Rofecoxib or the same volume of DMSO (fig. 5.12C). Both DMSO and Rofecoxib, 
demonstrated a slight increase in cell proliferation, especially when added to WPMY-
1 cells, presumably due to inhibition of background COX-2 activity. There was no 
growth suppression observed in any cell line tested, indicating that the addition of 








We sought to characterize, express and functionally elucidate the role of stromally 
derived ps20 in prostate cancer through a series of in vitro assays. We found no 
significant expression of ps20 in any prostate cancer cell line tested, nor in WPMY-1 
prostate stromal cells in line with the study by Madar et al that found WFDC1 is absent 
or down-regulated in tumours and in highly proliferative and cancer-associated cells 
(Madar et al., 2009). Despite their highly proliferative nature we previously observed 
expression and secretion of two isoforms of ps20 in HeLa cells, which corresponded 
to those previously identified in PCa lines by others (Watson et al., 2004b).  
 
It has been repeatedly observed that ps20 is present in healthy stroma in vivo 
(McAlhany et al., 2004) and fibroblasts derived from non-cancerous tissue ex-vivo 
(Madar et al., 2009) but is lost or decreased in tumour associated and cancerous 
samples (Madar et al., 2009) suggesting a potential tumour-suppressive function.  To 
investigate this we reconstituted expression of both FL and TR ps20 species in 
WPMY-1 cells, an SV-40 immortalised prostate stromal cell line, exhibiting features 
of fibroblasts and myofibroblasts (Webber et al., 1999) and in both PC-3 and DU145 
PCa lines. In contrast to studies investigating the role of rat-ps20 (Hung, 2005, Larsen 
et al., 1998, Rowley et al., 1995), we failed to observe ps20 dependent growth 
inhibition of either PC-3, or indeed in DU145 cells, suggesting that human and rat 
ps20 may have different functions, or that soluble ps20 requires specific biochemical 
processing to induce direct growth inhibition, in line with data presented in chapter 3. 
We did however observe growth inhibition of WPMY-1 stromal cells expressing both 
ps20FL and ps20TR. Likewise, ps20 expressing WPMY-1 cells showed a reduced 
proportion of cells in G2/S phase of the cell cycle and an increased proportion of cells 
undergoing apoptosis, suggesting ps20 secretion can confer an anti-proliferative and 
pro-apoptotic phenotype in an autocrine fashion on specific cell types. Again, the 
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producer and/or the target cell may be significant with regard to the direct growth 
inhibition by secretion of ps20.  
 
We then sought to model the expression of ps20 in healthy prostate stroma through 
the expression and collection of CM from ps20 or EV expressing WPMY-1 cells. A 
series of experiments showed potent growth inhibition of numerous PCa cell lines by 
WPMY-1 cell CM expressing ps20, with the exception of HeLa cells. Assessment of 
apoptosis levels on PC-3 and DU145 cells treated with ps20 containing WPMY-1 CM 
revealed that WPMY-1 cells expressing ps20 confer through paracrine mechanisms 
a potent pro-apoptotic phenotype. In contrast, the cell cycle of treated cells was 
largely unaffected, suggesting that cell-cycle blockade is not involved in the growth 
suppressive phenotype conferred in paracrine by WPMY-1 cells expressing ps20. 
 
Subsequent depletion of ps20 from the highly suppressive WPMY-1 CM strongly 
suggested that this growth inhibitory and pro-apoptotic phenotype was mediated 
indirectly, likely through ps20 dependent regulation of one or more paracrine effector 
molecules in WPMY-1 cells.  In chapter 4, I presented data showing the growth 
inhibition of PCa cells by ps20 purified both from HeLa and 293F cells. This would 
seem to disagree with the data herein that WPMY-1 CM containing ps20 does not 
suppress growth in a ps20 dependent manner. As demonstrated in fig. 5.2, ps20 
expressed by transduced WPMY-1 cells does not appear to be cleaved or processed 
in a manner analogous to that observed in the material purified from HeLa cells in the 
previous chapter (fig 4.3). The concentration of ps20 in WMPY-1 cell CM is in a similar 
range to that ps20 purified from HeLa cells. As such, I would argue that this data 
supports the previous conclusion that without post translational processing steps not 
yet elucidated which result in the presence of LMW protein species, FL or indeed TR 
ps20 does not efficiently suppress cellular growth. This is further supported by data 
suggesting that 293T CM from cells expressing ps20FL and ps20TR did not suppress 
177 
 
PCa growth, even given the high concentration of ps20 (>1.25μg/ml)(fig. 5.5). 
Together then this data supports the fact that CM from WPMY-1 cells expressing 
ps20 mediate growth suppression indirectly. This hypothesis was supported by the 
fact that the growth suppression by WPMY-1 CM containing ps20 could be abrogated 
following heat treatment.  
 
Towards elucidating how ps20 was able to regulate growth indirectly we performed a 
transcriptome analysis to assess differential regulation of downstream protein factors. 
Microarray analysis of transduced WPMY-1 cell lines identified numerous secreted 
targets upregulated in WPMY-1 cells expressing ps20 species, which were 
subsequently confirmed using qPCR analysis. Despite various published studies 
suggesting that IL-32 and SerpinF1 are capable of mediating growth suppression 
and/or the induction of apoptosis the use of neutralising antibodies in growth inhibition 
assays failed to abrogate the suppressive effects of the ps20 transduced WPMY-1 
CM. We then sought to investigate whether the up-regulation of PTGS2 in ps20 
expressing WPMY-1 cells may be mediating the growth suppression.  We added 
rofecoxib, a highly specific inhibitor of COX-2 to the EV, ps20FL and ps20TR expressing 
WPMY-1 cells for 72h prior to the collection of CM. WPMY-1 CM produced in the 
presence of this inhibitor was significantly less growth suppressive than that cultured 
in the presence of DMSO, on both the PC-3 and DU145 cells, abrogating suppression 
to the levels seen with the WPMY-1-EV cells.  
 
PTGS2 encodes COX-2, the rate limiting enzyme of the arachidonic acid pathway, 
and catalyses production of numerous prostanoids. COX-2 initially converts 
arachidonic acid to PGH2 before further enzymes then catalyse the formation of 
downstream prostanoids, many of which are known to have potent effects of cellular 
growth. Of pertinence to our findings, lipocalin-type prostaglandin D synthase (L-
PGDS), is responsible for the conversion of PGH2 into PGD2.  Expression of L-PGDS 
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is restricted to specific tissues, including the heart, brain, adipose tissue and notably 
the prostate (Jowsey et al., 2003). In line with this, significant amounts of PGD2 are 
found in the seminal fluid, and at least one study has confirmed expression of L-
PGDS at high levels in prostate tissue (Tokugawa et al., 1998).  PGD2 is 
spontaneously dehydrated into 15-deoxy-D12–14- PGJ2 the endogenous ligand of 
the peroxisome proliferator-activated receptor γ (PPARγ), an intracellular molecule 
responsible involved in numerous cellular processes including the inhibition of cell 
growth. Indeed, PGJ2 has been shown in increase apoptosis in ERα positive breast 
cancer cells (Yaacob et al., 2013), vascular epithelial cells (Haslmayer et al., 2002) 
and osteoblastic cells (Lee et al., 2008) via it’s interaction with the PPARγ receptor. 
Two studies to date have shown PGJ2 to be a potent inhibitor of prostate cancer cell 
proliferation. The first, demonstrated PGJ2 resulted in significantly reduced 
proliferation of PC-3, DU145 and to a lesser extent LNCaP cells (Nagata et al., 2008). 
A second study showed a similar pattern of proliferation inhibition by PGj2, with 
LNCaP cells showing reduced PGJ2 dependent growth abrogation relative to PC-2 
and DU145 cells. This study also demonstrated that PGJ2 was able to induce 
apoptosis in PC-3 cells, though this was not investigated on either DU145 or LNCaP 
cells (Chaffer et al., 2006).  
 
We hypothesis then that where ps20 is expressed in the healthy prostate stroma, it 
acts to induce COX-2 expression and regulate the formation of growth suppressive 
and pro-apoptotic prostanoids, and by doing so, places a restraint on epithelial growth 
and prevents emergence of neoplastic tissue. We propose that the loss of ps20 
expression in tumours demonstrated previously (McAlhany et al., 2004, Watson et 
al., 2004b, Madar et al., 2009) is driven by selective pressure on the tumour to escape 
this mechanism of growth suppression. Further experiments are required to confirm 
the exact mechanism of COX-2 dependent suppression induced by ps20 expression, 
and to elucidate how ps20 expression is regulated, and the mechanisms by which it 
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is turned off. Understanding of the role of ps20 in prostate tissue homeostasis will 
better clarify how the situation in disease, where ps20 is absent, differs from that of 




 ps20 as a suppressor of T cell immunity 




Tumours are surrounded and enmeshed by a reactive stromal compartment, 
composed of various cell types including fibroblasts and immune cells (Barron and 
Rowley, 2012). Reciprocal interactions between the stroma and tumour tissue cause 
the tissues to co-evolve resulting in a stroma which secretes growth factors and 
cytokines to support the growth of the tumour, and which manipulates the immune 
response to its advantage (Barron and Rowley, 2012). In chapter 2 we demonstrated 
that the expression of ps20 in prostate stromal WPMY-1 cells up-regulates PTGS2 
and induces a potent paracrine growth suppression of prostate cancer cell lines 
dependent on COX-2 activity. Ps20 has been previously demonstrated to inhibit 
proliferation of PC-3 cells (Hung, 2005, Larsen et al., 1998, Rowley et al., 1995), but 
data presented in chapter 4 suggests that this may require specific post-translational 
events and/or concentrations of ps20 in the μg/ml range that are unlikely to be 
achieved within the prostate micro-environment. However, a number of studies have 
demonstrated a reduced ps20 expression in prostate cancer (Watson et al., 2004b, 
Madar et al., 2009), especially in the stroma (McAlhany et al., 2004), suggesting that 
tumours may switch off ps20 expression in order to remove a barrier to further growth.  
 
Given the evidence from this thesis and elsewhere that ps20 can mediate both direct 
and indirect growth inhibition of PCa cells, there is a logical rational for investigating 
its potential for therapeutic use. Focally targeted tumour therapies utilise local 
delivery of growth suppressive and immune activating agents into the tumours to 
antagonise tumour growth and activate locally suppressive anti-tumour immunity 
(Galustian et al., 2011, Patel et al., 2006). The development of membrane-localising 
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or ‘cytotopic’ peptide technology enables locally delivered molecules to become 
anchored to cell-membranes serving to i) increase the local concentration of the 
therapeutic agent, and ii) prevent global distribution of the agent via the blood and 
lymphatics, and the deleterious effects this may manifest  (Bowles et al., 2007). Our 
lab is committed to investigating agents which may be candidates for inclusion in 
locally administered cytotopic therapy in the prostate. Despite our failure to elucidate 
completely the processing events that result in expression of a functionally active 
ps20 molecule, the experiments presented in chapter 4 suggest ps20 is able to 
induce a potent growth inhibitory phenotype on the tumour stroma, and could be a 
candidate for inclusion in such a therapeutic regimen. 
 
However, previous researches into fellow WFDC family proteins SLPI and elafin have 
demonstrated pleiotropic immunomodulatory functions, impacting both the adaptive 
and the innate immune responses. And as we have seen WFDC protein expression 
is frequently dysregulated in cancers, though no studies to date have established a 
direct link of the immunomodulatory effects of the these proteins with their pro- or 
anti-tumourigenic effects. Even so, it may be the case that expression of WFDC 
family proteins in health or disease may have implications within the tumour 
microenvironment. In line with this, SLPI treated monocytes were shown to inhibit the 
proliferation of CD4 T cel (Guerrieri et al., 2011).  Similarly, increases in elafin 
expression during the inflammatory response in the lung has been linked with an 
augmented TH1 response (Tremblay et al., 1996).  Both SLPI and elafin have been 
shown to regulate activation of the NFϰB pathway, which regulates the expression of 
multiple immune modulating cytokines and chemokines (Bingle and Vyakarnam, 
2008). As such, despite not sharing protease inhibitory or anti-microbial function, it is 
tempting to speculate that ps20 has a similar immunomodulatory role, albeit specific 




Three recent studies have already provided evidence that ps20 may elicit significant 
immune functions. Two studies have shown altered anti-viral response in mice which 
lack ps20. Experimentally infected ps20 null mice showed increased mouse hepatitis 
virus-1 (MHV-1) viral titres, relative to control mice (Rogers et al., 2012). In contrast, 
in an experimental model of influenza, ps20 null infected mice again had  significantly 
lower viral titres than control animals (Ressler et al., 2014). Both studies imply 
therefore that ps20 can manipulate innate anti-viral responses, though with disparate 
effects. Interestingly, these two studies observed similarly disparate features with 
relation to the migration of immune cells. In the MHV infection model, ps20 null mice 
demonstrated increased neutrophil infiltration in the lungs, and elevated levels of 
CXCL1 and CXCL2, both chemotactic for neutrophils (Bozic et al., 1994). In contrast, 
infection with the  influenza virus resulted in elevated migration of MФ into the lungs 
in ps20 null mice (Ressler et al., 2014). Both sets of contrasting results imply that 
ps20 has broad immune regulatory properties that are highly context specific. In both 
model systems ps20 served to regulate infiltration of immune cells into the lung, 
suggesting that the effect of ps20 expression in the lung is broadly anti-inflammatory 
and mediated at least in part by the regulation of chemokines. However, a third recent 
study demonstrated the up regulation of IL-8 expression in cells transfected to 
express WFDC1 (Wilson et al., 2014). IL-8 is potently chemotactic for neutrophils and 
has been shown to be pro-tumourigenic. So while this study again implicates ps20 in 
the regulation of chemokines, the increase in IL-8 is in contrast with the results 
showing reduced neutrophil influx, which migrate toward IL-8 gradients (Ribeiro et 
al., 1991). Again these results imply that ps20 function is likely cell- and tissue-type 
specific. 
 
Given the importance of neutrophils and MФ in tumourigenic processes (Panni et al., 
2013, Gregory and Houghton, 2011) it seems intuitive that ps20 expression in the 
prostate may have immune modulatory properties that could impact the outcome of 
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tumourigenic processes, either in modulating the inflammatory processes thought to 
precede the development of neoplastic cell growth, or at a later stage in the 
tumourigenic process. Our lab has previously observed a correlation between T cell 
phenotypes and WFDC1 expression in T cell clones, and we hypothesis that ps20 
expression may restrain TH1 type activation of T cells, including the secretion of IFNγ 
and proliferation in a similar way to the inhibition of T cells response by SLPI 
(Guerrieri et al., 2011). In the previous chapter we developed an in vitro model of 
ps20 expression in the prostate stroma whereby ps20 secretion is transgenically 
induced in prostate WPMY-1 stromal fibroblasts. In addition we observed that 
numerous immune factors e.g. IL-6 and IL-8, were upregulated in WPMY-1 cells 
expressing ps20 (Table 4.1). 
 
 In this chapter we will further interrogate that system to investigate the paracrine 
effect of ps20 expression in prostate stromal cells on T cell responses and 
phenotypes in vitro. From these experiments we hope to learn whether ps20 is able 
to elicit direct or indirect effects on T cells. These experiments will help us i) to 
establish the potential role for ps20 in regulating adaptive immunity in the prostate in 
health, and ii) will help us to extrapolate the potential impact of ps20 as a component 






6.2.1 ps20 expression by WPMY-1 cells suppresses anti-CD3/28 induced T cell 
proliferation. 
 
As we saw in chapter 4, the expression of COX-2, a rate limiting enzyme of the 
prostanoid pathway was highly upregulated in WPMY-1 cells expressing ps20 
isoforms. We found WPMY-1 CM suppressed growth of PCa cells in a COX-2 
dependent matter. COX-2 has been shown to regulate formation of numerous growth 
and immune regulating prostanoids and has been shown to affect T cell proliferation 
and cytokine expression (Schiffmann et al., 2014, Sha et al., 2013).  We assayed the 
proliferation of CD4 T cells treated with CM from WPMY-1 cells expressing ps20 (fig 
6.1A). Cells from two separate donors showed significant proliferation upon treatment 
with anti-CD3/28 beads (fig 6.1B-C). This was suppressed in a dose dependent 
manner in CD4 T cells treated with ps20 expressing WPMY-1 cell CM. Indeed, at 
75% CM proliferation of cells treated with ps20 CM was abrogated almost completely. 
Moreover, the effects of ps20FL and ps20TR CM were comparable. Notably, there was 
a degree of non-specific growth suppression, with cells showing moderately reduced 
proliferation in the presence of increasing concentrations of EV CM. However, the 
data indicate a clear ps20-expression dependent suppression of anti-CD3/28 induced 
CD4 T cell proliferation. 
 
In order to establish if the ps20 dependent suppression of T cell proliferation affected 
CD8 T cells in the same way as observed on CD4 T cells, we performed a series of 
assays using whole PBMCs. Cells were treated with WPMY-1 CM as before and anti-




Figure 6.1 Ps20 expressing WPMY-1 cell conditioned media inhibits CD4 T cell proliferation 
 
Figure 6.1 Ps20 expressing WPMY-1 cell conditioned media inhibits CD4 T cell 
proliferation. (A-C) CD4 positive T cells were negatively isolated, stained with CFSE,  and 
incubated with a titration of WPMY-1 EV, ps20FL or ps20TR CM followed by stimulation with 
anti-CD3/28 beads. Proliferation was measured 6 days later through CFSE dilution by 
FACS. (A) Representative plots of T cell suppression at by 75% CM. (B) and (C) show 
data using three separate batches of WPMY-1 CM respectively. *p<0.05 **p<0.01 relative 































































































markers CD3 and CD8 was used to assess the proliferation of both CD4 and CD8 T 
cell populations. Figure 6.2A shows an example of the staining regimen, indicating 
the gating of CD3+ cells into CD8+ and CD8- respectively, thereby delineating 
between CD4 and CD8 subsets of T lymphocyte. Subsequent analysis shows dilution 
of the efluor605 dye indicating cells had undergone significant cell division. As before, 
cells treated with CM from WPMY-1 cells expressing ps20 showed reduced 
suppression relative to EV treated counterparts. This effect was comparable both for 
CD4 and CD8 T cells (fig 6.2B-C), suggesting the effect was not specific to either 
population. Notably, the suppression of 25% ps20TR CM was not has pronounced in 
the PBMC assay, compared to the suppression of purified CD4 T cells (fig 6.1B-C), 
though suppression by ps20FL showed comparable dynamics.  
 
6.2.2 ps20 expression by WPMY-1 cells suppresses IL-7/15 induced T cell 
proliferation. 
 
Using anti-CD3/28 beads to stimulate T cells is an experimental analogue of TCR 
engagement simultaneous with the second activating signal, by activated APCs. 
Physiologically this mechanism induces clonal expansion of T cells in response to 
antigen restricted stimulation. However, within tissues and in the circulation T cells 
are also subject to stimulation with cytokines such as IL-7 and IL-15 which induce 
proliferation without antigen restricted activation (Tan et al., 2001). This stimulation 
is referred to as homeostatic proliferation.  
 
In order to investigate if ps20 can regulate the suppression of homeostatic 
proliferation of T cells, we stimulated PBMCs with IL-15 and IL-7 following treatment 
with 50% WPMY-1 CM (fig 6.3). We saw a significant levels of proliferation in both 




Figure 6.2 Ps20 WPMY-1 conditioned media inhibits CD4 and CD8 T cell proliferation 
Figure 6.2 Ps20 WPMY-1 conditioned media inhibits CD4 and CD8 T cell 
proliferation. Whole PBMCs were isolated, and incubated with a titration of WPMY-1 EV, 
ps20FL or ps20TR CM followed by stimulation with anti-CD3/28 beads. Proliferation was 
measured 6 days later by efluore670 dye dilution by FACS. A) Shows representative plots 
of suppression at by 75% CM. (B) and (C) show data using three separate batches of 




















































































































anti-CD3/28 stimulation, with cells undergoing 2-4 distinct cycles of division when 
treated with EV CM (fig 6.3A). However, as was seen with anti-CD3/28 proliferation, 
incubation with ps20FL or ps20TR expressing WPMY-1 CM completely abrogated 
proliferation of both CD4 and CD8 T cells, suggesting that ps20 is able to induce 
WPMY-1 cells to express a broadly anti-proliferative phenotype (fig 6.3B-C).  
 
6.2.3 Inhibition of T cell proliferation is caused by G0/G1 arrest. 
 
In order to further elucidate the nature of ps20 expressing WPMY-1 cell CM 
suppression of T cell proliferation, we used PI staining of purified T cells to investigate 
the effect on the cell cycle of anti-CD3/28 stimulated CD4 T cells.  As shown in fig. 
6.4 a significant proportion of T cells treated with WPMY-1 EV CM were in the G2 
phase of the cell cycle 48h following treatment, indicating that these cells were 
undergoing division. In contrast, cells treated with CM from WPMY-1 expressing 
either ps20FL or ps20TR remained in the G0/G1 phase of the cell cycle, with almost no 
dividing cells in evidence. This indicates that ps20 is inducing a stromal phentype 
which prevents cell cycling in T cells.  
 
6.2.4 ps20 does not directly inhibit T cell proliferation 
 
In chapter 5, using immuneaffinity depletion, I demonstrated that niether ps20FL and 
ps20TR were able to directly inhibit growth in PCa, but instead expression of either 
molecule in WPMY-1 induces a phenotype which includes the induction of COX-2 
alongside numerous growth factors and cytokines. This supported data presented in 
chapter 4 that processing of ps20 is required to produce active growth inhbitory ps20 





Figure 6.3 Ps20 transduced WPMY-1 conditioned media inhibits IL-7/-15 induced T cell 
proliferation 
 
Figure 6.3 Ps20 transduced WPMY-1 conditioned media inhibits IL-7/-15 induced T 
cell proliferation. (A-B) Whole PBMCs were isolated and incubated with 50% WPMY-1 
EV, ps20FL or ps20TR CM followed by stimulation with IL-7 and IL-15. Proliferation was 
measured 6 days later through efluore dye dilution, by FACS. (A) Representative plots of 
CD4 T cell proliferation. (B-C) Means of CD4 (A) and CD8 (C) proliferation from 2 batches 


























































































Figure 6.4 Ps20 transduced WPMY-1 CM restrains cells in phase G1/G0 of the cell cycle 
 
Figure 6.4 Ps20 transduced WPMY-1 CM restrains cells in phase G1/G0 of the cell 
cycle. CD4 T cells were isolated and stimulated with anti-CD3/28 beads in the presence 




Here we investigated if depletion of ps20 from WPMY-1 CM abrogated the 
suppressive effect on T cell proliferation.  As shown in fig. 6.5A, depletion using anti-
ps20 5B9 conjugated beads removed a significant amount of the ps20 from the CM 
as determined by the reduced signal in the ELISA assay. However, ps20 depletion 
had no discernible impact on the level of suppression observed following treatment 
of T cells with depleted versus non-depleted CM (fig 6.5B). Consequently, ps20 
appears to have little of no effect directly on the proliferation of T cells, sugesting that 
as is the case with PCa proliferation, ps20 is inducing a secondary phenotype 
responsible for the observed T cell suppression. 
PI 





Figure 6.5 ps20 does not inhibit T cell proliferation directly 
Figure 6.5 ps20 does not inhibit T cell proliferation directly. (A) CM from transduced 
WPMY-1 cells was incubated overnight with beads conjugated to anti-ps20 ab5B9 or with 
CM sepharose as a control. ps20 or control depleted CM was assayed by ps20 ELISA. (B-
C) Ps20 depleted or control CM (B) or CM which had been boiled for 20 mins (C) was then 
added to CFSE labelled CD4 T cells, stimulated with anti-CD3/28 and cultured for 6 days 
followed before measuring proliferation by FACS. 
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We then investigated if boiling of CM abrogated the suppresive phenotype. WPMY-1 
CM from cells expressing EV, ps20FL or ps20TR was boiled for 20mins, and added to 
T cells, prior to stimulation with anti-CD3/28 beads. While boiling did induce a slight 
increase in the percentage of proliferating cells treated with EV CM (fig 6.5C), it 
completely abrogated the specific growth suppression accociated with WPMY-1 CM 
collected from ps20 expressing cells, suggesting a labile soluble mediator was 
responsible for growth suppressive phenotype. 
 
6.2.5 IFNγ expression is not abrogated by ps20 expressing WPMY-1 cell CM 
 
Having observed that ps20 induces a WPMY-1 cells to express CM which suppresses 
the proliferation of T cells, we investigated the effect of WPMY-1 CM on the 
expression of TH1 cytokines in T cells. IFNγ is a TH1 cell associated cytokine which 
is secreted by activated T cells and has been shown to be critical in the elicitation of 
successful anti-tumour response (Heusinkveld et al., 2011). It has anti-tumourigenic 
properties and is an important component of an active TH1 and CTL response. 
Similarly, IL-2 is expressed by activated T cells and is responsible for inducing and 
maintaining T cell production (Ashwell et al., 1986).    
 
We assessed the IFNγ and IL-2 expression in T cells following WPMY-1 CM 
treatment. Cells were stimulated or for 48h with anti-CD3/28 beads and analysed by 
intracellular cytokine staining. Interestingly both CD4 and CD8 T cells treated with 
WPMY-1 CM showed increased secretion of IFNγ relative to cells treated with media 
alone (fig 6.6A). There was slightly reduced secretion of IFNγ in cell treated with CM 




Figure 6.6 WPMY-1 CM does not inhibit IFNγ and IL-2 production in T cells 
Figure 6.6 WPMY-1 CM does not inhibit IFNγ and IL-2 production in T cells. PBMCs 
were treated with CM and stimulated with anti-CD3/28 beads for 48 h. Cells were stained 
for T cell markers and cytokines and analysed by FACS as described. A) Shows 






























































































With respect to IL-2 secretion, a negligible population of T cells secreted IL-2 
following activation and it would not have been reliable to quantify the differences 
between IL-2 expression given such small percentages of IL-2 expressing cells 
regardless of conditions (6.6A). Together then, this data suggests that WPMY-1 cell 
CM enhances IFNγ expression from cells, but ps20 expression has no specific 
inhibitory effect on the secretion of either IFNγ or IL-2.  
 
6.2.6 Expression of T cell activation markers is unaffected by WPMY-1 CM. 
 
Following activation of T cells, surface molecules are upregulated whose 
measurement serves as a metric of cellular activation. Two such molecules which are 
highly expressed in a transient manner in the hours following stimulation of activation 
of T cells are CD69, and CD25. CD69 acts to retain cells in lymph nodes and CD25 
is the IL-2Rα component of the IL-2 receptor. In order to further investigate the 
inhibitory phenotype conferred upon T cells following treatment with CM from ps20 
expressing WPMY-1 cells, we assessed the expression of these key T cell activation 
markers on cells treated with CM from WPMY-1 cells expressing ps20 (fig 6.7). We 
observed high levels of induction of CD69 and CD25 in both CD4 and CD8 cells 
relative to un-stimulated controls (fig 6.7 A&B).  In both CD4 and CD8 T cells treated 
with CM, marginally higher numbers of CD25 induction was observed in cells treated 
with CM from WPMY-1 cells expressing ps20. However, when looking at CD69 
expression, no apparent difference was observed in cells treated with different 
WPMY-1 CM. Consequently, we suggest that WPMY-1 CM from cells expressing 
ps20 is not inducing T cell suppression through a mechanism which involves 





Figure 6.7 WPMY-1 CM treatment does not inhibit T cell activation 
Figure 6.7 WPMY-1 CM treatment does not inhibit T cell activation. PBMCs were 
treated with 50% CM and stimulated with anti-CD3/28 beads. At 16h following stimulation 
cells were harvested and stained for T cell activation markers. A) CD4 T cells, B) CD8 T 




6.2.7 Inhibition of COX-2 abrogates ps20 dependent growth suppressive effect. 
 
In chapter 2 we saw that the suppressive effect of ps20-expressing WPMY-1 cells of 
PCa could be abrogated through the inhibition of COX-2. Herein we have observed 
a similar growth suppressive phenotype on T cells leading us to ask if this is again 
dependent upon COX-2 up-regulation. In fig. 6.8 CD4 T cells are cultured in CM from 
WPMY-1 cells grown in the presence or absence or either DMSO or rofecoxib. As 
can be seen, WPMY-1 CM is suppressive relative to media controls, but WPMY-1 
CM from ps20 expressing cells is notably more suppressive, especially from ps20FL 
expressing cells, where proliferation is completely abrogated. T cells treated with 
rofecoxib proliferated marginally better than cells treated with DMSO alone, indicating 
a small amount of non-specific growth enhancement. In all conditions CM generated 
in the presence of rofecoxib is less suppressive than the DMSO control. However, 
addition of the inhibitor to cells treated with either ps20FL or ps20TR WPMY-1 CM 
reduced growth suppression to levels observed with the WPMY-1 EV CM, suggesting 
a specific effect. However, suppression mediated by EV WPMY1 CM was also 
dramatically reduced, suggesting COX-2 is active in these cells, albeit to a lesser 
extent than in WPMY-1 cells expressing ps20.  
 
6.2.8 WPMY-1 expression of ps20 regulates expression of growth factors and 
cytokines 
 
In the previous chapter we saw how the transgenic expression of two ps20 isoforms 
in WPMY-1 prostate stromal cells induced a potent phenotype change in those cells; 
regulating a number of cellular and secreted factors, including PTGS2, which led to 




Figure 6.8 Suppression of CD4 T cell proliferation by WPMY-1 CM is COX-2 dependent 
 
Figure 6.8 Suppression of CD4 T cell proliferation by WPMY-1 CM is COX-2 
dependent. Transduced WPMY-1 cells were seeded in 12 wells plates and cultured for 
72h in the presence of 50μM Rofecoxib or the same volume of DMSO. CM was then added 
to purified T cells at 50%CM to 50%x-vivo™ media. Cells were stimulated with anti-CD3/28 
and harvested 7 days later. Data shows means and SEMs of two separate experiments in 




































to be responsible for inhibition of T cell proliferation, though the levels of suppression 
indicate that this phenotype is only partially dependent on COX-2. To further 
investigate the change in phenotype induced following the expression of ps20, we 
assayed 5 batches of CM secreted by transduced WPMY-1 cells using a 
commercially available multiplex ELISA which quantifies the concentrations of 45 
growth factors, cytokines and chemokines (see materials and methods section).  
 
In fig. 6.10, I present data showing secreted factors which underwent differential 
regulation in WPMY-1 cells, or which were highly expressed but whose expression 
did not appear to be affected by ps20. WPMY-1 cells expressing ps20FL and ps20TR 
showed increased expression of GM-CSF, LIF, IP-10, IL-6, FGF-2, VEGF, IL-8, SDF-
1 and RANTES. However only IL-2 up-regulation was significant in both ps20FL and 
ps20TR WPMY-1 cells, while IL-8, GM-CSF up-regulation reached significance only 
in ps20TR WPMY-1 CM.  Interestingly numerous growth factors were regulated by 
ps20 expression in WPMY-1 cells such as fibroblast growth factor-2 (FGF-2) and 
platelet growth factor-1 (PIGF-1) though only the latter reached significance. We also 
observed minor increases in levels of vascular endothelial growth factor-1 (VEGF), 
and two members of the neurotropin family, beta-nerve growth factor (bNGF) and 
brain derived neurotropic factor (BDNF) in ps20 expressing WPMY-1 CM. 
 
WPMY-1 cells also showed significant expression of numerous secreted whose 
expression was not affected, such as hepatocyte growth factor (HGF), GROα and 
MIP-1α,  indicating that a global increase in secretion was not taking place, but rather 






Figure 5.9 ps20 regulates expression of growth factors and cytokines in WPMY-1 
cells. CM from WPMY-1 cells cultured for 72h was analysed by a multiplex ELISA. Data 
shows means and SEMs of 5 separate batches of CM. (This data was generated by 














































































































































































































































































































































6.3 Discussion  
 
Herein we have demonstrated for the first time, that ps20 expression in prostate 
stromal cells induces the expression of a potently T cell suppressive phenotype 
capable of severely abrogating proliferation in response to both anti-CD3/28 bead 
stimulation, and IL-7/ IL-15 stimulation. Interestingly, the suppression of proliferation 
was comparable in both CD4 and CD8 cells, and acted upon purified CD4 T cells with 
similar dynamics as upon PBMC cultures subsequently stained for CD4 and CD8 T 
cell populations, indicating that ps20 transduced WPMY-1 CM is capable of 
suppressing T cell proliferation directly without the presence of other cells such as 
monocytes. This is notable given that SLPI has been shown to inhibit CD4 T cell 
proliferation through conditioning of monocytes. This suppression was specific to 
CD4 T cells, having no effect on CD8 cells (Guerrieri et al., 2011).   
 
We have shown that ps20 is indirectly capable of regulating T cell division in response 
to stimulation with IL-7/15 (fig 6.3). The cytokines IL-7 and IL-15 share the common 
gamma (γ) chain receptor component with IL-2 and are known to induce T cell 
proliferation (Tan et al., 2001). T cell division in response to these proliferative 
cytokines has been called homeostatic proliferation and represents a mechanism for 
the persistence of memory T cells, and a means of immune reconstitution following 
immune-depletion, for example following chemotherapy (Martin et al., 2013). While 
these cytokines are probably not expressed at high level within the prostate (Olurinde 
et al., 2011) they have been shown to skew the T cell populations towards memory 
effector phenotypes for both CD4 and CD8 cell types and induce functionality 
beneficial to anti-tumour immunity (Kaiser et al., 2013). Stimulation with IL-7 and IL-
15 has been shown to reduce T cell anergy following activation (Lu et al., 2002) and 
confer resistance to T cell suppression by Tregs (Perna et al., 2013).  As such, both 
cytokines are translational targets for localized tumour therapy including in enhancing 
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activity of T cell - chimeric-antigen-receptor (CAR) based therapies (Xu et al., 2014). 
Indeed our group is investigating the use of locally delivered IL-15 to induce 
expansion of CD8 effector cells and target tumour cell killing (Galustian et al., 2011). 
Given these insights, the observation that ps20 expression induces a 
microenvironment which suppresses the proliferative response of T cells to these 
cytokines indicates that its expression within prostate tumours would likely be 
detrimental to anti-tumour immunity, favouring the growth of the tumour. It also 
suggests that the expression of ps20 in the healthy prostate stroma may have intrinsic 
modulatory function, perhaps involved in limiting T cell activation and proliferation 
within prostate tissue, perhaps as a means of limiting auto-immune activity. 
 
 In chapter 5 I described the induction of a pro-apoptotic phenotype in WPMY-1 cell 
CM following expression of ps20. In this chapter, however we have observed that 
unlike the effects on PCa cells in chapter 5, ps20 expressing WPMY-1 cell CM added 
to T cells was able to completely inhibit entry into S/G2 phase of the cell cycle. In 
addition, T cells used in these experiments were analysed by FACS which involved 
gating on viable cell populations. Consequently, no effect on increased cell death was 
observed on T cells. Together these data suggest that the pro-apoptotic phenotype 
observed on PCa cells is distinct from the anti-proliferative phenotype described in 
this chapter, on T cells, suggesting that ps20 has pleiotropic functions and acts in a 
cell specific manner. 
 
In order to assess whether the T cell suppressive phenotype exhibited by WPMY-1 
cells expressing ps20 was directly mediated by ps20 expression, we again depleted 
the CM of ps20. This had no discernible effect on the proliferation of T cells. However 
boiling of WPMY-1 cell CM showed complete abrogation of T cell suppression, again 
indicating that ps20 is not directly mediating the suppressive phenotype and is 
instead inducing expression of a labile soluble mediator. Boiling of functional CM also 
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served to rule out one potential T cell suppressive mechanism. Stromal tissues, 
including mesenchymal stem cells have been shown to suppress T cell proliferation 
by up-regulating IDO, which depletes tryptophan from the CM (Reading et al., 2013b, 
Reading et al., 2013a, Haniffa et al., 2007). However, tryptophan levels within CM 
would be unaffected by boiling, suggesting the suppressive effects are unlikely 
mediated by the presence expression of IDO and the subsequent depletion of 
tryptophan from the CM, and are fact mediated by a labile factor capable of acting 
directly upon T cells. 
 
In order to gain mechanistic sights into the means of T cell suppression elicited by 
ps20 expressing WPMY-1 cell CM we  investigated the expression of key T cell 
activation markers.  We chose to investigate expression of CD69, and CD25 both of 
which become highly and transiently expressed following activation of T cells (Testi 
et al., 1989, Cerdan et al., 1992). Both were unchanged by CM treatment indicating 
that the suppression of T cells by ps20 expressing WPMY-1 cells was not occurring 
at the level of T cells activation, which supports the evidence that the ability to 
produce IFNγ upon activation remained unchanged. CD25 is the cluster of 
differentiation nomenclature for IL-2Rα, a component of the heterotrimeric IL-2 
receptor, allowing us to rule out another mechanism of suppression. Unchanged 
CD25 expression also suggests that T cells are not being suppressed because of 
their inability to respond to IL-2, at least not at the receptor level.  
 
Following work in the previous chapter that demonstrated up-regulation of PTGS2 in 
ps20 expressing WPMY-1 cells, we sought to investigate if the suppression of T cells 
we have observed is dependent on COX-2 activity. As with our experiments 
addressing PCa cell growth in chapter 5, we observed herein that inhibition of COX-
2 in WPMY-1 cell cultures increased proliferation in CD4 T cells treated with ps20-
expressing WPMY-1 cell CM. However, this suppression was not complete and there 
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was a notable level of proliferation enhancement in control conditions, namely in T 
cells treated with the COX2 inhibitor but not-treated with CM, and in WPMY-1 EV CM 
treated T cells (fig 6.8). This makes it highly likely that COX-2 is a component of the 
T cell suppressive effect, but is also suggestive that there may be other mechanisms 
involved. There is prior in vivo evidence that COX-2 is a component of tumour 
associated T cell responses. Namely, it was recently found that antigen specific 
immunity was blunted in mouse tumours expressing COX-2 (Gobel et al., 2014).  
However, without further characterising the suppression of T cells in our culture 
systems, or the presence of individual prostanoids within ps20 containing WPMY-1 
CM we are unable to conclude precisely how the COX-2 dependent suppression is 
being mediated here.  
 
To speculate on how COX-2 activity may be mediating T cell suppression, There are 
numerous examples of PGE2, a prostanoid downstream of COX-2 and PGE synthase 
(PGES) enzymes, inducing an immune suppressive/tolerogenic environment within 
tumours, positing this molecule as a potential mechanism (Sharma et al., 2003, 
Obermajer et al., 2011). Indeed, PGE2, has been shown to have context dependent 
T cell suppressive activity; DU145 spheroids in 3D culture were shown to suppress 
IFNγ expression in CD4 and CD8 T cells in a PGE2 dependent manner(Sha et al., 
2013) which is in contrast to our data showing that WPMY-1 CM has little effect on 
the expression of IFNγ. However there are numerous instances of other prostanoids 
downstream of COX-2 capable of mediating immune suppressive phenotypes. For 
example, PGJ2 has been shown to inhibit NFϰB activation (Uchida and Shibata, 
2008), which while unlikely to elicit robust suppression of T cell proliferation as has 
been observed in this study, could contribute to a suppressive phenotype by 
restricting expression of numerous T cell derived factors which contribute to a TH1 
inducing milieu. We have found no evidence in the literature that PGE2 or any of the 
prostanoids downstream of COX-2 are able to mediate direct functional effects on T 
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cells, and more experiments will be required to dissect the mechanisms by which the 
COX-2-dependent component of the suppressive phenotype we have described in 
this chapter is impacting T cell function. 
 
Towards elucidating the mechanism by which T cells proliferation is supressed, we 
observed a number of factors to be upregulated in the CM of ps20 expressing WPMY-
1 cells (fig. 6.9). We performed extensive literature searches to elucidate precedence 
of any of these upregulated factors in the suppression of T cells. VEGF was the only 
factor other than COX-2 we found which has been shown to have a direct anti-
proliferative on T cells, acting through CD47 to inhibit CD3 and IL-2 induced 
proliferation in a dose dependent manner (Ziogas et al., 2012). It would be interesting 
to see if neutralisation or depletion of VEGF from WPMY-1 CM would synergise with 
COX-2 inhibition to restore T cell proliferation. Interestingly, the change in expression 
of a number of cytokines key to the regulation of T cell phenotype invokes further 
questions about the potential mechanism of ps20 dependent WPMY-1 CM 
suppression of T cell proliferation. IL-6, GM-CSF, and VEGF were all seen to be 
upregulated and are notable for their association with a TH17 type phenotype. The 
induction of a non-TH1 T cell phenotype is one potential mechanism to explain the 
failure of T cells to proliferate in response to either anti-CD3/28 or IL-7/15 stimulation. 
TH17 cells are not activated efficiently following anti-CD3/28 stimulation. However, 
without further experiments to better define the immune phenotype of T cells treated 
with ps20 expressing WPMY-1 cell CM it is impossible to accurately predict the 
mechanism by which proliferation is being suppressed. Further elucidation of the 
immune phenotype could be obtained by assessing the expression of T cell 
transcription factors. It is quite possible that the changes in the cytokine milieu 
secreted from WPMY-1 cells caused by ps20 expression could induce expression of 
a Treg or TH17 phenotypes respectively (Taflin et al., 2011). Assessment of T bet 
expression alongside induction of either FoxP3 or RORγt, would help to elucidate 
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what if any changes in immuno-phenotypes were being induced in T cells by ps20-
expressing WPMY-1 CM. 
 
Another factor we observed to be upregulated in ps20 expressing WPMY-1 CM was 
leukaemia inhibitory factor (LIF). LIF is an IL-6 family cytokine which signals through 
the LIF-Receptor, composed of glycoprotein (GP) 130 and 190 subunits (Metcalfe, 
2011). Interestingly, LIF has been a shown to be an inducer of FoxP3 expression in 
activated T cells, conferring a Treg phenotype (Gao et al., 2009), and is a potent 
inducer of an immuno-tolerogenic phenotype (Metcalfe, 2011). In addition, it has 
been shown to compete with IL-6 over the induction of TH17 versus Treg cells (Gao 
et al., 2009, Thompson et al., 2010). As presented in fig. 6.9, IL-6 was also 
upregulated by ps20 expression in WPMY-1 cells. It is possible that in regulating the 
expression of LIF and IL-6 ps20 transduced WPMY-1 cells are inducing either TH17 
and/or Treg cell phenotypes. As mentioned, neither of these T cell populations will 
proliferate efficiently in response to anti-CD3/28 beads providing a rational for the 
data presented herein (Annunziato et al., 2007). Increased Treg frequency likely 
would suppress proliferation of FoxP3 negative cells, further reducing the proliferative 
response of T cells within the culture. It will be important to further investigate the 
regulation of both IL-6 and LIF by ps20 and examine their role if any in the 
suppressive function of WPMY-1 cell CM. 
 
We observed an up-regulation of numerous chemokines in CM from ps20 expressing 
WPMY-1 cells (fig 6.9). With respect to the function of ps20 within the healthy prostate 
stroma, the regulation of chemokines may be significant. Chemokines are generally 
accepted to be responsible for regulating the migration of immune cells into and out 
of tissues, including the migration of T cells. Furthermore, there are two previously 
published reports of ps20 regulating the expression of IL-8 (Wilson et al., 2014)  and 
CXCL1/CXCL2 respectively (Rogers et al., 2012) demonstrating that ps20 is a 
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molecule capable of influencing the chemokine milieu within tissues. Both RANTES 
(CCL5), IL-8 and IP-10 (CXCL10) were upregulated in ps20 expressing WPMY-1 
cells, while there was notably little change in levels of MIP-1β or GROα. RANTES is 
a potent T cell chemotactic factor (Schall et al., 1990), while IL-8 is potently 
chemotactic for neutrophils (Ward and Newman, 1969). In addition, IP-10 has been 
shown to be chemotactic for monocytes, T cells, and NK cells, and is considered 
broadly pro-inflammatory and angiostatic (Ahmadi et al., 2013).  It is likely therefore 
that where ps20 is expressed within the prostate stroma it contributes to the 
regulation of specific chemokines. This implies a potential role for ps20 in shaping 
the compliment of infiltrating leukocytes and lymphocytes in the prostate in health 
and in disease. Whether this function would have significant implication on the 
development or progression of prostate neoplasms where ps20 expression is 
switched off remains to be seen.  Future work should seek to further explore the 
range of chemokines regulated by ps20 in stromal and other cell types and how this 
affects immune cell migration within tissues where ps20 is expressed. In the case of 
the prostate, it would be interestingly to compare the immune phenotype of infiltrating 








 General Discussion and Future work 
 
7.1 General Discussion 
 
In this thesis, I set out to investigate the role of WFDC1/ps20 in the context of prostate 
cancer (PCa). Previous work had indicated that ps20 has potent growth suppressive 
function on PCa cells (Larsen et al., 1998, Rowley et al., 1995) and our interest in 
studying ps20 was as a potential growth inhibitor for use in a cocktail of locally 
delivered therapeutics. Indeed, previous studies have employed WFDC family 
proteins therapeutically highlighting their translational potential (Zani et al., 2011, 
Shaw and Wiedow, 2011). However, in addition to therapeutically useful growth 
inhibitory properties, ps20, like SLPI and elafin, may have immunomodulatory 
functions (Ressler et al., 2014, Rogers et al., 2012). By understanding the relevance 
of these immunomodulatory functions within the prostate where ps20 is expressed, 
would allow us to anticipate the potentially deleterious effects that therapeutic 
delivery of ps20 to a prostate tumour would have on anti-tumour immunity. As such 
we set out to study the biochemistry, growth inhibitory, and immune regulatory 
functions of ps20 so as to close some of the gaps in our understanding of the 
functionality of this molecule. 
 
In chapter 3 I demonstrate that functional ps20 can be purified to near homogeneity 
by immune-affinity to anti-ps20 IgG. Unfortunately, due to the work being done 
externally as part of collaboration (Work performed by myself supervised by Dr Simon 
Jeff’s, Imperial College London) we were not able to upscale the production of this 
near pure ps20293F material in order to manufacture large quantities. Still, enough was 
obtained for functional experiments and numerous downstream biochemical 
characterisation assays. In Chapter 4, I present data describing the complexity of 
biochemical processing of ps20. I show conclusively that ps20 is able to interact with 
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fibronectin, transglutaminase and GAGs, and that cathepsin L is one means by which 
ps20 is post-translationally processed. However, data within this chapter also reveal 
the presence of multiple functional molecular forms of ps20. Indeed, in terms of 
growth inhibition of PC-3 cells, smaller, cleaved species of ps20 appeared to have 
far greater activity than highly-pure FL ps20. It is predictable, therefore, that the post-
translational processes which produce cleaved or oligomerised ps20 species do so 
to specific, ill understood functional ends.  These processes and the nature of the 
species of ps20 they produce will require further elucidation. Previous work has 
shown that WFDC proteins are cleaved physiologically; specifically cleaved forms of 
SLPI were found in bronchial lavage fluid from human samples, suggesting that 
cleavage of that nature does take place in vivo. Towards understanding the 
physiological relevance of individual ps20 protein species, it will be important to 
elucidate which species are present in the prostate, what processes they are 
associated with; and how they come about following secretion of the full length and/or 
truncated ps20 species. 
 
Based on the data presented in this thesis, we propose that ps20 has at least two 
mechanisms of activity. The first, which likely relies on ps20 cleavage, leading to 
generation of a growth inhibitory protein fragments, can be assumed to rely on the 
induction of ps20 expression, combined with the induction of the relevant protease to 
generate the active fragments. The second mechanism then, gleaned from data 
presented in chapter 4, is through the regulation of PTGS2/COX-2 expression. COX-
2 is an inducible enzyme, and the rate-limiting step in the prostanoid pathway. Our 
data, including a transcriptome analysis of ps20-expressing WPMY-1 cells, and 
subsequent qPCR confirmation of ps20 dependent COX-2 up-regulation, suggest 
ps20 is regulating this expression. However, PTGS2 was amongst 248 genes (fig 
5.8) leaving open the possibility the COX-2 up-regulation is further downstream and 
induced by a secondary factor.  Indeed, COX-2 being a pleiotropic inflammatory 
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mediator, the PTSG2 gene has been shown to be transcriptionally regulated by 
numerous pathways and transcription factors, including NFϰB, SP-1, ETS-1 and AP-
1 and its promoter possesses numerous other regulatory elements (Appleby et al., 
1994). Both SLPI and elafin, have been shown to regulate transcription factor 
activation (Drannik et al., 2012, Taggart et al., 2005) leaving room for speculation that 
ps20 may play a part in the regulation of a transcription factors which in-turn regulate 
PTGS2/COX-2 expression. Further experiments will be required to examine the 
nature and dynamics of ps20 dependent PTGS2 induction in WPMY-1 and other cell 
types.  
 
The function of COX-2 has features which fit with previous paradigms of ps20 function 
within the prostate.  COX-2 is upstream of numerous prostanoids with disparate 
functions. As such, COX-2 function within tissues specifically relies on the regulation 
of downstream enzymes, such as mPGES-1 and prostaglandin D synthase, which 
determine the ultimate physiological effect of local arachidonic acid metabolism. 
Interestingly, a recent meta-analysis of COX-2 expression and polymorphisms in PCa 
concluded that while there was no association of PCa with any known COX-2 
polymorphisms, and there was no correlation of COX-2 expression with gleason 
score of tumour, COX-2 expression was shown to be overexpressed in progressive 
and metastatic PCa (Shao et al., 2012). Given that ps20 expression is reduced or 
absent in PCa this would appear to be contradictory to our data presented herein, 
were it not for the previous work from David Rowley’s lab showing the concomitant 
down-regulation of ps20 in the prostate stroma with ps20 over-expression in the 
epithelial tissues of the cancerous prostate (McAlhany et al., 2004). Moreover, 
increased expression in epithelial tissue was significantly correlated with reduced 
survival (McAlhany et al., 2004). Of pertinence to this observation is the fact that the 
expression of PGDS is associated with stromal tissues, whereas mPGES-1 is known 
to be expressed in PCa (Finetti et al., 2015). PGDS catalyses the formation of the 
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pro-apoptotic and anti-inflammatory PGD2, which undergoes rearrangement to 
become PGJ2 (Ho et al., 2008, Koppal et al., 2000, Nakamura et al., 2013, Uchida 
and Shibata, 2008), whereas conversely, mPGES-1 and other PGE2 synthases 
catalyse formation of the PGE2 which is broadly pro-inflammatory. As such, it seems 
reasonable to suggest that stromally expressed ps20 may regulate pro-apoptotic, 
anti-inflammatory COX-2 activity. It remains to be seen if ps20 is also a regulator of 
COX-2 in epithelial tissues, which if this is the case, may have entirely disparate 
effects. This will be important to clarify, because the ps20 dependent overexpression 
of COX-2 in epithelial/cancerous tissues could induce different prostanoids 
downstream of COX-2 than in stromal tissue. This would provide a mechanistic 
rational for three key observations made previously, i) that ps20 is down-regulated in 
the prostate stroma during cancer (Orr et al., 2012, McAlhany et al., 2004), ii) that 
ps20 becomes associated with the epithelia during advanced prostate cancer 
(McAlhany et al., 2004), and iii) that ps20 expression in PC-3 xenografts induces 
angiogenesis and facilitates tumour growth (McAlhany et al., 2003). With reference 
to the last point, PGE2 is a well-known mediator of angiogenic processes, including 
in PCa (Cao and Prescott, 2002, Jain et al., 2008, Wang et al., 2005b).   
 
Our data presented herein showing the COX-2 dependent induction of apoptosis of 
PCa cells leads us to suggest that the expression of ps20 in the prostate stroma is 
incompatible with tumour growth. Consequently, we posit, as others have done 
(Ressler and Rowley, 2011), that tumours need to invoke changes in the stroma 
which switch off ps20 expression, allowing outgrowth of neoplastic tissues. However, 
we also observed in work presented in chapter 6, that ps20-induced stromal COX-2 
expression also reduces T cell proliferation. There would seem then to be a trade-off 
within the co-evolution of the stromal compartment with the developing tumour. The 
T cell suppression conferred by ps20 up-regulation of COX-2 is presumably less 
deleterious to the growth of the tumour than the more direct effect on cellular growth 
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and apoptosis. Given that most T cell activation and proliferation takes place in 
secondary immune sites such as lymph nodes, it is perhaps understandable that the 
type of T cell inhibition conferred by ps20  expression in the stroma may not in fact 
be advantageous to the tumour, which can instead invoke myriad suppression 
mechanisms to abrogate any such anti-tumour immune response (Arnold et al., 2014, 
Kraman et al., 2010, Young et al., 1996). However, the effect of ps20-dependent 
immune suppression becomes pertinent when considered therapeutically. The exact 
mechanism by which stromal ps20/COX-2 is able to suppress activated T cell 
responses therefore requires further elucidation. Understanding how broad the 
suppression is, and whether it acts upon other immune cell types such as MФ, DCs, 
and especially NK cells, will be important in elucidating how therapeutic ps20 may 
affect any active immunity within tumours. Understanding of these effects with regard 
to the ps20 dependent regulation of chemokines observed herein and elsewhere 
(Wilson et al., 2014, Rogers et al., 2012), as well the effects on suppression of 
homeostatic T cell proliferation observed herein will increase our understanding of 
prostate immunity in health, of which little is known. 
 
Principally, it should be considered that ps20 is a molecule present and active in the 
prostate stroma, and may be a component of the regulatory apparatus defining 
immune homeostatic processes within the healthy organ. This could be especially 
pertinent if the loss of ps20 acts as a suppressor of inflammation of the prostate, 
which would provide an etiological link between the loss of ps20 expression and 
tumour causing inflammation in the prostate. 
 
7.2 Future work 




The first objective of this study was to purify ps20. We developed a protocol which 
allowed simple and rapid purification of ps20 from serum free CM using immune-
affinity and the anti ps20 1G7 antibody. However, one disadvantage to using this 
protocol is the unpredictability of the protein’s response to treatment with low pH 
buffer. Despite being neutralized in TRIS buffer rapidly following elution, it is 
predictable that some degree of protein unfolding, or mis-folding may take place 
during this process. The extent of this damage is also impossible to assess without 
suitable functional standards and controls being available, as they are not for ps20.  
A modification of this technique which does not require elution in denaturing buffer 
involves elution with a peptide of high affinity to the antibody column. While no such 
peptide has yet been elucidated for the 1G7 Ab, other ps20 antibodies, namely the 
monoclonal C-terminal 5B9 AB, were raised to a specific peptide. A suitable next step 
in attempts to optimize an immune affinity protocol for ps20 purification could utilise 
a 5B9 conjugated antibody column, and would employ competitive binding elution 
using an ab specific peptide rather than low pH glycine buffer. This way, a lack of 
functionality with the resulting protein preparation could not be attributed to 
denaturing by low pH elution. 
 
A subsequent goal was to elucidate the interaction between ps20 and GAGs. While 
we demonstrated a high affinity interaction, we were unable to follow this through to 
demonstrate a functional consequence of such an interaction. Numerous proteins 
have been shown to be functionally dependent of protein GAG interacts and in the 
case of ps20, treating cells such as PC-3 or WPMY-1 with ps20 in the presence or 
absence of competing glycosaminoglycans would have indicated whether ps20-GAG 
interactions were required for ps20 dependent inhibition of proliferation. Alternatively, 
treatment with sodium chlorate to inhibit glycosylation of surface proteoglycans would 
also have serviced this end. Further insights into the nature of the ps20-GAG 
interaction could have been revealed using fluorophore conjugated ps20 as was 
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utilised in the study of SLPI internalisation. The limiting factor in these experiments is 
the availability of highly pure, functional ps20.  
 
An additional oversight of this project, was the failure to sequence the LMW species 
of ps20, despite resolving them using silver staining on a gel (fig. 4.5A). Indeed, 
numerous likely ps20 fragments could be predicted by their similarly increased 
electrophoretic mobility following treatment with cathepsin L. I had excised and 
destained these ps20 from the gel and they were ready to be sent for mass-
spectrographic analysis. However, it was decided it would have been an inefficient 
use of funds to sequence numerous ps20 species and those generated by controls, 
unless it was demonstrated that cathepsin L cleavage has a specific functional 
ramification. I believe this was the incorrect decision for two reasons; i), a direct 
functional consequence of cathepsin L may have been found further into the 
investigation, perhaps as a results of cloning, and expressing specific fragments 
shown to result from such a cleavage; ii) sequencing would have allowed us to 
identify the exact nature of at least two LMW ps20 species, which share proclivity to 
cathepsin L cleavage, but which do not result from it. This additional information 
would have allowed us to steer the investigation towards elucidation of the function 
of ps20 subspecies, rather than trying to elucidate how they come about. 
 
Regarding the use of cellular assays to investigate ps20 function, future work could 
use various cellular assays to investigate the functional consequence ps20 cross-
linking to fibronectin. Many cell types adhere to fibronectin and will migrate on a 
fibronectin solid-phase in culture. Given previous indications that ps20 may induce 
cellular migration (McAlhany et al., 2003), a simple migration assay using cells 
seeded on fibronectin coated plates in the presence or absence of cross-linked ps20 
would begin to interrogate the functional consequence of the fibronectin-ps20 
interaction. It would also be interesting to see if ps20 retained growth inhibitory 
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function when cross-linked to fibronectin, for which the same basic experimental set-
up could be used. However, the ability of cathepsin L to release the ps20 N-terminal 
region from the ps20-fibronectin conjugate adds complexity to such an investigation. 
Cells overexpressing secreted cathepsin L would be a useful tool in investigating this 
phenotype further, again utilising fibronectin coated culture plates in the presence or 
absence of cross-linked ps20 to investigate if the presence of increased levels of 
cathepsin L had functional effect on the ps20 dependent phenotype being 
investigated.  
 
All future work involving purified ps20 should take into account the prevailing lack of 
consensus on what constitutes a functional ps20 molecule. Work presented in this 
thesis proposes that unmodified FL ps20 is unlikely to be the most active growth 
inhibitory species, and that a post-translational cleavage or some other post-
translational modification produces a molecule with increased growth inhibitory 
function. The primary aim of future work pertaining to elucidate the function of ps20 
using purified protein should first elucidate decisively which ps20 species are 
functional and which are not, and base the production and purification strategy 
around the results. 
 
7.2.2 Chapters 5 and 6 
 
Our first observation was that while ps20 expression in WPMY-1 cells reduced 
proliferation, this effect was not noted in PC-3 or DU145 cells. I have already 
discussed the possible reasons for the absence of this phenotype. However, ps20 
may have been inducing other cellular changes, beside proliferation rates, that went 
unnoticed. Transcriptomic data was not obtained for either the PC-3 or DU145 
transduced cells, and so ps20-induced changes in expression profiles were never 
ascertained. This information would have been useful i) as a point of comparison with 
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the WPMY-1 cells where a potent growth inhibitory phenotype was observed, and ii) 
in order to note general changes in signalling within the cells which would have 
provided insights into ps20 function. There are numerous generic cellular assays that 
can be undertaken to investigate changes in phenotype which were not explored in 
this project. Firstly, adhesion assays may have uncovered ps20 dependent changes 
in expression of adhesion molecules. This would be especially pertinent in light of the 
two studies which observed ps20 dependent increases in expression of ICAM-1 in T 
cells. Secondly, changes in cellular migration may also have been investigated. The 
use of simple wound closure assays, or a more 3D set-up, such as migration through 
a transwell or into a substrate such as Matrigel™ would have allowed us to observe 
if ps20 mediates effects on cellular phenotypes other than on proliferation via COX-
2 expression. Study of cellular adhesion and migration are both pertinent to tumour 
biology. Surface expression of adhesion molecules holds cells together, both by 
allowing tethering of cells to each other, and to the ECM. Changes in expression of 
key families of adhesion factors such the cadherens (involved in tight junctions) and 
integrins (involved cell-to-cell and ECM-to-cell signalling) can have profound effects 
of cell shape and motility, and changes in patterns of adherence and cell motility 
contribute to greater levels of tumour invasion and subsequent metastasis (Mol et al., 
2007). To date there is no evidence that ps20 plays a role in either of these events, 
but the enhanced growth of ps20 expressing PC-3 xenografts in mice provides 
sufficient rational for performing experiments to investigate potential change in these 
phenotypes. 
 
Questions also remain regarding the nature the COX-2 dependent phenotypes 
induced by ps20 induction in WPMY-1 cells. COX-2 is upstream of numerous 
prostanoids, each with different, often pleiotropic, functions. As discussed in the 
previous section, a prominent candidate for a pro-apoptotic effects downstream of 
COX-2 expression is PGJ-2. Increases in this prostanoid can now be detected by a 
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commercially available ELISA. However, numerous other factors may be responsible 
for the effect. Ideally, proteomic analysis of ps20 expressing WPMY-1 CM would be 
performed to establish the levels of different prostanoids present, however, all the 
growth suppressive CM used in experiments presented within this thesis contained 
10% FCS, which would drastically obscure or invalidate data obtained through 
currently available mass-spec techniques. An obvious solution would be to generate 
growth suppressive media in serum free conditions. My attempts to do this were 
unsuccessful and the ps20 dependent suppressive phenotype was never observed 
in media developed without sera. This may be because i) WPMY-1 cells do not grow 
well in serum free media, ii) albumin is required for the spontaneous conversation of 
PGD2 to PGJ2 (Shibata et al., 2002), which remains our prime candidate for the 
suppressive phenotype observed. Experiments could be performed to find a suitable 
serum free media in which the growth suppressive phenotype of ps20 expressing 
WPMY-1 could be replicated. This would facilitate downstream analysis of the CM for 
identification of active factors downstream of ps20 expression. 
 
Another question which arises from work in chapter 5 and 6, is how ps20 is able to 
regulate PTGS2/COX-2 expression.  Given the complete lack of functional data on 
the mechanism of action of ps20 in the literature, and the additional questions of what 
constitutes functional ps20 raised in the fourth chapter of this thesis, this would likely 
prove a difficult area of investigation. None-the-less, our data demonstrate that 
WPMY-1 cells expressing ps20 have higher levels of PTGS2 expression. However, 
this regulation may be direct or indirect. Increased PTGS2 expression may be 
regulated downstream of other secreted or indeed non-secreted factors induced by 
ps20. In order to dissect the dynamics of PTGS2 upregulation in response to ps20, 
in lieu of reliably functional soluble ps20, transfection studies should be performed to 
assess how rapidly following ps20 expression PTGS2 is induced, using qPCR as 
readout of PTGS2 induction. Alternatively, PTGS2 promoter reporter plasmids (e.g 
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using luciferase) could help to elucidate the dynamics and mechanisms of ps20 
dependent PTGS2 regulation. 
 
More broadly, it remains to be seen whether COX-2 is a general mechanism of ps20 
function, or whether it is specific to the WPMY-1 model employed throughout this 
thesis. Given that the expression of ps20 is not limited to prostate tissue, future work 
aimed at elucidating ps20 function should employ cells from other tissues where ps20 
expression has been recorded, most notably the lung. Using numerous cell lines, 
alongside, where available, primary cells, would increase the power of results, 
allowing a more reliable assessment of whether COX-2 regulation is a common 
feature of ps20 function or is restricted to prostrate stromal tissue. Primary prostate 
cells are notoriously difficult to grow, and few studies utilise them, but given the 
unanimous reports of ps20 down-regulation in cancers derived from that tissue, their 
use may be key to unravelling the mysteries of ps20 function. 
 
7.2.3 WFDC1 in senescence: Loss of function vs Gain of function. 
 
In this thesis, we have used gain of function techniques to investigate a model of 
ps20 expression in prostate tumours and stromal tissue. However, the benefits of 
these types of assays in elucidating protein function are difficult to predict. For 
example within tissues, regulation of ps20 expression may be very tightly controlled, 
and its function may be limited to highly specific spatiotemporal scenarios. As such, 
a better understanding of how ps20 functions may be garnered from cells which have 
intrinsically high levels of ps20. So far, no study to date has described high levels of 
ps20 expression in cells in vitro, with the exception of HeLa cells. Thus, the question 
remains, which physiologically relevant cell types express ps20 at high levels, and 
what stimulus induces this? The Rowley lab showed induction of WFDC1 RNA in 
stromal cells in response to TGFβ, but our attempts to induce ps20 expression in 
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stromal and numerous other cell types have never shown any observable increase 
in expression. The best insight to date, then, as to how WFDC1 can be regulated 
physiologically has come from studies investigating senescent cells. Madar et al, 
showed significantly increased WFDC1 expression in two fibroblast cell lines grown 
to replicative senescence (RS) (Madar et al., 2009). At least one other study has 
published supplemental data showing WFDC1 up-regulation in transcriptome array 
data from cells grown to RS and we were able to confirm expression of WFDC1 in 
these senescent cells by qPCR (appendix fig. 8.5) (Nelson et al., 2014). Interestingly, 
the same phenomenon is not observed in cells induced to senescence by 
overexpression of oncogenes (oncogene induced senescence (OIS) (Nelson et al., 
2014). In line with this, our data taken from the microarray data presented in chapter 
5 and the multiplex ELISA data shown in chapter 6, show that in WPMY-1 cells 
transduced to express ps20, numerous secreted factors are upregulated. The 
combination of factors affected, including IL-6, IL-8, and numerous chemokines are 
all factors induced in cells grown to replicative senescence, and have become 
collectively known as the senescence associated secretory phenotype (Coppe et al., 
2010). Therefore, one hypothesis that emerges from this is that WFDC1 is involved 
either i) in the regulation of replicative senescence, or ii) that WFDC1 is upregulated 
during replicative senescence and is a regulator of the SASP. Unfortunately, we were 
unable to use our WPMY-1 cells to study this phenotype given they are immortalised, 
unable to undergo senescence, and therefore an inappropriate model of that 
particular physiological event. Our attempts to culture primary fibroblasts to 
senescence made it clear that the study of replicative senescence was beyond the 
remit of this project. By the time we had established the similarity between the ps20 
induced secretory phenotype and the SASP, there was simply not enough time 
available to culture cells long enough to reach replicative senescence, which can take 
between 6 months to 1 year for slow growing cells. However, it is likely that at least 
one of the roles of WFDC1/ps20 is involved in senescence. As such, future work 
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should seek to investigate this. The use of shRNA knockdown or the CRISPR/Cas9 
system to suppress WFDC1 expression would allow the role of WFDC1 in RS to be 












Figure 8.1 purified rps20 contains non-labile oligomers and higher MW contaminants 
Figure 8.1 purified rps20 contains non-labile oligomers and higher MW 
contaminants.  (A) anti-V5 western blot of rps20V5 boiled for indicated time in 500mM 
DTT. (B) rps20V5 was analysed by SDS-PAGE and stained with coomassie blue, lane 1 





Figure 8.2 Contaminating factors in 293F generated ps20 purification 
Figure 8.2 Contaminating factors in 293F generated ps20 purification  
Screenshot from scaffold programme showing results of MS analysis of 293F ps20 
material. The only protein factor besides WFDC1 (ps20) identified was G3BP and 
numerous keratins. Keratins are frequently detected in sample dues to contamination from 
skin, hair in dust etc. Tryspin appears as it was the protease used to digest the sample. 
 
 
Figure 8.3 Galectin 3 binding protein does not inhibit cell proliferation 
Figure 8.3 Galectin 3 binding protein does not inhibit cell proliferation. 
DU145, PC-3 and WPMY-1 cells were seeded at 2000 cells per well and treated with the 
indicated concentration of G3BP in complete media for 96h. Proliferation was assayed by 
MTS reagent and read at 490nm. 
DU145, PC-3 and  WPMY-1
cell proliferation
































































Figure 8.4 Crosslinking of ps20 to pre-prepared ECM solid-phases 
Figure 8.4 Crosslinking of ps20 to pre-prepared ECM solid-phases 
25ng/ml ps20 was incubated on pre-prepared ECM plates. 0.02U/ml TG was added for 











Figure 8.5 WFDC1 expression increases as cells reach replicative senescence 
 
Figure 8.5 WFDC1 expression increases as cells reach replicative senescence 
A) IMR90 fibroblasts cultured for the indicated number of population doublings were x-gal 
stained, and photographed using a light microscope. Blue cells are x-gal positive. B) Young 
(PD36) and senescent (PD86) IMR90 cells were harvested and WFDC1 expression 
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